Microbiota in development and stress management by Murphy, Amy
UCC Library and UCC researchers have made this item openly available.
Please let us know how this has helped you. Thanks!
Title Microbiota in development and stress management
Author(s) Murphy, Amy
Publication date 2021-01-04
Original citation Murphy, A. B. 2021. Microbiota in development and stress management.
PhD Thesis, University College Cork.
Type of publication Doctoral thesis











MICROBIOTA IN DEVELOPMENT AND STRESS 
MANAGEMENT 
A thesis presented to the National University of Ireland for the degree of 
Doctor of Philosophy 
By 
Amy Murphy, B.Sc. 
 
Teagasc Food Research Centre, Moorepark, Fermoy, Co. Cork, Ireland 
School of Microbiology, University College Cork, Cork, Ireland 




Professor Catherine Stanton, PhD 
Professor Timothy G. Dinan, MD, PhD 





TABLE OF CONTENTS 
TABLE OF CONTENTS ........................................................................................................  
DECLARATION.....................................................................................................................  
PUBLICATIONS ....................................................................................................................  
THESIS ABSTRACT .............................................................................................................  
CHAPTER 1 .............................................................................................................................  
PROBIOTICS AS CURATORS OF A HEALTHY GUT MICROBIOTA: 
DELIVERING THE SOLUTION .........................................................................................  
ABSTRACT ............................................................................................................................ 2 
INTRODUCTION ................................................................................................................... 3 
GUT MICROBIOTA COMPOSITION IN INFANTS AND ADULTS .......................................... 4 
FACTORS DISRUPTING THE GUT MICROBIOTA ................................................................. 7 
PREBIOTICS AND PROBIOTICS ........................................................................................... 12 
Potential Benefits of Prebiotics and Probiotics .............................................................. 12 
DELIVERY OF VIABLE AND FUNCTIONAL PROBIOTICS ................................................... 14 
Non-Food Based Probiotic Delivery............................................................................... 17 
Food Based Probiotic Delivery ....................................................................................... 19 
GUT MICROBIOTA MODULATION USING PROBIOTICS AND PREBIOTICS ...................... 27 
Infant Microbiota Modulation ....................................................................................... 27 
Adult Microbiota Modulation ....................................................................................... 29 
THE GUT-BRAIN AXIS AND PROBIOTICS ......................................................................... 31 
Preclinical studies .......................................................................................................... 31 
Clinical studies .............................................................................................................. 35 
CONCLUSION .................................................................................................................... 38 
REFERENCES ...................................................................................................................... 41 
CHAPTER 2 ......................................................................................................................... 59 
MICROBIOME IN BRAIN FUNCTION AND MENTAL HEALTH ....................... 59 
ABSTRACT .......................................................................................................................... 60 
INTRODUCTION ................................................................................................................. 61 
HEALTHY GUT MICROBIOTA COMPOSITION .................................................................. 62 
THE MICROBIOTA-GUT-BRAIN AXIS ............................................................................... 64 
MICROBE TO BRAIN SIGNALING PATHWAYS .................................................................. 66 
The Vagus Nerve ............................................................................................................ 66 
Microbial Regulation of Neuro-immune Signaling ....................................................... 66 
Microbiota-Mediated Tryptophan Metabolism .............................................................. 67 
Microbial Control of Neuroendocrine Function ............................................................ 68 
Microbial Neuro-metabolite Production ........................................................................ 69 
Microbial Short-Chain Fatty Acid Production and Brain Function ............................. 70 
Microbes, Neurotransmitters & Neurophysiology ........................................................ 71 
THE MICROBIOTA IN BRAIN-GUT AXIS AND PSYCHIATRIC DISORDERS ....................... 72 
Irritable bowel syndrome (IBS): The prototypical brain-gut axis disorder .................... 72 
Microbes, Mood & Anxiety ........................................................................................... 73 
Microbiota, Social Behaviour and Autism ..................................................................... 76 
The Gut Microbiota and Age-related Cognitive Decline ............................................... 78 
MICROBIOTA-TARGETED FUNCTIONAL FOODS FOR BRAIN HEALTH ........................... 79 
Prebiotics and Probiotics ................................................................................................ 79 
Polyphenols .................................................................................................................... 82 
Omega-3 Polyunsaturated Fatty Acids ......................................................................... 85 
OTHER DIETARY FACTORS THAT MAY IMPACT BRAIN AND BEHAVIOUR BY 
MODULATING THE GUT MICROBIOTA ............................................................................ 89 
FUTURE TRENDS & CONCLUSIONS .................................................................................. 90 
REFERENCES ...................................................................................................................... 93 
CHAPTER 3 ....................................................................................................................... 105 
INFLUENCE OF C-SECTION BIRTH MODE AND ANTIBIOTIC EXPOSURE 
ON THE INFANT GUT .................................................................................................. 105 
ABSTRACT ........................................................................................................................ 106 
INTRODUCTION ............................................................................................................... 107 
MATERIALS AND METHODS ........................................................................................... 109 
Participants and sample collection .............................................................................. 109 
Culture-Dependent Analysis ....................................................................................... 109 
DNA Extraction .......................................................................................................... 110 
16S Compositional Sequencing ................................................................................... 111 
Microbiome Statistical Analysis .................................................................................. 112 
Bioinformatic Analysis ................................................................................................ 113 
RESULTS ........................................................................................................................... 114 
Culture Dependent Analysis ....................................................................................... 114 
16S Compositional Sequencing ................................................................................... 115 
Statistically significant taxa across taxonomic levels and timepoints ......................... 121 
DISCUSSION ..................................................................................................................... 137 
REFERENCES .................................................................................................................... 144 
CHAPTER 4 ....................................................................................................................... 148 
BIRTH BY CAESAREAN SECTION HAS LONG-TERM PSYCHOLOGICAL 
CONSEQUENCES ........................................................................................................... 148 
ABSTRACT ........................................................................................................................ 149 
INTRODUCTION ............................................................................................................... 150 
MATERIALS AND METHODS ........................................................................................... 152 
Participants and Sample Collection ............................................................................. 152 
Culture-Dependent Analysis ....................................................................................... 155 
Faecal Water Preparation ............................................................................................ 155 
DNA Extraction .......................................................................................................... 156 
16S Compositional Sequencing ................................................................................... 157 
Metabolomics ............................................................................................................... 158 
Psychological Measures ............................................................................................... 160 
Statistical analyses for human data ............................................................................. 163 
Microbiome Statistical Analysis .................................................................................. 165 
Bioinformatic Analysis ................................................................................................ 166 
RESULTS ........................................................................................................................... 167 
Culture Dependent Analysis ....................................................................................... 167 
16S Compositional Sequencing ................................................................................... 168 
Metabolomics ............................................................................................................... 172 
Psychological Measures ............................................................................................... 179 
DISCUSSION ..................................................................................................................... 186 
REFERENCES .................................................................................................................... 190 
CHAPTER 5 ....................................................................................................................... 192 
A PLACEBO-CONTROLLED INTERVENTION STUDY OF 
BIFIDOBACTERIUM LONGUM 1714™ IN EXAM STRESS ................................. 192 
ABSTRACT ........................................................................................................................ 193 
INTRODUCTION ............................................................................................................... 194 
MATERIALS AND METHODS ........................................................................................... 196 
Participants and Sample Collection ............................................................................. 196 
Culture-Dependent Analysis ....................................................................................... 199 
DNA Extraction .......................................................................................................... 199 
16S Compositional Sequencing ................................................................................... 200 
Microbiome Statistical Analysis .................................................................................. 202 
Bioinformatic Analysis ................................................................................................ 202 
Psychological Measures ............................................................................................... 203 
RESULTS ........................................................................................................................... 205 
Participant metadata .................................................................................................... 205 
Pittsburgh Sleep Quality Index (PSQI) ...................................................................... 206 
Perceived Stress Scale .................................................................................................. 206 
Beck’s Depression Inventory (BDI-II) ......................................................................... 206 
Cortisol awakening response (CAR) ............................................................................ 206 
Microbiome Results ..................................................................................................... 209 
DISCUSSION ..................................................................................................................... 216 
REFERENCES .................................................................................................................... 222 
CHAPTER 6 ....................................................................................................................... 225 
REVISITING METCHNIKOFF: AGE-RELATED ALTERATIONS IN 
MICROBIOTA-GUT-BRAIN AXIS IN THE MOUSE .............................................. 225 
ABSTRACT ........................................................................................................................ 226 
INTRODUCTION ............................................................................................................... 227 
MATERIALS AND METHODS ........................................................................................... 230 
Animals ........................................................................................................................ 230 
Behavioural testing ...................................................................................................... 230 
Caecal microbiota analysis ........................................................................................... 236 
RESULTS ........................................................................................................................... 240 
Aged mice do not differ in spontaneous alternation behaviour, but exhibit impaired 
displaced object recognition. ........................................................................................ 240 
Aged mice exhibit behaviours associated with anxiety but not depression. ................. 240 
Aged mice exhibit behaviours associated with reduced social recognition and/or 
preference for social novelty. ........................................................................................ 242 
Aged mice exhibit increased basal gut permeability, which is further exacerbated by 
acute stress exposure. ................................................................................................... 242 
Aged mice exhibit alterations in corticosterone response to acute stress exposure. ..... 243 
Circulating plasma cytokines are elevated in aged mice and correlate with gut FITC-D 
permeability ................................................................................................................. 244 
The caecal microbiota of mice is significantly altered with ageing .............................. 247 
The relative abundance of Porphyromonadaceae correlates with anxiety-like behaviour 
in aged mice ................................................................................................................. 250 
DISCUSSION ..................................................................................................................... 252 
REFERENCES .................................................................................................................... 259 
CHAPTER 7 ....................................................................................................................... 266 
GENERAL DISCUSSION AND CONCLUSIONS .................................................... 266 
GENERAL DISCUSSION AND CONCLUSIONS ................................................................. 267 





I hereby certify that this material, which I now submit for assessment on the programme of 
study leading to the award of PhD, is entirely my own work (except as declared, hereafter), 










Kennedy, P.J., Murphy, A.B., Cryan, J.F., Ross, P.R., Dinan, T.G. and Stanton, C., 2016. 
Microbiome in brain function and mental health. Trends in Food Science & 
Technology, 57, pp.289-301. 
 
Scientific Articles 
Scott, K.A., Ida, M., Peterson, V.L., Prenderville, J.A., Moloney, G.M., Izumo, T., 
Murphy, K., Murphy, A., Ross, R.P., Stanton, C. and Dinan, T.G., 2017. Revisiting 
Metchnikoff: Age-related alterations in microbiota-gut-brain axis in the mouse. Brain, 
Behavior, and Immunity. 
 
Crowley, E., Long-Smith, C., Murphy, A., Patterson, E., Murphy, K., O’Gorman, D.,... 
& Nolan, Y. (2018). Dietary supplementation with a magnesium-rich marine mineral 
blend enhances the diversity of gastrointestinal microbiota. Marine drugs, 16 (6), 216. 
 
Moloney, G., Long-Smith, C. M., Murphy, A., Dorland, D., Hojabri, S. F., Ramirez, L. 
O.,... & Fouhy, F. (2020). Improvements in Sleep Indices During exam stress due to 
Consumption of a Bifidobacterium Longum. Brain, Behavior, & Immunity-Health, 
100174. 
 
Bastiaanssen, T.F., Gururajan, A., van de Wouw, M., Moloney, G.M., Ritz, N.L., Long-
Smith, C.M., Wiley, N.C., Murphy, A.B., Lyte, J.M., Fouhy, F. and Stanton, C., 2021. 
Volatility as a concept to understand the impact of stress on the 
microbiome. Psychoneuroendocrinology, 124, p.105047. 
 
Schellekens, Harriët, et al. "Bifidobacterium longum counters the effects of obesity: 




Chapter 5: Probiotics as curators of a healthy gut microbiota. Murphy, A.B., Dinan, T.G., 
Cryan, J.F., Stanton, C. and Ross, R.P in Hyland, N. and Stanton, C. eds., 2016. The 




Poster presentation at FEMS 2017, Valencia 






The gut microbiota plays a significant role in health and development from 
birth and continues to affect several processes throughout life. The infant gut is 
unstable, and colonisation is influenced by a variety of factors. Many of these factors 
can contribute to an altered microbiota profile in infancy which can subsequently be 
associated with negative consequences later in life, due to interactions between the 
microbiota and the brain. The microbiota-gut-brain axis is a bi-directional 
communication network, which allows the microbiota to affect and influence a variety 
of psychological processes including mood and cognition. There is evidence to support 
the co-maturation of the infant brain with the early gut microbiota, and alterations in 
this parallel sequential maturation have been associated with long-term effects on 
brain signalling, immune, and metabolic function and mental health. 
While many aspects of the microbiota-gut-brain axis are not covered in this 
thesis, an examination of participants from infancy to adulthood and a study of aged 
mice provides an insight into these populations. This thesis explores many of the early 
factors which contribute to gut microbiota disturbances and investigates the long-term 
consequences associated with these early microbiota maturation disruptions. 
Following on from this, a potential strategy to positively influence gut and brain health 
is considered. In Chapter 1, the use of probiotics and prebiotics as modulators of gut 
health are discussed, including methods of use, and previous investigations. Chapter 
2 examines the microbiota-gut brain axis and details specific mechanisms involved in 
signalling pathways between the gut and the central nervous system (CNS). 
Chapter 3 focuses on the gut microbiota composition of infants up to 24 weeks 
old who have been delivered by C-section and have received antibiotic treatment in 
the first four days of life. This observational study explores the immediate 
 
 
consequences of these perinatal factors on the gut microbiota colonisation pattern, 
showing significantly different microbiota profiles between infants born vaginally, 
those born by C-section, and those who were also born by C-section and were treated 
with antibiotics. In Chapter 4, the long-term consequences of mode of delivery are 
examined. The gut microbiota composition of a cohort of 18-24-year-old males who 
were born by C-section is analysed and compared with those who were born vaginally. 
This investigation shows the significance of an altered microbiota during infancy on 
immune-brain signalling processes, as participants who were born by C-section 
exhibit increased vulnerability to psychological stress and anxiety. 
Chapter 5 investigates the effects of a potential psychobiotic, Bifidobacterium 
longum 1714™, on stress, mood, and cognition in a healthy population. No differences 
are noted in gut microbiota profile, mood, or cognition in response to the intervention. 
However, a statistically significant difference is seen in sleep quality in participants 
consuming the strain, suggesting that this microbe may be beneficial to maintain sleep 
quality during periods of stress. 
In Chapter 6, the caecal microbiota composition of aged (20-21 months old) 
and young mice (2-3 months old) was examined. The behavioural and psychological 
profiles of these mice were also assessed, as well as gut permeability and 
inflammation. It was found that older mice showed increased anxiety-like behaviours 
and reduced memory capabilities when compared to young mice. Additionally, the 
caecal microbiota profile differed between the two groups in terms of composition and 
gut permeability. This suggest that caecal microbiota changes seen in the aged mice 
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In recent years, the influence of the gut microbiota on many aspects of human 
health has become clear. Accumulating evidence suggests that perturbations of the gut 
microbiota have consequences that extend beyond the gastrointestinal (GI) tract and 
have been associated with the development of several immunological, metabolic, and 
mental disorders. Consequently, the use of probiotics to modulate the gut microbiota 
has gained significant interest. In this review, we describe a typical healthy gut 
microbiota composition in both infants and adults, followed by the factors known to 
cause disturbances. Strategies to restore the gut microbiota using probiotics are 
discussed, with examples of food- and non-food based probiotic carriers, in addition 
to probiotic bacteria which affect brain function and mental health. The potential of 
probiotic therapy for a variety of conditions is evident however, further research is 
necessary to develop successful probiotic treatments focused on modulating the gut 






The gut microbiota plays a vital role in human health and are essential for key 
processes such as nutrition, metabolism, and pathogen resistance (Lozupone et al., 
2012). Significant advances in sequencing technologies have increased our 
understanding and appreciation of the complexity of the gut microbiota and the 
importance of a healthy gut ecosystem. Large-scale projects (Human Microbiome 
Project Consortium, 2012) have made significant progress in the characterisation of 
microbial communities in the gut that are crucial to human health. Defining the 
features of a healthy gut microbiota is essential to identify and examine the key 
alterations which can lead to disease. 
The dominant influence of the gut microbiota in host physiology is becoming 
evident and thus, disruptions in the normal gut microbiota composition and function 
can have significant consequences for affected individuals. Microbiota disturbances 
are associated with an increased risk of disease development both in infants and adults 
(Lozupone et al., 2012). Moreover, a role for the gut microbiota in the regulation of 
several processes relating to brain function and mental health has emerged. Gut-brain 
interaction has emerged as an area of considerable investigation, with a multitude of 
preclinical studies suggesting that alterations in the gut-brain axis are involved in the 
development of several GI and psychiatric disorders such as irritable bowel syndrome 
(IBS), anxiety and depression (Mayer et al., 2015). 
Given the prominent role of the gut microbiota in several functions that are 
essential to the maintenance of human health, modulation of the gut microbiota using 
functional food-based approaches is a rapidly growing area of research. Evidence from 
epidemiological and animal studies suggests a role for probiotics in the restoration of 




probiotics have also been used as potential therapies for psychiatric disorders, with 
some promising initial results. 
In this review, we describe the development of a healthy gut microbiota from 
infancy to adulthood, followed by the range of factors known to disrupt the 
composition in both infants and adults including mode of delivery, antibiotic 
treatment, diet, stress, and infection. We then examine the use of probiotics as a 
possible therapeutic strategy for the reversal of gut microbiota alterations and 
subsequently, the beneficial effects of probiotics on human health. Strategies for 
effective delivery of probiotics are discussed, with examples of food- and non-food 
based probiotic carriers. Finally, we describe preclinical and clinical studies where 
probiotics have been found to positively affect brain function and mental health. 
 
Gut Microbiota Composition in Infants and Adults 
The concept of a “placental microbiome” was previously proposed with studies 
reporting that the placenta contains non-pathogenic commensal bacteria with a similar 
profile to that of an oral microbiome (Aagaard et al., 2014). However, recent robust 
studies investigating this have shown that there is not enough evidence to support this 
(Kauperman et al., 2019; Gschwind et al., 2020; Olomu et al., 2020). At birth the infant 
gut is rapidly colonised by either maternal faecal and vaginal bacteria or microbes 
from the hospital environment depending on the mode of delivery (Ferretti et al., 
2018). Initial colonisers of standard vaginally delivered (SVD) infants such as 
Enterobacteriaceae, Staphylococcus and Streptococcus consume oxygen in the gut 
which prepares the environment for the establishment of strict anaerobes such as 
Bifidobacterium and Bacteroides (Adlerberth & Wold, 2009; Penders et al., 2006). 




compositional changes until approximately 2 years of age when the microbial 
community is similar to that of an adult (Sekirov et al., 2010). 
Defining a healthy adult gut microbiota is vital to illustrate the compositional 
differences associated with disease (Lozupone et al., 2012). In recent years, due to 
substantial improvements in sequencing technologies, it has become clear that four 
main phyla (Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria) dominate 
the healthy adult gut microbiota with members from the Firmicutes and Bacteroidetes 
phyla being most abundant (Eckburg et al., 2005; Qin et al., 2010; Turnbaugh et al., 
2009). Although these four phyla make up a healthy phylogenetic core in adults, there 
is considerable inter-individual diversity at lower taxonomic levels with some studies 
suggesting that at species or strain level, the gut microbiota profile is highly unique 
and person-specific (Eckburg et al., 2005; Turnbaugh et al., 2010). It has been 
suggested that three enterotypes or core bacterial clusters exist based on the dominance 
of a particular genus - Bacteroides, Prevotella or Ruminococcus (Arumugam et al., 
2011). However, this concept has been debated previously with suggestions that this 
approach may be an oversimplification of the gut microbiota composition (Jeffery et 
al., 2012). This is supported by a study in which Knights and colleagues reported that 
over the course of a year, a healthy individual's microbiota profile can fluctuate 
between clusters and is not restricted to a single enterotype (Knights et al., 2014). 
Alternatively, it has been proposed that rather than discrete groups or clusters, the gut 
microbiota composition is dynamic and should be viewed as a continuous gradient 
(Jeffery et al., 2012). It has been shown that some bacterial groups are bi-modally 
distributed; either being highly prevalent or nearly absent (Lahti et al., 2014). It was 
reported that these contrasting states are stable while intermediate abundance appears 




influenced by many host and environmental factors. Additionally, it has been stated 
that a combination of both diversity and functionality are necessary to maintain a 
stable microbiota. 
Given that the microbiome (the gene pool of the microbiota) is highly 
conserved among individuals (Qin et al., 2010; Turnbaugh et al., 2009), the concept 
of functional redundancy has been suggested whereby essential processes may be 
carried out by several taxa (Jalanka-Tuovinen et al., 2011). Furthermore, it has been 
proposed that there are key species which may contribute considerably to the 






Factors Disrupting the Gut Microbiota 
It is well established that colonisation of the infant gut at birth influences 
normal development (Mueller et al., 2015). While caesarean-section (CS) delivery 
rates have increased rapidly over the last decade (Roberts et al., 2012), it has become 
apparent that CS delivery can greatly affect the infant gut colonisation pattern and can 
result in negative consequences for the infant. When compared with standard vaginally 
delivered (SVD) new-borns, infants born by CS are colonised with less beneficial 
microbes including lower numbers of Bifidobacterium and Bacteroides and higher 
numbers of potentially detrimental bacterial species such as Clostridium difficile 
(Biasucci et al., 2010; Penders et al., 2006). This disruption of maternal bacterial 
transmission in CS delivered infants was illustrated in a study which showed that in 
SVD infants, 72% of the initial bacterial species colonising the gut match species from 
the mother while only 41% of the maternal bacterial species are found in CS infants 
(Bäckhed et al., 2015). It has been suggested that these initial microbial alterations can 
persist for months (Bäckhed et al., 2015) or years after delivery (Jakobsson et al., 
2014). 
In addition, these colonisation disturbances at birth are associated with an 
increased risk of developing several disorders later in life such as inflammatory bowel 
disease, asthma, obesity, and type I diabetes (Hyde & Modi, 2012; Moore et al., 2019). 
Epidemiological studies have also suggested that that CS delivery may negatively 
affect normal CNS development (Juárez et al., 2008). It has been proposed that this 
influence is dependent on alterations in gut-brain signalling during critical 
neurodevelopmental time-windows (Borre et al., 2014). Given that microbiota 




of developing mental and immune related disorders, it is of relevance to investigate 
the use of early microbiota-targeted interventions to reduce later risk. 
Antibiotic use is widespread with almost 50% of adults and 70% of children 
receiving antibiotics each year (Morgun et al., 2015). Antibiotic use in infancy can 
considerably disrupt the gut microbiota colonisation pattern and has been linked to 
childhood asthma and obesity (Murphy et al., 2014; Penders et al.,2011). Furthermore, 
short term treatment with antibiotics after birth has been shown to reduce bacterial 
diversity and has been associated with a significant reduction in Bifidobacterium spp. 
(Hussey et al., 2010; Savino et al., 2011) accompanied by increased levels of 
Proteobacteria (Fouhy et al., 2012). These initial disruptions can result in prolonged 
consequences and the altered microbiota composition can persist for at least 1 year 
after perinatal antibiotic exposure (Persaud et al., 2014). The adult gut microbiota is 
also susceptible to the effects of antibiotic use with some reports suggesting that the 
post-antibiotic compositional shift may take years to return to pre-treatment state, and 
in some cases, may never fully recover (Dethlefsen & Relman, 2011; Jakobsson et al., 
2010; Jernberg et al., 2007). It has also been reported that intestinal disturbances due 
to antimicrobials can influence behaviour and brain chemistry (Bercik et al., 2011; 
Desbonnet et al., 2015). Indeed, antibiotics have been used positively to treat 
schizophrenia and depression. For example, Ghanizadeh and colleagues reported that 
using minocycline, which acts on both gram positive and negative bacteria, as an 
adjuvant treatment with risperidone yielded positive results when administered to 
schizophrenia patients, compared with placebo (Ghanizadeh et al., 2014). 
Diet is a key factor affecting the colonisation and diversity of the human gut 
microbiota. From birth, the effects of diet can be seen between infants who are 




Human breast milk contains a variety of lipids, proteins and an abundance of human 
milk oligosaccharides (HMOs) (Subramanian et al., 2015) which promote the growth 
of Bifidobacterium spp. and have been associated with many beneficial effects on 
health including enhanced intestinal barrier function (Weng et al., 2014) and improved 
response to vaccinations (Huda et al., 2014). Bacterial diversity and stability have been 
shown to differ between breastfed and formula fed infants, with breast fed infants 
having a lower overall bacterial diversity (Azad et al., 2013) but a more stable and 
uniform bacterial community (Bezirtzoglou et al., 2011). Formula feeding, on the 
other hand leads to increased levels of Verrucomicrobiaceae and C. difficile (Azad et 
al., 2013). It has been stated that once breastfeeding concludes and solid food is 
introduced, the microbial community dominated by Lactobacillus, Bifidobacterium 
and Enterobactericeae becomes colonised by Clostridium spp. and Bacteroides spp. 
(Bergström et al., 2014; Fallani et al., 2011). Several studies have shown strong links 
between adult diet and microbial diversity in the gut (Doré & Blottière, 2015). A diet 
rich in animal proteins and fat is associated with high levels of Bacteroides while 
individuals consuming a diet high in fibre, fruit and vegetables, and low in meat and 
dairy are dominated by Prevotella (Wu et al., 2011). Diet and gut microbiota 
composition have also been linked in older adults. Claesson and colleagues reported 
that elderly individuals in long-term residential care (who had a less diverse, high fat, 
low fibre diet) had higher levels of Bacteroidetes, while those individuals living in the 
community (low fat, high fibre diet) had higher proportions of Firmicutes (Claesson 
et al., 2012). Preclinical studies investigating a link between diet and depression-like 
symptoms in mice have shown that a diet high in saturated fat impacts on behaviour 
and immune function (Jørgensen et al., 2014). Furthermore, it has been shown that 




inflammation and decreases in cortical brain-derived neurotrophic factor (BDNF) 
(Pistell et al., 2010). 
It is well known that geographical location can affect the gut microbiota 
composition in both infants and adults. De Filippo and colleagues reported that 
children consuming a high fibre diet in Burkina Faso have increased levels of 
Prevotella and Xylanibacter accompanied by a reduction in Firmicutes when 
compared with children from Italy (De Filippo et al., 2010). This finding is consistent 
with many of the other studies comparing the gut microbiota of westernised and non-
westernised individuals. Consumption of a Western diet is characterised by the 
presence of Faecalibacterium, Bacteroides, Ruminococcus and Bifidobacterium while 
individuals consuming non-Western diets are dominated by Prevotella (Martínez et 
al., 2015). It has been argued that dietary habits are not entirely responsible for the 
differences found between the gut microbiota composition in Western societies and 
non-industrialised societies but that the variation is also influenced by modern lifestyle 
and cultural background (Martínez et al., 2015). However, the substantial influence of 
diet can be seen in a study comparing the gut microbiota of a hunter-gatherer 
community in northwest Tanzania to European individuals (Schnorr et al., 2014). The 
diet of the Hazda people is largely plant based which is evident in the composition of 
their gut microbiota; increased levels of Prevotella and Treponema. Furthermore, 
individuals in this region lack Bifidobacterium spp. in the gut bacterial community 
which is reflective of the absence of dairy and meat products in the diet (Schnorr et 
al., 2014). Geographical location appears to significantly affect the gut microbiota 
composition; however, the large proportion of this variation that can be attributed to 




Stress can have a substantial effect on the gut microbiota composition (Cryan 
& Dinan, 2012). This is particularly evident in studies investigating the effects of 
prenatal stress and early life stress. Maternal stress during pregnancy has been shown 
to disrupt the gut microbiota in offspring and is also associated with a higher 
prevalence of neurodevelopmental disorders (Golubeva et al., 2015; Jašarević, 
Rodgers, & Bale, 2015). Early maternal separation can also result in a variety of 
behavioural and physiological alterations, accompanied by gut microbiota 
disturbances (O'Mahony et al., 2009). Additionally, chronic stress in adulthood has 
been associated with altered microbiota composition characterised by a decrease in 
Bacteroides spp. accompanied by an increase in Clostridium spp. (Cryan & Dinan, 
2012). 
Accumulating evidence has indicated that maternal infection during pregnancy 
is associated with brain and behavioural impairments in the offspring (Atladóttir et al., 
2010; Brown & Derkits, 2010). Preclinical investigations have reported that offspring 
of mice infected with influenza show significant alterations in the expression of genes 
associated with neurodevelopmental disorders, accompanied by brain atrophy in 
several regions and altered levels of neurochemicals including serotonin and taurine 
(Fatemi et al., 2008). In addition, clinical studies have also reported that maternal 
hospitalisation with infection during pregnancy is associated with a higher risk of 
autism spectrum disorder (ASD) development in children (Lee et al., 2015). Some 
studies have shown that this risk is elevated if the infection occurs in the first and 
second trimesters (Atladóttir et al., 2010), with others reporting that timing did not 
influence the risk and that increased likelihood of ASD development in offspring is 
associated with infection at any time during gestation (Lee et al., 2015). Previously, it 




GI abnormalities accompanied by alterations in gut microbiota composition (Hsiao et 
al., 2013) indicating that in addition to influencing behaviour, maternal infection can 
also impact the gut microbiota. 
It is evident that a variety of factors can influence the gut microbiota of both 
the infant and adult and may contribute to alterations in brain function and behaviour. 
It is also of great importance to investigate new therapies such as those which may 
have the potential to reverse the gut microbiota disturbances, as well as prophylactic 
therapies which may help to prevent microbial alterations in the gut which can lead to 
disease. 
 
Prebiotics and Probiotics 
Potential Benefits of Prebiotics and Probiotics 
It has become apparent that many neurological and GI conditions are linked 
with gut bacterial disruptions (Clemente et al.,, 2012). Dietary habits can have a large 
influence on the gut microbiota composition. Consequently, modulation of the gut 
microbiota through functional foods containing such ingredients as prebiotics and 
probiotics may be a promising intervention strategy to alleviate symptoms associated 
with GI and mental conditions. 
 The definition of prebiotics as determined by the International Scientific 
Association for Probiotics and Prebiotics is “a substrate that is selectively utilised by 
host microorganisms conferring a health benefit” (Gibson et al., 2017). 
Prebiotics must be selectively utilised and have adequate evidence of health benefit. 
Prebiotics can act as substrates for probiotic bacteria in the gut such as Lactobacillus 




classified as a prebiotic, there are certain criteria which need to be met. Firstly, it must 
be resistant to gastric acid secretion and to hydrolysis by mammalian digestive 
enzymes, it must be absorbed in the upper GI tract and fermented by the gut 
microbiota, and it must stimulate the growth or activity of beneficial gut bacteria 
(Gibson et al., 2017). The most well-known prebiotics include galactooligosaccharides 
(GOS), fructooligosaccharides (FOS) and inulin (Al-Sheraji et al., 2013), and can be 
found naturally in a variety of foods including asparagus, garlic, tomato, and banana 
(Sangeetha et al., 2005). They can also be found in human breast milk as a substrate 
for Bifidobacterium (Morozov et al., 2018). 
Prebiotics exert many positive effects on human health through the stimulation 
of beneficial microbes including improving host immunity, gut barrier function, and 
SCFA production while reducing potentially pathogenic bacteria (Slavin, 2013). 
Prebiotics have been shown to stimulate the bifidogenic effects of human breast milk 
and reduce the incidence of allergies and infection in infants for up to 2 years 
(Arslanoglu et al., 2008; Boehm & Moro, 2008). In addition, prebiotic treatment in 
mice has been shown to alter the caecal microbiota composition with differences seen 
in over 100 taxa when compared to controls (Everard et al., 2011). Prebiotics can be 
used in combination with probiotics (synbiotic) to enhance the effects of a probiotic. 
This has been shown to be more effective at altering the gut microbiota composition 
than using a probiotic alone (Saulnier et al.,, 2008). 
Probiotics are live bacteria that can confer a beneficial effect on an individual 
when consumed in sufficient amounts (Butel, 2014). The most common probiotics are 
Lactobacillus spp. and Bifidobacterium spp. (Cammarota, Ianiro, Bibbò, & 
Gasbarrini, 2014). Probiotics exert a beneficial effect through several mechanisms 




compounds or direct competition for adhesive sites. Furthermore, they enhance 
epithelial barrier function and modulate immune responses (Power et al., 2014; El 
Aidy et al., 2015). 
Probiotics have been reported to have a variety of beneficial effects on humans. 
For example, Lactobacillus plantarum 299 v and Lactobacillus rhamnosus GG 
increase the production of intestinal mucins which prevent adherence to epithelial cells 
by pathogenic microbes (Mack et al.,1999). Lactobacillus GG, Bifidobacterium lactis 
Bb-12 and Saccharomyces boulardii have also been reported to enhance IgA 
production and secretion (Rautava et al.,, 2006; Rodrigues et al., 2000). As IgA 
maintains homeostasis in the mucosal barrier, increased secretion can protect the 
epithelium and defend against pathogens (Mantis et al.,2011). Other studies have 
shown the protective effects of probiotics against pathogenic strains including the 
production of bacteriocins (Rea et al., 2011), and the ability to increase production of 
human beta-defensins (Kabeerdoss et al., 2011). Probiotics should have "Generally 
Recognised As Safe" (GRAS) status (Nagpal et al., 2012), be stable during processing 
and drying, and be capable of withstanding conditions encountered in the GI tract 
(Iannitti & Palmieri, 2010). 
Delivery of Viable and Functional Probiotics 
For a probiotic to exert beneficial effects, it must be remain viable and reach 
the GI tract in adequate numbers (at least 106-107 CFU/g) (Bosnea et al., 2009). Thus, 
there are many challenges in the successful delivery of probiotics, as the fate of 
ingested probiotics needs to be considered. Probiotic strains ingested orally pass 
through the GI tract where they are subject to low pH levels in the stomach and high 




and lipase in the small intestine (Derrien & van Hylckama Vlieg, 2015). Survival in 
these harsh physiochemical conditions appears to be strain-specific with strains of B. 
animalis, L. casei, L. rhamnosus and L. plantarum proving to be most resilient 
(Derrien & van Hylckama Vlieg, 2015). 
An attractive solution to increase viability of probiotic cells in the GI tract is 
encapsulation (Frakolaki et al., 2021). Microencapsulation must protect the probiotic 
cells from chemical degradation and must produce capsules large enough to allow for 
a sufficient bacterial load to be delivered (McClements et al., 2009). Moreover, the 
microencapsulation method needs to allow for controlled release of the probiotic into 
the GI tract (Cook et al., 2012). Microencapsulation of probiotics is performed using 
three main methods: extrusion, emulsion and spray drying (Kailasapathy, 2002). A 
range of materials are used for microencapsulation including alginate, gellan gum, 
chitosan, starch, and milk proteins (Burgain et al., 2011). The process involves the 
production of microcapsules through the formation of a water-in-oil emulsion, 
stabilised by surfactants. Microencapsulation using extrusion is a physical technique 
which projects a solution containing the probiotic cells through a nozzle at high 
pressure, while spray drying involves dissolving the probiotic and polymer matrix and 
subsequently atomising in heated air (de Vos et al., 2010). Spray freeze drying is also 
used in combination with cryoprotectants which produces microcapsules by drying a 
frozen sample under vacuum (Cook et al., 2012). Encapsulation is used to protect cells 
from heat and moisture which is frequent during processing of food products for 
probiotic delivery (D'Orazio et al., 2015). 
The benefits of microencapsulation were highlighted in a study investigating 
the effects of this technique on the viability of several strains in conditions mimicking 




(D’Orazio et al., 2015). It was found that the non-encapsulated strains were destroyed 
on exposure to GI conditions as well as exposure to heat and osmotic stress. Chitosan-
coated alginate microcapsules were found to significantly enhance protection and 
probiotic viability. The benefits of microbial encapsulation were demonstrated in a 
study which investigated the survival of commercial probiotics (Millette et al., 2013). 
Twenty-nine commercially available probiotics in various forms (fermented milk; 
powder; capsules, and yogurt) were assessed for bacterial viability in simulated gastric 
and intestinal fluids. It was found that probiotic capsules covered with an enteric 
coating had a higher rate of survival than uncoated forms. Only one fermented milk 
product and one probiotic powder showed high survival rates. 
It is evident that further research is needed on viability of commercial probiotic 
products as the majority of those examined were unable to survive conditions 
consistent with the GI tract and thus, may not exert beneficial effects on the consumer. 
In addition to survival in the gut, probiotic strains must also reach the area in the GI 
tract where they can benefit the host. The addition of specific excipients can allow the 
probiotic to be released in a controlled manner. The use of chitosan has been shown 
to retain bacterial strains in vitro for over 2 hours in stimulated gastric and intestinal 
juices before release (Cook et al., 2011). However, given the timing of passage through 
the GI tract, these capsules would only allow for probiotic release into the small 
intestine, whereas the target area for various conditions is the large intestine (Cook et 
al., 2012). However, a study by Lin and colleagues described the use of alginate 
microcapsules coated with chitosan followed by a second coat of alginate and reported 
that these capsules were stable and remained intact in the GI tract of rats for 6 hours 




gum and carrageenan are very effective at enhancing probiotic survival (Ding & Shah, 
2009). 
Non-Food Based Probiotic Delivery 
Probiotic products are currently available in a variety of non-food based forms 
including chewing gum, lozenges, sachets and capsules (Klayraung et al., 2009). 
Tablet based delivery systems have several benefits, including accurate dosage 
administration and targeted delivery to the site of action (e Silva et al., 2013). In 
addition, they are very stable during storage and easy to administer (Vorländer et al., 
2020). A disadvantage of tablets, however, is the level of heat produced during 
compression, with temperatures reaching up to 60°C, which can be detrimental to the 
survival of many bacterial strains (Roueche et al.,, 2006). Several attempts have been 
made to prevent this damage using a variety of tablet excipients. Tablets have been 
shown to act as good carriers for probiotics (Mirzaeei et al., 2017). Several functional 
polymer compositions have been investigated for probiotic viability in simulated GI 
conditions. For example, a hydrophilic tablet was proposed containing carboxy-
methyl high amylose starch (CM-HAS) and chitosan for the delivery of L. rhamnosus 
(Calinescu & Mateescu, 2008). It was found that alterations in the molecular weight 
and percentage of chitosan used affected the timing of bacterial release in simulated 
GI conditions and improved the percentage of bacteria delivered. This suggests that 
this formulation may have potential as a carrier for probiotics intended for colonic 
release. Klayraung and colleagues investigated the use of tablets as delivery systems 
for freeze-dried L. fermentum 2311 (Klayraung et al., 2009). It was found that tablets 
containing hydroxypropyl methylcellulose phthalate (HPMCP) were successful for 
enhancing survival of the probiotic bacterial strain (80% viability). Incorporation of 




tablets were found to have a slow disintegration time (approx. 5 hours). A novel tablet 
excipient was proposed by Poulin and colleagues (Poulin et al.,, 2011). These tablets 
containing B. longum HA-135 were assessed in simulated gastric conditions and it was 
found that increased compression during tablet formation decreased bacterial viability, 
while compression at 67 MPa resulted in tablets containing 109 viable cells. Viability 
decreased rapidly for non-compressed freeze-dried cells during gastric incubation. 
This was also true for tablets composed of β-lactoglobulin which dissolved after 30 
minutes in gastric fluid. However, tablets were also prepared using succinylated β-
lactoglobulin at 50% and 100%, resulting in survival of 107 CFU/tablet, two hours 
following exposure to gastric conditions. It was also noted that the tablets were stable 
for three months at 4°C. Therefore, manufacturing tablets at 67 MPa appears to be a 
stable pressure to allow for tablet formation but also to reduce probiotic viability loss. 
Several other formulations have been examined as tablet based probiotic 
carriers (El Kadri et al., 2018) and have shown some promising results, including 
sodium alginate, hydroxypropylcellulose (Chan & Zhang, 2005), 
hydroxypropylmethylcellulose acetate succinate (Stadler & Viernstein, 2003), 
cellulose acetate phthalate in combination with sodium croscarmellose (e Silva et al., 
2013), and a bi-layered mini-tablet-in-tablet system containing ovalbumin, lactose and 
eudragit S100 (Govender et al., 2015). 
In addition to tablet carriers, there are a variety of well-known commercial 
probiotics available including Probio-Tec® probiotic strains available in a variety of 
dosage forms, BioGaia probiotic straws, chewable tablets and drops, Align (Proctor & 
Gamble); Florastor (Biocodex); Idoform/Bifiform (Ferrosan); Probiotica (McNeil 




Food Based Probiotic Delivery 
The demand for ‘functional foods’ which provide a health benefit to the 
consumer has gained popularity in previous years (Terpou et al., 2019)). In this 
respect, a variety of food products have been evaluated as delivery systems for 
probiotics (see Table 1). The dairy industry, in particular, has developed several 
probiotic carriers including fermented milks, yogurt, powdered infant milk, butter, 
cheese, mayonnaise and ice-cream (Cruz et al., 2009). Many factors need to be 
considered when developing functional food products harbouring viable probiotics, 
given that several aspects of food processing and storage can negatively affect the 
viability of probiotic strains. Factors including pH, the presence of salt, sugar and 
artificial flavourings, heat treatment and oxygen levels need to be taken into account 
(Tripathi & Giri, 2014). In addition to the stability of the probiotic strain, the sensory 
aspects of the food product also need to be examined. As such a high number of 
probiotic cells are necessary to exert a beneficial effect, this can result in some 
unpleasant flavours in the food product, such as the undesirable flavours associated 
with acetic or lactic acids produced by Bifidobacterium. This may require the addition 
of extra ingredients to mask undesirable flavours (Granato et al., 2010). Some common 
food products and their effectiveness as probiotic carriers are discussed below. 
Yogurt 
Fermented milks and yogurts have been used for the delivery of several 
probiotic strains (Terpou et al., 2019). As yogurts are natural carriers of bacteria and 
have a high consumer acceptance, they can be considered a good food based probiotic 
carrier (Sanders & Marco, 2010). Several studies have examined the sensory impact 




was found to have the same appearance, flavour, texture, and overall quality as non-
probiotic yogurt (Hekmat & Reid, 2006). Similarly, probiotic Greek yogurt containing 
L. paracasei had a rich, smooth and traditional taste, and good acceptance among 
consumers (Maragkoudakis et al., 2006). However, it has been noted that there is a 
texture change in yogurt which has been modified with encapsulated probiotics 
(Fatima et al., 2020). Different types of yogurt have shown changes in probiotic 
viability levels; skimmed-set yogurt retains higher levels of viable probiotics than 
whole-set yogurt (Birollo et al., 2000). It has also been noted that plain yogurt sustains 
probiotic viability during storage better than fruit yogurts (Kailasapathy et al., 2008). 
This appears to be due to reductions in pH which occur after addition of fruit pulp (. 
Ranadheera et al., 2010). The addition of prebiotics such as inulin and 
fructooligosaccharides to yogurt products to create a synbiotic has also proven 
effective for probiotic viability enhancement (Capela et al., 2006). A study reported 
that probiotic yogurt containing L. rhamnosus GG, B. lactis Bb-12 and L. acidophilus 
La-5 was effective for the reduction of antibiotic-associated diarrhoea in children (Fox 
et al., 2015). 
Although yogurt appears to be an effective probiotic carrier, there are many 
challenges during processing which need to be taken into consideration. Dairy 
products such as yogurt have a low pH and it has been suggested that previous strain 
exposure to lower pH values is useful to allow for acid tolerance during processing 
(Granato et al., 2010; Sanz, 2007). In addition, care should be taken to prevent the 
introduction of oxygen during processing as several anaerobic strains may lose 
viability upon exposure (Ahn et al., 2001). It is also necessary to consider the 




Ice-cream and desserts 
Ice-cream as a potential probiotic carrier has been demonstrated to provide 
greater protection than milk and yogurt (Ranadheera et al., 2012). It is also highly 
consumer friendly and is attractive to children and adults (Cruz et al., 2009). Ice-cream 
has several properties which makes it an effective probiotic carrier including the 
presence of milk proteins, fat, and lactose, in addition to a relatively high pH (5.5-6.5) 
(Cruz et al., 2009). Several studies have demonstrated the potential of ice-cream as a 
delivery vector for probiotics. Two different ice-cream formulations containing L. 
acidophilus, L. agilis and L. rhamnosus and either sucrose or aspartame were stable 
for 6 months stored at -20°C (Başyiğit et al., 2006). It was also found that the probiotic 
strains were resistant to a variety of conditions including bile salts and antibiotics. Ice-
creams containing L. johnsonii La-1 with different fat and sugar amounts were found 
to retain high probiotic viability after 8 months of storage at -16°C and -28°C 
(Alamprese et al., 2005). L. acidophilus La-5 and B. animalis Bb-12 showed increased 
probiotic survival in ice-cream containing inulin and fructooligosaccharides (Akalın 
& Erişir, 2008). It was also noted that the prebiotic containing ice-cream was firmer 
and had less variation in melting properties compared with control product. 
 Several studies have examined the sensory properties of probiotic ice-cream 
and desserts. Ice-cream containing L. acidophilus and B. lactis was shown to have 
good overall sensory qualities and no “probiotic flavours” were detected (Akın et al., 
2007). Strawberry ice-cream supplemented with L. acidophilus was found to be 
acceptable with the addition of fruit improving the taste, suggesting that acidic fruit 
may be a useful additive to ensure masking of any unpleasant “probiotic flavours” 




paracasei and/or inulin was evaluated for sensory characteristics (Aragon-Alegro et 
al., 2007) and no significant differences were found between the probiotic, synbiotic 
and control mousse. However, upon sensory evaluation of each chocolate mousse, the 
probiotic mousse was preferred, followed by the synbiotic product. Sensory evaluation 
was performed on a probiotic coconut flan containing B. lactis and L. paracasei 
(Corrêa et al., 2008). While several sensory parameters, such as flavour and texture 
were found to be similar at 7, 14 and 21 days of storage, there was a tendency for 
preference of the probiotic flan over the control product. 
 Due to the high acceptance among testers and the probiotic viability noted 
during storage, ice-cream shows potential as a probiotic carrier. However, as with 
yogurt, many manufacturing and processing concerns need to be addressed. Most 
notable is the fact that oxygen incorporation is a key step in the manufacture of ice-
cream and is vital for texture properties of the final product and thus, cannot be 
avoided (Sofjan & Hartel, 2004). Therefore, it may be necessary to select oxygen 
tolerant probiotic strains or use encapsulated probiotics during manufacture. It has 
been reported that microencapsulation of L. casei and B. lactis in ice-cream increased 
the probiotic survival by 30% (Homayouni et al., 2008). However, the effect of 
microencapsulation on the sensory and texture properties of the ice-cream should be 
considered. 
Cheese 
Several cheese varieties have been successfully used as probiotic delivery 
systems, including Cheddar cheese, goat cheese, Crescenza cheese, cottage cheese and 
fresh cheese (Ross et al., 2002). Cheese has a relatively high pH when compared to 




during transit through the GI tract (Stanton et al., 1998). These properties provide a 
stable medium for the bacteria and may support long-term viability (Mushtaq et al., 
2019). A variety of studies have examined the potential of cheese as probiotic carrier. 
For example, survival of L. rhamnosus and L. acidophilus was shown to be enhanced 
in simulated GI conditions (using GI tract and colon simulator) when present in Gouda 
cheese (Mäkeläinen et al., 2009). Furthermore, the cheese appeared to increase the 
levels of Lactobacillus in the simulation and increased the concentrations of fatty acids 
produced. Cheddar cheese containing L. acidophilus, L. casei, L. paracasei and 
Bifidobacterium spp. was produced, and strains showed high viability during 
manufacturing (Ong et al., 2006). This was also seen in a study containing the same 
probiotic species in Cheddar cheese (Ganesan et al., 2014). Two L. salivarius strains 
were shown to remain viable in fresh cheese for up to 21 days and their presence did 
not modify cheese texture (Cárdenas et al., 2014). Addition of L. paracasei, B. bifidum 
and L. acidophilus did not impact negatively on sensory properties after storage for 15 
days at 5°C (Vinderola et al., 2009). This was noted in probiotic cheese supplemented 
with L. fermentum and L. plantarum with reports of similar flavour, texture, and 
appearance in both probiotic and control cheeses (Kılıç et al., 2009). Health benefits 
associated with the consumption of probiotic cheese include improvements in blood 
pressure, increased phagocytic activity and reduction of salivary yeast counts, based 
in clinical and animal studies (Lollo et al., 2015; Ouwehand et al., 2010). 
Beverages and other probiotic foods 
Many non-dairy and vegetarian foods have been used to deliver probiotics 
(Aspri et al., 2020; Min et al., 2019), including fruits (Lavermicocca et al., 2005), 




2004), as well as probiotic beverages, such as fruit and vegetable juices. It has been 
shown that several probiotic strains can tolerate the low pH environment of orange, 
pineapple and cranberry juices, surviving above 106 CFU/mL for at least 12 weeks 
(Sheehan et al., 2007). Carrot juice has been shown to promote the viability of B. 
bifidum and B. lactis for up to 24 hours (Kun et al., 2008). In addition, probiotics 
remain viable in tomato juice for up to 4 weeks at 4°C (Yoon et al., 2004). Although 
these juices may be potentially effective probiotic carriers, the sensory properties need 
to be examined, as strong or unpleasant flavours can result in a negative perception of 
probiotic juices (Granato et al., 2010). This was evident in a study by Luckow and 
Delahunty who reported that consumers were able to distinguish between orange juice 
containing probiotics and conventional orange juice and described the flavours as 
“medicinal”, “dairy” and “dirty” (Luckow & Delahunty, 2004). Sensory properties of 
whey beverages were enhanced following incorporation of probiotic B. longum and L. 
acidophilus, (Zoellner et al., 2009), while fermented goat milk containing probiotic L. 
acidophilus and B. bifidum were also found to be highly acceptable (Martın-Diana et 
al., 2003; Vinderola et al., 2000). 
 Several other foods have been examined as probiotic carriers including soy 
cheese, soy milk and table olives (Peres et al., 2012; Min et al., 2019). The use of table 
olives is an interesting choice as a serving of 10-15 olives can carry 109-1010 
Lactobacillus spp. which suggests that olives may be an effective probiotic delivery 
vector (Lavermicocca, 2006). The colonisation of the surface of olives was 
investigated using L. paracasei (De Bellis et al., 2010) and it was found to be 
successful. The addition of probiotics to vegetables provides an attractive option for 




other fruits have been investigated as probiotic delivery vectors including strawberry 
and apple (Pérez-Cobas et al., 2013). 
It is evident that both chemical composition and physical structure of the 
proposed food carrier are important parameters for probiotic viability. Moreover, 
slight changes in the fat and sugar composition can greatly impact bacterial survival 
(Ranadheera et al., 2010). In many of these food products, stability has been enhanced 
through the use of microencapsulation methods mentioned previously, with 
encapsulation proving to significantly enhance probiotic viability in comparison to 
free cells, during exposure to simulated gastric conditions and during storage (Capela 
et al., 2006; Dias et al., 2018; McMaster et al., 2005). However, further investigation 
is necessary to examine the sensory properties associated with encapsulated bacterial 


















Table 1: Food products investigated as potential probiotic carriers 
Carrier Products Probiotic Reference 
Dairy-based Yogurt L. casei 
L. acidophilus, L. casei, B. bifidum 
(Aryana & McGrew, 2007) 
(Sendra et al., 2008) 
Ice-cream L. casei, B. lactis 
L. johnsonii 
(Homayouni et al., 2008) 
(Alamprese et al., 2002) 
Chocolate L. helveticus, L acidophilus (Possemiers et al., 2010) 
Whey protein drink B. breve, B. infantis, B. lactis, L. plantarum, L. casei, Streptococcus 
thermophilus 
(Dalev et al., 2006) 
Cheddar cheese B. longum, B. lactis, L. casei, L. acidophilus (Ong & Shah, 2009) 
Feta cheese L. acidophilus, B. lactis (Kailasapathy & Masondole, 2005) 
Soy-based Soymilk L. acidophilus, L. gasseri 
L. plantarum 
 
(Ewe et al., 2010) 
(Bao et al., 2012) 
Soy cream cheese L. acidophilus (Liong et al., 2009) 
Fruit and vegetable based Carrot juice B. lactis Bb12, B. bifidum B7.1, B3.2 (Kun et al., 2008) 
Tomato, orange and grape juice L. plantarum, L. acidophilus 
L. casei A4, L. delbrueckii D7 
(Nagpal et al., 2012) 
(Yoon et al., 2004) 
Cabbage juice L. plantarum, L. acidophilus (Yoon et al., 2006) 
Banana puree L. acidophilus (Tsen et al., 2009) 
Blackcurrant juice L. plantarum 299 v (Luckow & Delahunty, 2004) 
Oat based Oat based drink L. plantarum B28 (Angelov et al., 2006) 
Malt based drink L. reuteri (Kedia et al., 2007) 




Gut Microbiota Modulation Using Probiotics and Prebiotics 
Infant Microbiota Modulation 
The use of probiotics during the perinatal period is an important area of 
investigation, due to the role of initial colonisation of the infant gut in health and 
disease prevention (Mueller et al., 2015). Disruption in the colonisation pattern of the 
infant microbiota during critical developmental windows can have long-lasting health 
consequences (Cox et al., 2014). As the gut microbiota in infancy is relatively simple 
and unstable, the use of probiotics could potentially have a large and long-lasting 
impact on the composition. 
The administration of probiotics during pregnancy is still a somewhat new 
concept with relatively few clinical trials conducted to date. Many studies have 
focused on pregnancy outcomes and associated conditions including pre-term 
delivery, gestational diabetes, gestational weight gain and preeclampsia (Arango et al., 
2015). Administration of Lactobacillus acidophilus LA-5, Bifidobacterium lactis 
Bb12 and Lactobacillus rhamnosus reduced the risk of atopic eczema in infants at 6 
months (Bertelsen et al., 2014), while L. rhamnosus GG administration alone was also 
shown to reduce the risk of atopic eczema in children up to 7 years old (Kalliomäki et 
al., 2007). Beneficial effects of probiotics have also been noted for the 
treatment/prevention of allergies, diarrhoea, and necrotizing enterocolitis in pre-term 
infants (Di Gioia et al., 2014). 
In a clinical trial, Bifidobacterium breve M-16 V and Bifidobacterium longum 
BB536 were given to pregnant mothers one month prior to delivery and to their infants 
for the first 6 months of life to assess the effects of a probiotic formulation on the 
prevention of allergic diseases (Enomoto et al., 2014). It was found that infants who 




proportions of Actinobacteria and higher proportions of Proteobacteria than those 
without symptoms. It was also noted that mothers given probiotics had a significantly 
lower abundance of Proteobacteria while infants in the probiotic group had higher 
levels of Bacteroidetes at 4 months of age. No differences in gut microbiota 
composition were seen between infants in the probiotic and placebo groups at 10 
months of age. Interestingly, the occurrence of AD tended to be lower in the infants 
given probiotics at 4 months of age and was significantly reduced in this group at both 
10 and 18 months. Several studies have indicated that children affected with allergic 
diseases have more Clostridium spp. accompanied by decreases in Bifidobacterium 
and Enterobacteriacae (Enomoto et al., 2014). Moreover, it is of interest to note that 
in this study, differences in microbial composition between AD symptomatic infants 
and healthy infants were apparent at 4 months but not at 10 months, suggesting that 
the early microbiota plays an important role in atopic dermatitis and related conditions. 
The gut microbiota modifications reported here suggest a role for Bifidobacterium 
breve M-16 V and Bifidobacterium longum BB536 during the perinatal period as a 
possible prophylactic treatment to reduce the risk of AD development. However, 
further analyses of the composition of the infant gut at lower taxonomic levels are 
necessary to examine the use of this probiotic formula as a possible intervention 
strategy. 
Other studies have shown that the use of L. rhamnosus GG in both infants and 
pregnant mothers can result in higher levels of Bifidobacterium, specifically B. longum 
and B. breve (Gueimonde et al., 2006; Lahtinen et al., 2009). As breast milk is the gold 
standard for early infant nutrition (Hassiotou et al., 2013), due to the range of health 
benefits provided for the developing infant, interventions with strains targeted to the 




Moreover, it has been proposed that strains isolated from human breast milk for use 
in infant formula may be more beneficial than probiotics isolated from infant 
microbiota or fermented foods (Chassard et al., 2014; Korpela et al., 2018, Li et al., 
2019). This may prove to be a promising avenue of investigation; however further 
clinical studies are necessary. 
 
Adult Microbiota Modulation 
Several clinical trials have examined the use of probiotics in adult cohorts to 
maintain health or alleviate disease (Lew et al., 2019; Bagga et al., 2018). A study by 
Zhang and colleagues investigated the use of the potential probiotic Lactobacillus 
casei Zhang which was isolated from fermented mare’s milk (Zhang et al., 2014). The 
probiotic was administered to adults in the form of chewable tablets over a 28-day 
period. Significant differences in the gut microbiota composition were observed 
during and after treatment with the probiotic. It was found that consumption of L. casei 
Zhang was associated with increases in Prevotella, Lactobacillus, Faecalibacterium, 
Propionibacterium and Bifidobacterium while Clostridium, Phascolarctobacterium, 
Serratia, Enterococcus, Shigella and Shewanella either decreased in abundance or 
were eliminated during the treatment period. Similar clinical studies have also 
indicated that Bifidobacterium lactis and L. casei Shirota can result in increases of 
Bifidobacterium (Matsumoto et al., 2006). Administration of probiotic biscuits 
containing L. helveticus Barl3 and B. longum Bar33 to elderly subjects reversed age-
related increases of opportunistic intestinal pathogens, such as Clostridium cluster XI, 
Clostridium difficile, Clostridium perfringens, Enterococcus faecium and 
Campylobacter (Rampelli et al., 2013). By reversing the increase of pathobionts in the 




maintain healthy gut function in elderly adults (Kim et al., 2021). The beneficial effect 
of probiotics on adults has been demonstrated in additional studies with reports 
concluding that four main probiotic treatments are effective for primary prevention of 
Clostridium difficile infection: Saccharomyces boulardii, L. casei DN1140011, a 
mixture of L. acidophilus and B. bifidum, and a mixture of L. acidophilus, L. casei and 
L. rhamnosus (McFarland, 2015). L. rhamnosus LC705, L. rhamnosus GG, 
Propionibacterium freundenreichii ssp. shermanii JS and B. animalis ssp. lactis Bb12 
have also proven to be effective for IBS, with reductions in distension and abdominal 
pain reported, accompanied by stabilisation of the gut microbiota (Kajander et al., 
2008). 
It is important to note that while the clinical trials discussed here are examples 
of positive effects on the gut microbiota, there are a substantial number of studies 
where similar probiotic strains have had little or no effect (Cryan et al., 2019). There 
are many factors to consider when drawing conclusions about the effects of certain 
probiotics used in clinical studies. Considerable variability exists with respect to the 
potential probiotic used and the dosage. Similarly, the delivery of probiotics varies 
between studies with several examples of food based delivery and more conventional 
delivery such as tablets or capsules (Govender et al., 2014). The duration of 
administration also needs to be taken into consideration, in addition to the health status 
of subjects in the study. In healthy individuals, probiotic-induced gut microbiota 
modulation has been reported in some studies, while in others no effects were 
apparent. This has been noted in studies where the treatment conditions and strain did 
not differ between participants which suggests that in some cases, the effect of 
probiotics may depend on a person’s own intestinal ecosystem before the intervention 





The Gut-Brain Axis and Probiotics 
It is widely recognised that the bi-directional communication network between 
the gastrointestinal tract and the brain is vital for maintaining health (Cryan & 
O’Mahony, 2011). Disruption of the gut-brain axis can have important physiological 
and psychological consequences and has been implicated in a variety of disorders 
including IBS, ASD, Parkinson’s disease, mood disorders and chronic pain (Mayer et 
al., 2015). Increasing evidence has accumulated supporting the view that the gut 
microbiota can substantially influence the brain and behaviour through the microbiota-
gut-brain axis (Heijtz et al., 2011). Consequently, several studies have examined the 
use of probiotics for brain related disorders including anxiety, autism and depression 
(Borre et al., 2014). This has led to the emergence of a new field of probiotics, termed 
“psychobiotics” (Dinan et al., 2013). A psychobiotic is defined as “a live organism 
that, when ingested in adequate amounts, produces a health benefit in patients 
suffering from psychiatric illness” (Dinan et al., 2013). 
 
Preclinical studies 
Given that certain bacteria can secrete neurochemicals such as gamma 
aminobutyric acid (GABA), serotonin, norepinephrine and dopamine which play an 
important role in brain function and behaviour, it has been proposed that these 
microbes may act as delivery vehicles for neuroactive compounds (Lyte, 2011). As 
dysfunction in neurotransmitter signalling has been associated with several 
neuropsychiatric conditions (Wall et al., 2014), the use of probiotic bacteria capable 
of producing these neuroactive metabolites is emerging as an attractive, novel 




the brain and disruptions in the GABAergic system have been linked to anxiety 
disorders and depression (Cryan & Kaupmann, 2005). 
A pivotal study by Bravo and colleagues showed that long-term administration 
of the probiotic L. rhamnosus JB-1 to healthy mice resulted in alterations in GABA 
receptor expression (Bravo et al., 2011). Treatment with L. rhamnosus JB-1 decreased 
expression of GABAB1b subunit mRNA in the amygdala, hippocampus and locus 
coeruleus while increased expression was noted in the cortical areas. Furthermore, 
reductions in GABAAα2 expression were seen in the prefrontal cortex and amygdala 
accompanied by increases in the hippocampus. In addition to the physiological 
changes, the treated animals also showed behavioural changes with reductions in 
anxiety-like and depressive-like behaviours (Bravo et al., 2011). These GABA 
receptors have been implicated in stress and anxiety and decreases in GABAB1b are 
consistent with the GABAB receptor antagonists which have anti-depressant effects 
(Cryan & Slattery, 2010). 
Serotonin is a metabolite of the essential amino acid tryptophan and plays a 
vital role in the regulation of several physiological functions (Kema et al., 2000). Low 
serotonin levels have been associated with depression and many currently available 
anti-depressant drugs result in increased concentrations in the brain (Wall et al., 2014). 
As serotonin synthesis is dependent on tryptophan availability, regulation of 
tryptophan has important implications. It has been shown that the probiotic 
Bifidobacterium infantis 35624 can increase plasma tryptophan levels in rats 
accompanied by elevated levels of kynurenic acid (Desbonnet et al., 2008). 
Interestingly, the kynureine pathway produces many neurotoxic metabolites including 
quinolinic acid (Orlando et al., 2001) but can also produce kynurenic acid which has 




authors proposed that the increased levels of plasma tryptophan accompanied by 
increases in kynurenic acid suggests that B. infantis 35624 can preferentially direct 
kynurenine to produce the neuroprotective kynurenic acid through an alternative 
pathway rather than neurotoxic metabolites (Desbonnet et al., 2008). As there is 
growing attention in the kynurenic pathway in relation to psychiatric conditions 
(O’Mahony et al., 2015), information on the potential anti-depressant effects of B. 
infantis 35624 is of great importance. 
A subsequent study using this bacterial strain was carried out by Desbonnet 
and colleagues in a maternal separation (MS) model of depression (Desbonnet et al., 
2010). Mice were maternally separated and treated with either B. infantis 35624 or a 
commonly prescribed anti-depressant, citalopram hydrobromide. Maternal separation 
was seen to induce behaviours indicative of a state of behavioural despair. In addition 
to these behavioural changes, biochemical changes were also apparent including 
decreases in noradrenaline (NA) in the brain, elevations in corticotrophin-releasing 
factor (CRF) expression in the amygdaloid cortex and enhanced IL-6 release following 
immune stimulation. MS mice treated with the probiotic showed restoration of NA 
concentrations in the brain but to a lesser extent than the group treated with the anti-
depressant. This probiotic was also seen to reverse the behavioural abnormalities 
associated with MS and normalise the exaggerated IL-6 response. As these 
physiological changes seen in MS animals are consistent with stress and depression 
(Pace et al., 2006; Wong et al., 2000), further investigation into the use of B. infantis 
as a treatment option for mood disorders is necessary. 
Savignac and colleagues investigated the potential of two Bifidobacterium 
strains, B. longum 1714 and B. breve 1205 on behaviour and physiology in BALB/c 




longum 1714, B. breve 1205, escitalopram or vehicle and subjected to a variety of tests 
relating to depression, anxiety and stress. B. longum 1714 was seen to reduce stress, 
anxiety, and depressive behaviours while B. breve 1205 reduced general anxiety 
behaviours and induced weight loss. It was also noted that both strains reduced 
anxiety-like behaviours to a greater extent than the anti-depressant, escitalopram. This 
finding is of great importance and may hold potential for patients who are resistant to 
currently available anti-depressant treatment (Savignac et al., 2014). Furthermore, it 
was also shown that this B. longum strain can also improve cognition in BALB/c mice 
(Savignac et al., 2015). This reinforces the view that the effects of commensal bacteria 
are highly strain-specific and thus the effects of a particular strain cannot be 
extrapolated from one probiotic species to another. 
It is widely established that there is a high co-morbidity between psychiatric 
conditions such as anxiety and depression and gastrointestinal disorders such as 
irritable bowel syndrome and inflammatory bowel disorder (Kennedy et al., 2012; 
Walker et al., 2008). Co-occurring anxiety-like behaviour was investigated in a study 
by Bercik and colleagues (Bercik et al., 2011). Chronic colitis was induced in adult 
male mice using low dose dextran sodium sulphate (DSS) and the effects of a 
probiotics B. longum NCC3001 were examined. Colitis was shown to induce anxiety 
in the animals, as expected. The administration of the probiotic not only reversed the 
anxiety-like behaviour but also increased exploratory behaviour when compared with 
control mice. It was also demonstrated that the effect of B. longum is mediated by the 
vagus nerve. This is consistent with several other preclinical studies which have shown 
that vagal nerve integrity is important in mediating microbiota-brain interactions (de 




Several additional preclinical studies have demonstrated the positive effects of 
probiotics on mood and behaviour. For example, combination of L. helveticus R0052 
and B. longum R0175 has been shown to positively affect post-mycocardial infarction 
(MI) behavioural symptoms in rats (symptoms which are consistent with depression 
in humans) and can restore intestinal barrier integrity in MI rats (Arseneault-Bréard et 
al., 2012). Positive effects on stress have also been noted in animal models after 
administration with L. farciminis (Ait-Belgnaoui et al., 2012), L. helveticus (Ohland 
et al., 2013) and a combination of L. helveticus and B. longum (Ait‐Belgnaoui et al., 
2014). Taken together, these studies provide compelling evidence for the possible use 
of psychobiotics for the treatment of brain related disorders. However, it is important 
to note that many underlying gut-to-brain signalling mechanisms remain unclear and 
caution is necessary when applying these findings to clinical populations. 
 
Clinical studies 
In contrast to the substantial literature investigating the use of psychobiotics in 
animal studies, clinical validation of the above findings is scarce. Examples of some 
clinical studies which have shown positive results are discussed. In a double-blind, 
placebo-controlled, randomised study by Diop and colleagues, the effects of a 
probiotic combination of Lactobacillus helveticus R0052 and B. longum R0175 on 
stress-induced gastrointestinal and psychological symptoms in healthy volunteers 
were investigated (Diop et al., 2008). Volunteers were eligible if they were affected 
by stress daily and had 2 or more stress-related symptoms. It was found that this 
probiotic combination helped to reduce stress-induced gastrointestinal symptoms such 




significant effects on other symptoms of stress including emotional, psychological, 
and mental stress, or sleeping patterns. 
Following this, a double-blind placebo-controlled, randomised, parallel study 
was conducted using the same probiotic combination to investigate effects on distress, 
anxiety and depression in healthy men and women (Messaoudi et al., 2011). 
Participants were subject to a variety of tests including the Hopkins Symptom 
Checklist-90, Hospital Anxiety and Depression Scale, Perceived Stress Scale and 
Coping Checklist. Cortisol levels in urine were also measured. It was found that the 
probiotic formula helped to reduce anxiety and depression. Furthermore, cortisol 
levels in the treatment group decreased while levels in those consuming the placebo 
remained stable. 
The effects of a probiotic drink containing L. casei Shirota were investigated 
in a double-blind placebo-controlled, randomised study containing 124 participants ( 
Benton et al., 2007). The probiotic did not improve the overall mood in the 
participants, except for those individuals whose mood at baseline was initially low. 
Interestingly, participants in the test group reported an improvement in memory recall, 
however these effects were small. Although this probiotic did not improve mood 
among all the participants, patients suffering from depression are likely to have 
initially low baseline scores. This was examined in a subsequent study by Rao and 
colleagues who investigated the potential of L. casei Shirota to alleviate symptoms of 
depression and anxiety resultant from chronic fatigue syndrome (CFS) in a double-
blind placebo-controlled, randomised pilot study (Rao et al., 2009). After an 8-week 
period, a significant improvement in anxiety was seen in the treatment group when 




Consumption of a fermented milk drink containing a probiotic cocktail was 
shown to modulate brain activity in healthy women (Tillisch et al., 2013). The 
probiotic drink containing Streptococcus thermophilus, Bifidobacterium lactis, 
Lactococcus lactis and Lactobacillus bulgaricus was taken by participants twice daily. 
Functional magnetic resonance imaging (fMRI) was employed before and after the 
intervention period to examine brain responses. A standardised emotional faces 
attention task was used to examine changes in emotional regulation. Changes during 
the task were seen in the treatment group with activity reductions noted in several 
regions of the brain accompanied by conductivity changes. 
A study investigated the use of a multispecies probiotic containing 
Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus 
W37, Lactobacillus brevis W63, L. casei W56, Lactobacillus salivarius W24, and 
Lactococcus lactis (W19 and W58) on cognitive reactivity to sad mood as well as 
anxiety and depressive symptoms (Steenbergen et al., 2015). The study was blind at 
three levels, placebo-controlled, randomised, and assessment was conducted pre- and 
post-intervention. Participants were assessed using a variety of questionnaires which 
investigated vulnerability to depression and the existence and severity of current 
depressive and anxiety symptoms. It was found that the treatment group showed 
reduced cognitive reactivity to sad mood. This probiotic therefore may help to reduce 
the negative or aggressive thoughts associated with depression. 
Several additional clinical studies have been carried using probiotics and 
prebiotics to target a specific population and condition including aged individuals 
(Chung et al., 2014), IBS (Pinto-Sanchez et al., 2017), major depressive disorder 




Although these studies present interesting evidence to support the use of 
probiotics as positive modifiers of brain function and mental health, much additional 
work is necessary to examine the underlying mechanisms of this modulation. 
Additionally, continued human intervention studies are necessary to examine the 
impact of probiotic strains on disorders associated brain-gut axis dysregulation with a 
view to developing potential disease specific bacterial treatments. 
 
Conclusion 
Consumer interest in probiotic containing functional foods and supplements 
has increased in recent years. This review examined the latest literature, with regard 
to what defines a healthy gut microbiota from infancy to adulthood, the factors which 
cause disruption and the effectiveness of probiotic interventions in prophylaxis, 
alongside strategies to improve probiotic delivery. 
A stable microbiota appears to be the prerequisite for host health and while 
there is still much debate on what constitutes this stability in terms of bacterial 
composition. It is accepted that diversity and functionality are key elements to a 
healthy microbiota which has been suggested as being person-specific at species, or 
indeed, strain level. Disruptions in normal colonisation patterns increase the risk of 
disease development both in infancy and adulthood, and these effects are as far 
reaching as brain function. From womb to tomb, several factors can disrupt the 
microbiota, beginning at the very earliest stages of life from maternal infection during 
pregnancy to mode of delivery, antibiotic usage, diet, and stress. 
Indeed, colonisation disturbances at birth or indeed as a result of antibiotic 
usage throughout life can persist for months or years and have been linked to disorders 




development and function. Restoration of the gut microbiota using prebiotics and 
probiotics has emerged as an attractive intervention strategy. Indeed, in terms of 
probiotics, several clinical studies have yielded positive results ranging from reduction 
in diarrhoea, necrotizing enterocolitis and the development of allergies in pre-term 
infants and children in receipt of antibiotics, to an increase in beneficial gut microbiota 
profiles in adults with a concomitant reduction in intestinal pathogens and a proven 
ability to reduce the symptoms of IBS. However, not all studies have yielded such 
outcomes, with many failing to demonstrate the ability of probiotic interventions to 
positively impact human health. Several factors must be considered when selecting a 
potential probiotic which span the spectrum from strain selection to the individual’s 
own ecosystem. For example, strains from human breast milk may be more beneficial 
for use in infant formula than strains isolated from the infant intestine (Chassard et al., 
2014). The timing of delivery is also essential, with recent studies touting the benefits 
of probiotic administration during pregnancy. 
Another major hurdle is the mode of probiotic delivery, since viable bacteria 
must reach the target site in sufficient numbers to exert an effect. Food based delivery 
systems are already in use and available on the market-place. Probiotic cheese and 
yogurts have the advantage of appealing to the “ready-to-go” consumer market. 
Interestingly, ice-cream has proven to be an effective matrix to protect bacterial 
viability. However, ice-cream itself is not considered a healthy option due to its high 
fat and sugar contents. In this respect, one must consider the conflicting message of 
such a product and ensure delivery of effective probiotic numbers in a healthy-size 
portion. In addition to dairy products, other food based options have emerged, 
including soy-based products, fruits and cereal, important alternatives for non-dairy 




with a variety of tablets, powders, straws and chewing gums on the market. Such 
carriers have the advantage of eliminating many of the technological challenges 
associated with food vectors including interactions with starter cultures, detrimental 
pH levels and negative effects on sensory aspects. However, this method does not 
benefit from the advantages of a food based carrier which include growth promotion, 
increased probiotic viability and enhanced protection in the GI tract after consumption. 
In addition to carrier choice, methods for enhancing probiotic survival are necessary 
to ensure that sufficient numbers of bacterial cells are ingested and delivered to the 
target site, generally the large intestine. These include microencapsulation, protective 
agents, packaging materials which protect against oxygen and optimal storage 
conditions. 
In conclusion, research continues to illustrate the benefits of a healthy gut 
microbiota on host health, linking gut microbiota perturbations to increased risk of 
disease. Probiotic intervention is a promising avenue to examine for restoring a stable 
microbiota and hence positively influencing health. However, the variability of 
effectiveness reported in clinical studies continues to be a cause for concern. Various 
factors can influence outcomes, ranging from the choice of probiotic strain to the 
processing procedures used for probiotic delivery. Carefully designed clinical trials 
are essential whereby selected probiotic strains, along with their carrier systems are 
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Over recent years it has become evident that the physiological influence of the 
gut microbiota extends beyond the periphery to the central nervous system (CNS). 
Current data derived from preclinical studies indicate that the gut microbiota can 
influence CNS function. Despite limited attempts to translate these findings to clinical 
populations, emerging evidence suggests that alterations in the composition of the gut 
microbiota, across the lifespan, may have a fundamental role in the pathophysiology 
of a number of mental health disorders. Moreover, accumulating evidence 
demonstrates the central role of food consumed in programming gut microbiota 
composition, diversity and functionality throughout life. 
In this review, we outline what is considered a healthy infant and adult gut 
microbiota composition followed by describing how the gut microbiota can influence 
the CNS via signalling pathways of the microbiota-gut-brain axis. Current findings 
from preclinical investigations, observation and intervention studies in humans, 
indicating the gut microbiota in brain function and mental health, are reviewed. 
Finally, we consider microbiota-targeted functional food interventions with potential 
application in promoting normal brain function. 
Much work is yet to be carried out in determining the role of the gut microbiota 
in brain function and behaviour in human populations. Nevertheless, the potential for 
microbiota-targeted functional food interventions is evident. As new findings emerge 
in this rapidly developing field, it is envisaged that a greater understanding of microbe-
brain interactions will herald a new era of psychotropic therapies to promote normal 





Although a key role for gut bacteria (the gut microbiota) in specific aspects of 
health and disease, such as regulating immune function and metabolic activity, has 
been recognised for some time (Sampson & Mazmanian, 2015). It has become 
apparent that the physiological influence of the microbiota extends beyond the 
periphery to the central nervous system (CNS). Clinically, the phenomenon of hepatic 
encephalopathy which, in the extreme, is characterised by dementia like symptoms 
that can be ameliorated by treatment with antibiotics (Strauss & da Costa, 1998) is 
often cited as a unique example of how perturbing the microbiota can influence brain 
function. It has also long been recognised that the acute phase reaction to microbial 
infection is accompanied by a number of neuro-immune mediated behavioural 
symptoms such as depressed mood and cognitive impairment (Dantzer, 2009). 
However, the realisation that not only pathogenic microorganisms, but the 
commensal/symbiotic gut bacteria can influence CNS activity has have led to a 
‘Paradigm Shift’ in brain and behavioural research (Mayer et al., 2014). Moreover, 
discoveries in microbe-brain interactions have revolutionised our approach to 
investigating psychopathology and spurred the development of microbiota-targeted 
interventions (psychobiotics) which hold great potential as a new therapeutic approach 
in mental health disorders (Dinan et al., 2013). 
In this review we first provide an outline of what is, conceptually, considered 
a healthy infant and adult gut microbiota composition, followed by a description of 
the key pathways by which the gut microbiota signal to the brain to influence brain 
function and behaviour. Next, we review current evidence demonstrating a role for the 
gut microbiota in brain function and mental health, incorporating both preclinical and 




approaches which have shown promise or have potential in the management of mental 
health. 
 
Healthy Gut Microbiota Composition 
Despite large variation in composition between healthy individuals due to a 
variety of environmental, physiological, genetic and psychological factors, a ‘core’ or 
‘normal’ gut microbiota composition is emerging and despite large taxonomic 
diversity between individuals, colonisation trends can be observed in both infants and 
adults. 
The infant gut is colonised during delivery, either from contact with the vaginal 
and faecal bacteria from the mother during standard vaginal delivery (SVD) or, in the 
case of caesarean-section (CS) delivery, from the hospital environment and maternal 
skin microbes (Borre et al., 2014). Culture-based studies have shown that at birth the 
healthy infant gut is initially colonised by facultative anaerobes such as 
Enterobacteriaceae, and once oxygen has been depleted and an anaerobic environment 
is present, strict anaerobes such as Bifidobacterium and Bacteroides appear 
(Adlerberth & Wold, 2009). Improvements in 16 S rRNA sequencing have led to a 
more accurate description of the gut microbiota composition inclusive of the 
substantial number of unculturable bacteria found in the gut. In healthy, vaginally 
delivered infants, the most prevalent initial bacterial groups include Staphylococcus, 
Lactobacillus, Enterobacteriaceae and Bifidobacterium, followed by later increases in 
the abundance of Veillonella and Lachnospiraceae and a decline in Staphylococcus 
(Palmer et al., 2007; Ferretti et al., 2018). During infancy, the composition of the gut 




before resembling an adult gut microbiota at approximately 2 years of age, after the 
introduction of solid foods (Borre et al., 2014). 
What constitutes a ‘healthy microbiota’ in adults is not entirely clear and 
indeed may be person-specific. Nevertheless, many advances have been made in 
defining a healthy phylogenetic core, which have led to a consensus that the healthy 
adult gut is dominated by Firmicutes, Bacteroidetes, Actinobacteria, and 
Verrucomicrobia (Human Microbiome Project Consortium, 2012). Within these phyla 
there is still large inter-individual diversity, with each person harbouring a unique 
microbiota profile (Moore et al., 2019). 
It has been proposed that the gut microbiota can be categorised into three core 
clusters or enterotypes (Arumugam et al., 2011). These are broad clusters which are 
defined by the presence of a particular bacterial genus - Bacteroides, Prevotella or 
Ruminococcus. However, this approach to defining the gut microbiota composition is 
the subject of ongoing debate and is questionable when considering that over the 
course of year a healthy individual's microbiota can vary between clusters and is not 
strictly defined within one enterotype (Knights et al., 2014). Alternatively, rather than 
a taxonomic core, the composition may be viewed as a core set of functional profiles, 
in which some key bacterial species may contribute significantly to the functional 
profile and play an important role in health and disease (Flint et al., 2012). 
A range of factors are known to disrupt the infant and adult gut microbiota 
composition which have been extensively reviewed elsewhere (Rodriguez, 2015), and 
include mode of delivery at birth, antibiotic treatment, diet, stress, infection and host 
genetics. The extent to which each of these factors influences brain function and 
mental health via disrupting the gut microbiota composition is not entirely clear and 




integrate current findings in which these factors are implicated in brain function and 
behaviour via interactions with the gut microbiota. 
 
The Microbiota-Gut-Brain Axis 
The microbiota-gut-brain axis is a bi-directional communication network 
encompassing the central nervous system (CNS), sympathetic and parasympathetic 
branches of the autonomic nervous system (ANS), the enteric nervous system (ENS), 
neuroendocrine and neuroimmune pathways, and the gut microbiota (Cryan & Dinan, 
2012). A complex reflexive network of efferent fibers projecting to the gastrointestinal 
(GI) tract and afferent fibers that project to a number of interconnected regions of the 
CNS facilitate communication within the axis (Dinan et al., 2015). Bi-directional 
communication along neural, hormonal and immune pathways thus enables the brain 
to influence secretory, sensory, and motor functions of the GI tract, and conversely, 
signals arising from the viscera to influence CNS activity (Aziz & Thompson, 1998). 
Although interactions between the brain and enteric nervous system have been 
the focus of intense study over the past two decades, particularly in the context of 
functional GI disorders such as irritable bowel syndrome, over recent years there has 
been growing recognition that the gut microbiota has a dominant influence on 
signalling along this axis (Figure 1) (Cryan & Dinan, 2012; Mayer et al., 2014; 




Figure 1. The Microbiota-Gut-Brain Axis.  There are a number of pathways through which the gut microbiota can signal to the brain. These include, regulating 
immune activity and thus the production of inflammatory cytokines which can impact directly on the brain or can, stimulate the HPA axis to produce CRH, ACTH 
and cortisol; by mediating tryptophan metabolism which may alter the downstream production of serotonin quinolinic and kynurenic acid; through the production of 
SCFAs such as butyric, acetic and propionic acid; and by the production of neurotransmitters. Afferent signaling pathways of the vagus nerve are crucial in mediating 
the effects of the gut microbiota on brain function and behavior. Abbreviations: ACTH, adrenocorticotropin hormone; CRH, corticotropin-releasing hormone; GABA, 




Microbe to Brain Signalling Pathways 
The Vagus Nerve 
The vagus is the major nerve mediating parasympathetic activity of the 
autonomic nervous system. Vagal afferent sensory neurons relay information from the 
GI tract to the nucleus of the solitary tract, which projects to the thalamus, 
hypothalamus, locus coeruleus, amygdala and periaqueductal grey (Wang et al., 
2007). A number of preclinical studies have demonstrated afferent pathways of the 
vagus nerve are fundamental in mediating the effects of the gut microbiota on brain 
function and behaviour. For example, in a landmark preclinical study with 
conventional mice, treatment with the probiotic Lactobacillus rhamnosus (JB-1) 
reduced anxiety and depressive-like behaviour and stress-induced corticosterone 
levels, however, these behavioural effects were not evident in vagotimized mice 
(Bravo et al., 2011). Despite the importance of vagal pathways, it must be noted that 
vagotomy does not mediate all effects of the microbiota on brain function and 
behaviour (Bercik et al., 2011), and the mechanisms underlying vagal mediated 
microbiota-brain interactions have not yet been determined (Cryan & Dinan, 2012; 
Cryan et al., 2019). 
 
Microbial Regulation of Neuro-immune Signaling 
Bacterial colonisation of the gut during early life influences normal 
development and maturation of the immune system, and across the lifespan, the gut 
microbiota regulate innate and adaptive immune responses (Shanahan & Quigley, 
2014). A previous ground-breaking report has elegantly demonstrated that maturation 




the gut microbiota (Erny et al., 2015). Of note, this effect was demonstrated in both 
germ-free (GF) and conventional mice following ablation of the gut microbiota with 
antibiotics. Microglia have been implicated in the pathophysiology of a host of 
neurodegenerative and psychiatric disorders and as such, this study has major 
implications for our understanding of how the microbiota interact with CNS immune 
activity to affect brain function and mental health (Schafer et al., 2015). Finally, pro-
inflammatory cytokines released from macrophages following immune activation can 
act on receptors of afferent pathways of the vagus nerve to signal to the CNS, or if 
released systemically following a GI immune response, they may influence the CNS 
via other mechanisms including, direct stimulation of the hypothalamic-pituitary-
adrenal (HPA) axis at the anterior pituitary or hypothalamus, active transport via 
saturable transport molecules, passage through leaky portions of the BBB or by 
activation of endothelial cells (Dantzer, 2009). 
 
Microbiota-Mediated Tryptophan Metabolism 
Tryptophan is an essential amino acid which is the precursor molecule to 
serotonin (5-HT), kynurenine, and metabolites of the kynurenine pathway (Clarke et 
al., 2012). Despite a focus on the 5-HT system in brain-gut axis and psychiatric 
disorders, only around 5% of systemic tryptophan is metabolised into 5-HT, while 
around 90% is metabolised along the kynurenine pathway (O’Mahony et al., 2015). 
The rate of tryptophan metabolism along the kynurenine pathway is dependent on 
expression of indoleamine-2,3-dioxygenase (IDO), found in all tissues, and 
tryptophan-2,3-dioxygenase (TDO) which is localised to the liver (Clarke et al., 2012). 
IDO expression can be induced by the action of inflammatory cytokines (Interferon-γ 




noted previously, the microbiota regulates host immune function, and as will be 
discussed below, can modulate HPA axis activity and the production of 
glucocorticoids (Cryan & Dinan, 2012). Thus, the gut microbiota can affect the rate 
of tryptophan metabolism along the kynurenine pathway. Indeed, an informative study 
conducted in GF animals indicates that peripheral tryptophan levels are under 
microbial control (Clarke et al., 2012; Patel et al., 2011). Moreover, the probiotic 
Bifidobacterium infantis was found to increase plasma tryptophan and kynurenine 
levels in a preclinical study in rats (Desbonnet et al., 2008). This has important 
implications for brain function and behaviour; downstream metabolites of the 
kynurenine pathway- kynurenic acid and quinolinic acid- have been shown to be 
neuroactive and can act on N-methyl-D-asparate receptors and nicotinic receptors in 
the CNS, and as such, there is increased interest in the role of the kynurenine pathway 
in psychiatric disorders and neurodegenerative disease (O’Mahony et al., 2015). 
The mechanisms by which the gut microbiota regulate tryptophan metabolism 
have not been fully elucidated. However, delineating this process may be pivotal in 
understanding microbiota-brain interactions in brain function and mental health. 
 
Microbial Control of Neuroendocrine Function 
A seminal report by Sudo and colleagues was the first to demonstrate that the 
HPA axis, the core neuroendocrine system in humans and rodents, is under microbial 
control (Sudo et al., 2004). GF mice exhibited an exaggerated corticosterone and 
ACTH response to mild-restraint stress in comparison to specific pathogen free 
controls (Sudo et al., 2004). Importantly, the exaggerated HPA axis response in GF 
mice could be partly normalised by reconstitution with faecal matter from specific 




monoassociation with Bifidobacterium infantis (Sudo et al., 2004). In addition to 
elegantly demonstrating the intricate interplay between microbes and neuroendocrine 
function, this study also highlights two critical points; that a microbiota during 
development is essential for normal HPA axis function in later life; and that there are 
critical neurodevelopmental time-windows during which microbes must colonise the 
gut for development of a normal stress response (Dinan et al., 2015; Cryan et al., 
2019). This finding has subsequently been replicated by independent investigators 
(Clarke et al., 2013). 
These findings are important when considering that HPA axis dysfunction is a 
key factor in the pathophysiology of psychiatric disorders such as depression (O'Brien 
et al., 2004) and functional GI disorders with marked psychiatric co-morbidity, such 
as irritable bowel syndrome (IBS) (Kennedy et al., 2014). However, to date, it is 
unknown if microbiota-targeted interventions have positive effects on HPA axis 
function in psychiatric populations. Nevertheless, promising findings from 
preliminary studies with healthy control participants indicate that pre and probiotic 
interventions can modulate HPA axis functioning (Messaoudi et al., 2011; Schmidt et 
al., 2015). 
 
Microbial Neuro-metabolite Production 
Gut bacteria can produce a number of neuroactive compounds which have 
potential to influence brain function and mental health (Dinan et al., 2013). For 
example, in vitro studies have demonstrated that Candida, Streptococcus, Escherichia 
and Enterococcus species produce 5-HT; Bacillus and Serratia species produce 
dopamine; Escherichia, Bacillus, Saccharomyces species produce noradrenaline; 




Bifidobacterium secrete GABA (Barrett et al., 2012). Given the key role of these 
neurotransmitters in all aspects of brain function and behaviour, that gut bacteria 
secrete these is a striking finding. However, replicating this in-vivo still poses a 
significant challenge and the mechanism(s) by which neurotransmitters secreted by 
gut bacteria can influence the CNS is unclear at present as some neurotransmitters 
such as GABA do not cross the blood brain barrier (Hyland & Cryan, 2010). 
Nevertheless, utilising neuroactive metabolite secreting bacteria to promote normal 
brain function and mental health is a promising avenue of investigation. 
 
Microbial Short-Chain Fatty Acid Production and Brain Function 
Short chain fatty acids (SCFAs), such as butyric, acetic and propionic acid are 
produced by microbial fermentation of complex carbohydrates in the GI tract 
(Macfarlane & Macfarlane, 2003; Gill et al., 2018). SCFAs can cross the BBB and 
have been shown to possess some neuroactive properties (Sampson & Mazmanian, 
2015). For instance, a high dose of propionic acid administered direct to the CNS 
(MacFabe et al., 2011) or peripherally (Foley et al., 2014), in rats, induces a range of 
behavioural alterations relevant to neurodevelopmental disorders. Butyrate, on the 
other hand, has potential pro-cognitive and beneficial behavioural properties via 
epigenetic mechanisms, due to potent inhibition of histone deacetylase (Stilling et al., 
2014). SCFAs also regulate immune activity locally in the GI tract which may have 
downstream effects on CNS function (Dantzer, 2009). Moreover, the study by Enry 
and colleagues which reported that maturation of microglia within the CNS of GF 
animals was impaired, also demonstrated that treatment with a mix of SCFAs could 
rescue microglial function in the same manner as re-colonisation of a complex 





Microbes, Neurotransmitters & Neurophysiology 
Clear mechanistic links between microbiota-mediated levels of peripheral 
biochemical parameters and central neurobiological changes are difficult to establish. 
Nevertheless, it is clear that the microbiota, and specific bacterial species, can regulate 
central neurotransmitter levels and receptor expression. For example, GF mice have 
decreased 5-HT levels and 5-HT1A receptor expression in the amygdala and 
hippocampus (Bercik et al., 2011; Clarke et al., 2013; Heijtz et al., 2011; Neufeld et 
al., 2011), increased 5-HT, noradrenaline and dopamine turnover in the striatum 
(Heijtz et al., 2011), and increased activity-related transcriptional pathways in the 
amygdala (Stilling et al., 2015). In conventional mice, treatment with the probiotic L. 
rhamnosus (JB-1) led to a number of brain region specific changes in GABA receptor 
expression; GABAB1b mRNA was increased in cortical regions, but reduced in the 
hippocampus, amygdala, and locus coeruleus; GABAAα2 mRNA expression was 
reduced in the prefrontal cortex and amygdala, but increased in the hippocampus 
(Bravo et al., 2011). Many of these neurochemical changes likely regulate numerous 
neurophysiological process which are thought to underlie key aspects of brain function 
and behaviour, such as hippocampal neurogenesis (Ogbonnaya et al., 2015). 
In summary, there is clear evidence that the gut microbiota can signal to the 
CNS and also regulate many neurobiological processes that underlie the full spectrum 
of behavioural, emotional and cognitive functions. Much of this evidence is, by 
necessity, gleaned from preclinical studies in rodents and the extent to which the 
mechanisms described above, through which the gut microbiota influence brain 




Nevertheless, the following sections outline what is currently understood as regards 
microbiota-brain interactions in healthy individuals and clinical populations. 
 
The Microbiota in Brain-Gut Axis and Psychiatric 
Disorders 
Irritable bowel syndrome (IBS): The prototypical brain-gut axis disorder 
IBS is a stress-related, brain-gut axis disorder in which GI symptoms are 
accompanied by functional and structural brain abnormalities, HPA axis dysfunction, 
subtle cognitive impairment and significant psychiatric co-morbidity (Kennedy et al., 
2014). The role of the microbiota in the pathogenesis of GI and extra-intestinal 
symptoms in IBS has received significant attention over recent years with a growing 
body of evidence that the diversity, stability and metabolic activity of the gut 
microbiome is altered in IBS when compared to healthy individuals (Jeffery et al., 
2012; Enck et al., 2018). At the phylum level, a relatively consistent finding across 
studies determining the gut microbiota composition in IBS is decreased abundance of 
Bacteroidetes and increased Firmicutes (Jeffery et al., 2012). Although the functional 
relevance of alterations in the composition of specific microbial species in IBS is not 
clear, correlational studies have documented a relationship between Ruminococcus-
torques related bacterial phylotype and Firmicutes, Gammaproteobacteria and 
Verrucomicrobia phylum and symptom scores (Kennedy et al., 2014). In addition, 
some probiotic strains have shown efficacy in ameliorating symptoms in patients with 
IBS (Clarke et al., 2012). Visceral pain hypersensitivity has long been considered a 
key feature of symptomatology in IBS and may be underpinned by abnormal CNS 
processing of signals arising from the GI tract (Tillisch & Labus, 2011). It is 




treatment in early life can induce visceral hypersensitivity (O'Mahony et al., 2014), 
while probiotic strains such as B. infantis 35624 can alleviate hypersensitivity 
(McKernan et al., 2010). 
Although a clear link between alterations in the gut microbiota and other 
centrally mediated features of IBS, including psychiatric co-morbidity, HPA axis 
dysfunction and cognitive impairment is yet to be established, it is conceivable that an 
altered gut microbiota composition may underlie the manifestation of extra-intestinal 
CNS symptoms in the disorder (Kennedy et al., 2014). 
 
Microbes, Mood & Anxiety 
Major depression is a highly prevalent, debilitating, mental health condition, 
affecting up to 1 in 5 adults and is associated with marked symptom severity, 
chronicity, role impairment and substantial socioeconomic cost (Kessler et al., 2003). 
Major depression is rarely a principal diagnosis and up to 60% of patients have a co-
morbid anxiety disorder (Kessler et al., 2003). As such, the role of the gut microbiota 
in depression and anxiety is considered together. 
Stress is a key factor in the pathophysiology of depression and patients exhibit 
HPA axis dysfunction as evidenced by elevated cortisol levels, increased 
cerebrospinal fluid levels of corticotrophin-releasing factor (CRF) and impaired 
negative feedback in response to the dexamethasone challenge test (O'Brien et al., 
2004). In addition, elevated plasma pro-inflammatory cytokines levels have been 
documented by a number of studies in individuals with depression (O'Brien et al., 
2004). Given that the gut microbiota can regulate HPA axis and immune activity 
(Shanahan & Quigley, 2014; Sudo et al., 2004), in addition to other physiological 




(Dantzer, 2009), a prominent role for the microbiota in depressive and anxiety 
disorders is likely (Dinan & Cryan, 2013; Lew et al., 2019). 
Using a number of approaches, it has been shown in preclinical studies, with 
some consistency, that the gut microbiota leverages a significant influence on 
depressive and anxiety-like behaviour. For example, GF mice exhibit both decreased 
(Clarke et al., 2013; Heijtz et al., 2011; Neufeld et al., 2011) and increased (Bercik et 
al., 2011) anxiety-like behaviour, which can be normalised by bacterial colonisation 
prior to critical neurodevelopmental time-windows (Clarke et al., 2013). Treatment 
with the probiotic B. breve 1205 (Savignac et al., 2014), or ablation of the gut 
microbiota through administration of an antibiotic cocktail (Desbonnet et al., 2015 
reduces anxiety-like behaviour in conventional mice. Moreover, it has been shown 
that an anxiety-like behavioural phenotype can be transferred from one mouse strain 
to another via faecal microbiota transplantation (Bercik et al., 2011). Finally, studies 
examining the role of the gut microbiota in depressive-like behaviour in rodents 
indicate that specific probiotic strains such as B.infantis (Desbonnet et al., 2008), L. 
rhamnosus (Bravo et al., 2011) and a cocktail of L. helveticus and B. longum 
(Messaoudi et al., 2011) possess potential anti-depressant qualities. 
Investigations with healthy human volunteers lend some support to this 
preclinical data indicating a microbial influence on mood and anxiety. For example, 
probiotic treatment has been shown to reduce self-reported depression (Messaoudi et 
al., 2011), increase self-reported happiness in participants with low baseline mood (D. 
Benton et al., 2007) and decrease ruminative thinking (Steenbergen et al., 2015). 
Moreover, intervention with a probiotic combination of L. helveticus and B. longum 
reduced 24-hour urinary cortisol output (Messaoudi et al., 2011) and 4-week treatment 




healthy volunteers. Finally, at the cognitive level, a prebiotic intervention increased 
response time to positive versus negative stimuli in an emotional attention task 
(Schmidt et al., 2015), while a brain imaging study showed that 4-week intake of a 
fermented milk product containing probiotic modulates functional brain activity 
during a similar task (Tillisch et al., 2013). 
In a Norwegian sample of 37 patients with a diagnosis of major depression and 
18 healthy control participants, no significant group difference in overall gut microbial 
diversity or richness was found, but an underrepresentation of Bacteroidales was 
associated with depression (Naseribafrouei et al., 2014). In contrast, an independent 
report documented increased bacterial α-diversity in patients with major depression 
who were ‘actively’ (Hamilton Rating Scale For Depression (HAMDS) score ≥20) 
depressed, in comparison to patients who had responded to treatment (HAMDS score 
≥20 at baseline with a 50% reduction after 4 weeks) and healthy controls (Jiang et al., 
2015). At the phylum level, reduced levels of Firmicutes and increased Bacteroidetes, 
Proteobacteria, and Actinobacteria were found in patients with major depression, 
regardless of treatment status. Furthermore, differences in specific genera were 
documented, with increased Enterobacteriaceae and Alistipes, but decreased 
abundance of Faecalibacterium which negatively correlated with HAMDS scores 
(Jiang et al., 2015). 
With limited data available in clinical populations, it is not possible to draw 
meaningful conclusions as to the nature of microbiota alterations in patients with 
depressive and anxiety disorders. Moreover, conflicting findings between studies is 
perhaps not surprising as considering major depression or anxiety disorders as singular 
clinical entities does not capture the breadth and inter-individual variability of 




are needed to fully determine if mood and anxiety disorders are characterised by an 
altered gut microbiota composition in general, and if specific microbial compositions 
are associated with specific symptomatology. 
 
Microbiota, Social Behaviour and Autism 
Autism spectrum disorders (ASD) are neurodevelopmental disorders typified 
by marked deficits in reciprocal social interaction, communication and language 
development, and restricted, repetitive patterns of activities and behaviours (Dinan et 
al., 2015; Masi et al., 2017). A role for the gut microbiota in neurodevelopmental 
disorders such as ASD has become a topic of significant interest over recent years 
(Borre et al., 2014). Clinically, this interest has been spurred by the recognition that a 
subset of individuals with ASD suffer problematic GI symptoms, an altered 
composition of the gut microbiota and increased intestinal permeability (Julio-Pieper 
et al., 2014; Kang et al., 2018). 
In parallel, preclinical studies with GF animals have demonstrated that in the 
complete absence of a microbiota, rodents exhibit impairments in social behaviours 
relevant to ASD (Desbonnet et al., 2014). Of note, bacterial colonisation of the gut in 
post-weaning GF animals can normalise impaired social novelty preference, with no 
effect on other aspects of social-cognitive function (Desbonnet et al., 2014). As has 
been indicated for other types of behaviour such as anxiety and stress responsiveness, 
studies with GF animals suggest that the presence or absence of the gut microbiota 
during critical neurodevelopmental windows can modulate the expression of normal 
or abnormal social behaviours in later life. 
Maternal infection during pregnancy is a known risk factor for ASD (Atladóttir 




offspring exhibiting both ASD like behavioural deficits and GI disturbances, including 
increased gut permeability and an altered gut microbiota (Malkova et al., 2012). 
Interestingly, in this model treatment, Bacteroides fragilis can repair intestinal barrier 
function and normalise deficits in communicative, stereotypic and anxiety-like 
behaviours (Hsiao et al., 2013). 
Previous epidemiological studies suggest that mode of delivery at birth (C-
section vs. vaginal) may also influence normal central nervous system (CNS) 
development leading to cognitive and motor problems during infancy (Al Khalaf et 
al., 2015). Furthermore, CS delivery has been associated with an increased risk of 
developing ASD (Curran et al., 2015). However, future studies are needed to 
determine if such associations may be better accounted for by genetic or 
environmental factors (Curran et al., 2015). 
Taken together, the preclinical and clinical evidence suggests the gut 
microbiota significantly influence neurodevelopment and may have a role in the 
pathophysiology of ASD. However, as with other mental health disorders, clinical 
studies to determine the efficacy of microbiota-targeted therapies in ASD are lacking. 
Over a decade ago, it was shown in a small sample of children with regressive-onset 
autism, that treatment with oral vancomycin could improve symptoms (Sandler et al., 
2000). The beneficial effect of this antibiotic was not apparent following the cessation 
of treatment at follow-up, and of course, long-term antibiotic treatment is not a viable 
therapeutic strategy in ASD. Nevertheless, when taken with the preclinical work 
which has been conducted to date, developing safe approaches to targeting the gut 
microbiota through food based approaches, to ameliorate symptoms in ASD has 
potential, and presents an exciting and hopeful prospect in new treatment approaches 





The Gut Microbiota and Age-related Cognitive Decline 
As the world’s ageing population is rapidly expanding, it has become a major 
societal goal to promote health and wellbeing in later life, and a number of innovative 
strategies have been implemented over recent years (Rechel et al., 2013). A prominent 
consequence of ageing is a steady decline in cognitive functions including the ability 
to encode new episodic memories, working memory/executive functions and 
processing speed (Deary et al., 2009). Ageing is accompanied by a plethora of age-
related neurobiological changes, including altered HPA axis function, decreased 
neurotransmitter/neurotrophin concentration and receptor expression, and increased 
oxidative stress (Prenderville et al., 2015). Moreover, the concept of inflamm-ageing, 
indicating a general increase of inflammatory tone during ageing, has been 
championed as a key process mediating many of the age-related changes occurring in 
the CNS and periphery (Franceschi et al., 2000; Kim et al., 2021). In a seminal study, 
the ELDERMET consortium identified that age-related change in the composition of 
the gut microbiota in elderly individuals was associated with number of health 
parameters including inflammation and cognitive function (Claesson et al., 2012). 
Based on these findings, it is tempting to speculate that the gut microbiota plays a 
significant role in age-related cognitive decline (Mahmoudian Dehkordi et al., 2019). 
Further lines of evidence lend weight to this speculation. For instance, heightened 
immune activity and HPA axis dysfunction are considered to be key in pathological 
cognitive decline during ageing (Prenderville et al., 2015), and as outlined above, both 
systems are influenced by the gut microbiota. A number of studies utilising various 
approaches have demonstrated that the microbiota can regulate some aspects of 




in a small sample of healthy elderly adults revealed that treatment with a Lactobacillus 
helveticus probiotic strain had some positive effects on attentional performance 
(Chung et al., 2014). 
Further clinical interventions studies are needed to determine the potential pro-
cognitive effects of microbiota-targeted interventions in elderly individuals, either in 
healthy or clinical populations (Kim et al., 2021). Nevertheless, as preclinical data 
indicate that the gut microbiota can mediate various aspects of cognitive performance, 
there is clear potential for microbial targeted prophylactic interventions to tackle age-
related cognitive decline and promote normal cognitive function in later life. 
 
Microbiota-Targeted Functional Foods for Brain Health 
Prebiotics and Probiotics 
As the studies reviewed above indicate, modulation of the gut microbiota using 
dietary intervention, in particular with prebiotics and probiotics (Korpela et al., 2018), 
is a promising intervention strategy in promoting normal brain function and mental 
health. 
  However, to progress the field, it is of great importance to understand the 
mechanisms by which prebiotics and probiotic species exert their effect on brain 
function and behaviour. Prebiotics are may exert a beneficial brain effect through 
improving host immunity, enhancing SCFA production, reducing potentially 
pathogenic microbes and improving gut barrier function (Slavin, 2013). Lactobacillus 
spp. and Bifidobacterium spp. are the most commonly used probiotics and may act via 
a number of mechanisms to alter the gut microbiota of the host in order to improve 
brain health, including production of antimicrobial compounds, reduction of the 




preventing other microbes from adhering to epithelial cells), production of growth 
substrates such as vitamins and exopolysaccharides, enhanced barrier function, and 
modulation of immune responses (Power et al., 2014, Wang et al., 2019). Future 
studies to fully understand the mechanism of prebiotic and probiotic interventions for 
brain function and behaviour are needed to determine those species which may have 




Table 2.1: Human trials investigating the effects of probiotic and prebiotic interventions on mood and cognition 
 




Probiotic delivery Findings Reference 
Bifidobacterium bifidum W23 
Bifidobacterium lactis W52 
Lactobacillus acidophilus W37 
Lactobacillus brevis W63 
Lactobacillus casei W56 
Lactobacillus salivarius W24 and 
(W19 and W58) 
 
Investigate whether a 
multispecies probiotic may 
reduce cognitive reactivity 
in non-depressed individuals 
-Triple-blind, placebo- 
controlled, randomised, pre- 
and post-intervention 
assessment 
-4 week intervention 
 
40 20.2 ± 2.4 -2 g/day freeze-dried 
powder 
-2.5 x 109 CFU/g 
-Participants who received the multispecies probiotic 
showed reduced overall cognitive reactivity to sad 
mood 
-Participants showed reduced aggressive and 
ruminative thoughts in response to sad mood 
(Steenbergen et al., 
2015) 
Lactobacillus helveticus R0052 
Bifidobacterium longum R0175 
Effects of the probiotic 
formulation on anxiety, 
stress, depression and 





-30 day intervention 
55 30 - 60 -1.5 g/day probiotic stick 
-3 x 109 CFU/stick 
-Probiotic treatment showed a beneficial effect on 
general signs of anxiety and depression 







consumption of a fermented 
milk product with probiotic 
alters brain intrinsic 
connectivity or responses to 
emotional attention tasks in 
healthy women 
-Single centre, randomised, 
controlled, parallel-arm design 
-4 week intervention 
36 18 - 55 -Fermented milk 
-125 g pot consumed twice 
daily 
-1.25 x 1010 CFU/cup B. 
lactis 
-1.2 x 109 CFU/cup S. 
thermophilus and L. 
bulgaricus 
 
-Intake of fermented milk product with probiotic 
affected brain activity in regions controlling central 
processing of emotion and sensation 
(Tillisch et al., 2013) 
 
Lactobacillus casei Shirota Effect of consumption of a 
probiotic containing milk 




-3 week intervention 
124 48 - 79 -Probiotic milk drink 
-65 ml pots 
108 CFU/ml L. casei Shirota 
-Probiotic consumption improved mood in 
participants whose mood was initially poor 
(Benton et al., 2007) 
 
Lactobacillus casei Shirota Effect of probiotic 
intervention on symptoms of 
depression and anxiety in 





-8 week intervention 
35 18 - 65 -Sachet containing 8 x 109 
CFU L. casei Shirota 
-Participants consumed three 
sachets per day (24 x 109 
CFU/day) 
- Increase in Lactobacillus and Bifidobacterium in 
participants taking the probiotic 
-Decrease in anxiety symptoms in comparison to the 
placebo 
(Rao et al., 2009) 
Oligofrucrose-encriched inulin Examine the acute effects of 
oligofructose-enriched 




-4 hour period in the laboratory 
(test sessions before and after 
intervention) 
47 19 - 30 -Sachet containing 5 mg of 
inulin in de-caffeinated tea 
or coffee at 9am 
-Participants who consumed inulin felt happier, had 
less indigestion and were less hungry. They also 
showed improvements in episodic memory (recall and 
recognition) 





Polyphenols are a large group of compounds naturally occurring in plants and 
a variety of foods, including citrus fruits, cocoa, red wine, tea and coffee (Gomez-
Pinilla & Tyagi, 2013). Based on their structure, the main classes of polyphenols are 
phenolic acids, flavonoids, lignans, and stilbenes (Valdes et al., 2015). Large-scale 
epidemiological investigations suggest that a diet rich in polyphenols may help 
maintain normal brain function and mental health (Letenneur et al., 2007). 
Interventional studies in humans provide some supportive evidence for this 
epidemiological data (see Table 2.2). Although a number of mechanisms, including 
anti-inflammatory, anti-oxidant and modulation of enzyme activity have been 
proposed to account for the positive CNS effects of polyphenols (Letenneur et al., 
2007), these actions are presumed to be indirect as bio-availability of native 
polyphenols is low (Crozier et al., 2009). Approximately 90-95% of total dietary 
polyphenols accumulate in the large intestine where they are broken down into less 
complex metabolites by the gut microbiota (Selma et al., 2009). Conversely, 
polyphenol metabolites modulate gut microbiota composition. For example, black and 
green tea (epigallocatechin, epicatechin, catechin) have been shown to affect the 
growth of Helicobacter pylori, Staphylococcus aureus, Salmonella typhimurium, 
Listeria monocytogenes, while other polyphenols have been shown to promote the 
growth of beneficial bacteria, such as Bifidobacterium spp, in animal models and in 
human studies (Duda-Chodak et al., 2015). 
It is likely that the beneficial CNS effects of polyphenol compounds are 
mediated, at least in part, by interactions with the gut microbiota (Schaffer & 
Halliwell, 2012). As such, one key consideration when developing polyphenol 




individual variation in gut microbiota composition which may significantly affect 
polyphenol bioefficacy (Selma et al., 2009). Furthermore, it is not entirely clear which 
specific constituents of polyphenol rich food exert beneficial effects on brain function. 
Nevertheless, future studies to determine the positive effects of polyphenol-microbe 





















Effect of Concord grape juice on 
memory performance in older 
adults with age-related memory 
decline 
-Double-blind, randomised, placebo-controlled 
-7 control subjects and 5 test subjects given grape juice 
-Duration : 12 weeks 
12 78.2±5 Significant improvement in verbal learning with trends 
toward improved spatial memory  







Effect of blueberry juice on 
memory performance in older 
adults with age-related memory 
decline 
-Single-blind, placebo-controlled 
-7 control subjects and 9 test subjects 
-Duration : 12 weeks 
16 80.2 ± 
6.3 
Paired associate learning and word list recall were 
significantly improved. 
Trends toward reduced depressive symptoms were seen  




Cocoa polyphenols - 
Epicatechin, Catechin 
Effects of cocoa polyphenols on 
cognition and mood in healthy 
middle-aged adults 
-Double-blind, randomised, placebo-controlled 
-Participants given either drinks with a high dose of cocoa 
polyphenols (500 mg), a low dose (250 mg) or placebo (0 mg) 
-Duration : 30 days 
 
72 40–65 Significant increases in calmness and contentedness seen for 
the group given the high dose of cocoa polyphenols but not 
for the low group or the placebo 
No improvement in cognition seen for any group 
(Pase et al., 2013) 
Dark 
chocolate 
Cocoa flavanols (CF) Investigated whether visual and 
cognitive function is influenced 




-Single-blind, randomised, counterbalanced, cross-over 
-Consumed 35 g of dark chocolate (720 mg CF) and were subjected 
to cognitive/visual tests 2 hours later 
-One week later consumed 35 g of white chocolate and subjected to 
same cognitive/visual tests 
 
30 18-25 Improvements in visual function, spatial memory and 
performance in individuals after CF consumption 
(Field et al., 2011) 
Cocoa drink Cocoa flavanols (CF) Impact of cocoa flavanol (CF) 
consumption on 
cognitive function in elderly 
individuals with mild cognitive 
impairment 
-Double-blind, randomised, parallel 
-Participants were given a dairy-based cocoa drink once daily 
containing either a high dose of CF 
(990 mg/serving), intermediate (520 mg/serving), or low 
(45 mg/serving) 
-Duration : 8 weeks 
 
90 65-82 Improvements in cognitive performance were seen in 
individuals give either high or intermediate doses of CF but 
not in the group given the low dose  
(Desideri et al., 2012) 
Tablet form Isoflavones Effects of isoflavones on mood 
and cognitive function in 
postmenopausal 
women 
-Double-blind, randomised, cross-over, placebo-controlled 
-Participants given either phytoestrogens tablets (600-mg tablets 
containing 60 mg of isoflavones) or placebo tablets -1 tablet/day 
-Duration: 6 months on phytoestrogens/placebo and then those given 
a placebo were given phytoestrogens and those given phytoestrogens 
were given a placebo for another 6 months 
 
78 49-50 Better cognitive performance compared to placebo 
Individuals reported feeling less depressed when taking the 
phytoestrogens 
49 individuals preferred the phytoestrogens over placebo 
 
(Casini et al., 2006) 
Cocoa drink Cocoa flavanols (CF) Investigate the relationship 
between cerebral blood flow 
and a single acute dose of 
flavanol-rich cocoa in young 
adults 
Investigate the behavioural and 
fMRI response to a cognitive task 
- Double-blind, randomised, placebo-controlled 
-Participants received a high flavanol cocoa drink 
(172 mg flavanols per drink) for 5 days before one fMRI session and 
a low flavanol cocoa drink (13 mg flavanols per drink) before the 
second fMRI 
-Duration : One drink/day for 5 days before each scan with the final 
drink 1.5 hours before the scan 
 
16 18-30 High flavanol comsumption was seen to increase the 
cerebralblood flow to grey matter 
No effects on behavioural responses or heart rate were seen 
 
(Francis et al., 2006) 
Tablet form Restaverol and 
piperine 
Investigate whether piperine is 
capable of enhancing the 
bioefficacy of resveratrol 
Subsequent effect on cerebral 
blood flow and cognitive 
performance in healthy adults 
-Double-blind, randomised, cross-over, placebo-controlled 
-Three study visits 
-The participants received three single-dose treatments 
-The three treatments comprised two capsules, with each combination 
delivering a placebo, 250 mg of trans-resveratrol or 250 mg of trans-
resveratrol plus 20 mg of piperine 
23 19-34 Participants given 250 mg trans-resveratrol showed no 
changes in cerebral blood flow during cognitive tests 
Co-administration of the same dose of resveratrol with 20 mg 
piperine resulted in significantly increased cerebral blood 
flow. There were no significant differences in any cognitive 
or mood measures 




Omega-3 Polyunsaturated Fatty Acids 
A major characteristic of the modern Western diet is an increased consumption 
of pro-inflammatory omega-6 polyunsaturated fatty acids (PUFA) relative to anti-
inflammatory omega-3 PUFA (Simopoulos, 2002). A such, a diet consisting of a 
greater intake of omega-6 PUFA than omega-3 PUFA has been associated with a 
number of inflammatory related diseases (Simopoulos, 2002). Dietary intakes of 
omega-3 PUFA, in particular, eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA) have been studied in the context of almost every aspect of brain function and 
mental health, from neurodevelopment to age-related cognitive decline, and the 
manifestation and treatment of all the major psychiatric disorders (Freeman et al., 
2006; Baxter et al., 2019). 
Epidemiological data suggest that dietary intake of omega-3 is protective 
against unipolar and bipolar depression (Freeman et al., 2006), and dementia (Huang 
et al., 2005). Although concern has been raised over the methodological quality of 
clinical trials conducted in this field (Bloch & Hannestad, 2012), EPA and DHA have 
purportedly shown some efficacy when used an as adjunct therapy in patients with 
major depression and schizophrenia (Freeman et al., 2006). In addition, a previous 
meta-analysis indicates that omega-3 intervention is beneficial in preventing age-
related cognitive decline (Zhang et al., 2015). 
Preclincial studies have outlined many potential mechanisms by which omega-
3 PUFAs may act in the CNS to promote normal brain function and mental health. 
These include regulation of monaminergic neurotransmission and BDNF levels, 




activity (Pusceddu et al., 2015). Many of these central effects may be mediated by the 
gut microbiota. For example, in-vitro and animal studies suggest that PUFA can 
promote the growth of Lactobacillus strains and conversely Lactobacillus can 
modulate PUFA absorption (Laparra & Sanz, 2010). Interestingly, it has been shown 
that in-vivo treatment of conventional mice with B. breve NCIMB 702258 increases 
brain levels of DHA (Wall et al., 2012). In support of this preclinical data, 
supplementing infant formula with Bifidobacterium Bb-12 increased plasma alpha-
linolenic acid in a small sample of infants with atopic eczema (Kankaanpää et al., 
2002). 
In summary, the evidence indicates that PUFA may have a number of 
physiological effects which are beneficial to brain function and mental health which 














Effect of omega-3 
supplementation on 
cognition and physiology 
in healthy participants  
- Double-blind, placebo-controlled, randomised 
-35 day intervention 
-Treatment group consumed 4 g of fish oil per day 
containing 2.8 g omega-3 PUFA (1.6 g EPA and 0.8 g 
DHA and 0.4 g other types of omega-3 PUFA: alpha-
linolenic, stearidonic, eicosatetraeonic and 
docosapentaenoic acid) 
-Participants were tested on day 1 and day 35 of the 
study 
33 22 - 51 -Omega 3 supplementation associated 
with improvements in reactivity, 
attention and cognitive performances 
-Improvements in mood state were 






Investigate the efficacy of 
EPA as a treatment for 
schizophrenia  
-Double-blind, placebo-controlled, randomised 
-Treatment group given 2 g/day EPA 
-Patients were still given conventional anti-psychotic 
medication if this was necessary  
30 34.4± 8.5 – 
treatment 
36.7 ± 8.1 – 
placebo 
-In the placebo group, all patients 
required conventional anti-psychotic 
medication at the end of the study 
while 6 patients in the treatment group 
were not taking medication 
-Treatment group also had 
significantly lower scores on the 
Positive and Negative Syndrome Scale 
(PANSS)  




Assess the effects of 
omega-3 long chain PUFA 
supplementation during 
pregnancy on infants 
-Double-blind, placebo-controlled, randomised 
-Pregnant mothers given supplementation from 20 
weeks gestation until delivery 







Infants : 2.5 
Mothers : 
30.9 ± 3.7 – 
treatment 
32.6 ± 3.6 – 
placebo 
group 
-Significant positive correlation 
between the eye and hand coordination 
score at 34 months and omega-3 PUFA 
composition of cord blood erythrocytes 
-Omega-6 levels negatively correlated 





Investigate the effects of 
omega-3 supplementation 
on depression-relevant 
cognitive functioning in 
healthy individuals  
-Double-blind, placebo-controlled, randomised 
-4 week intervention 
-Participants given 3 g fish oil/day in 3 soft capsules 
-Each test participant consumed 2.3 g omega-3 
PUFA:1.74 g EPA, 0.25 g DHA 
54 22.2 ± 3.6 – 
treatment 
group 
22.6 ± 4.1 – 
placebo 
group 
-Treatment group made fewer risk-
averse decisions compared with the 
placebo 
-Participants in treatment group also 
showed improved scores on a 
control/perfectionism scale of 
cognitive reactivity measure  












Determine whether long 
chain omega-3 PUFA can 
reduce the rate of 
progression to first-
episode psychotic disorder 
in young adults at ultra-
high risk of psychosis  
-Double-blind, placebo-controlled, randomised 
-12 week intervention period followed by 40 week 
monitoring period 
-Treatment group received 700 mg of EPA/day and 
480 mg of DHA/day 
-Coconut oil was used as placebo 
76 13 - 25 -Treatment group showed reduction in 
rate of transition to psychosis 
accompanied by symptomatic and 
functional improvements during the 
40-week monitoring period 
-By the end of the monitoring period, 2 
of 41 participants in the treatment 
group transitioned to psychosis 







7:1 ratio of 
EPA to 
DHA 
Examine whether omega-3 
supplementation can 
attenuate loneliness-related 
episodic memory problems 
-Placebo-controlled, randomised 
-Participants were given either the placebo, 1.25 g/day 
of omega-3, or 2.50 g/day 
138 40 - 85 -Lonelier participants consuming the 
higher dose supplement had better 
verbal episodic memory compared 
with lonelier participants consuming 
the placebo 
-Improvements in plasma omega-
6:omega-3 ratio were related to better 






Other Dietary Factors That May Impact Brain and 
Behaviour by Modulating the Gut Microbiota 
Previous evidence has indicated that food additives such as emulsifiers and 
food colorants may alter the gut microbiota composition and impact negatively on host 
health (He et al., 2013). For example, administration of the food emulsifiers, 
carboxymethylcellulose (CMC) and polysorbate-80 (P80) to normal mice induced 
low-grade inflammation, metabolic syndrome and induced colitis when administered 
to a genetically predisposed mouse strain (Il10−/− and Tlr5−; (Chassaing et al., 
2015)). Moreover, administration of CMC and P80 altered the gut microbial 
composition in normal mice, and FMT from normal mice induced metabolic syndrome 
and low-grade inflammation in GF animals (Chassaing et al., 2015), thus 
demonstrating that changes in the gut microbiota were necessary for the metabolic 
changes to occur following CMC and P80 treatment. It is yet to be determined if this 
startling finding translates to humans. Nevertheless, it will be important to understand 
if these emulsifiers in food, such as CMC and P80, impact not only on metabolic 
function, but brain function and behaviour. Although the impact of other food 
additives such as colorants on the gut microbiota, have not been extensively studied, 
there is evidence that some may alter the microbial composition (Pan et al., 2012). It 
is of note then, that symptoms of the neurodevelopmental disorder attention deficit 
hyperactivity disorder (ADHD) show a modest response to dietary exclusion of food 
colorants (Sonuga-Barke et al., 2013). This raises the intriguing possibility that food 
colorants may induce symptoms in ADHD via modulation of pathways of the 





Emerging evidence that food additives can alter the composition of the gut 
microbiota must be considered in the context of how these microbial changes might 
impact on brain function and behaviour. Exclusion of such additives from an 
individual’s diet should be considered in complement to additions of functional foods 
which are beneficial for microbial composition and thus brain function and behaviour. 
 
Future Trends & Conclusions 
As the growing body of evidence outlined herein indicates, the gut microbiota 
can influence mammalian brain development and function, ultimately affecting 
numerous psychological processes such as mood, emotion, social interaction and 
cognitive function. The preclinical data are strong in this regard, and studies in rodents 
will continue to be fundamental in providing a mechanistic understanding of 
microbiota-brain interactions. Despite limited attempts to translate these findings to 
humans, emerging data suggest that the microbiota can regulate certain aspects of 
emotional and neuropsychological functioning. 
Pre and probiotic interventions in healthy human adults have demonstrated that 
some bacterial species exert positive effects on emotion, cognition and HPA axis 
function. While these data are encouraging, such studies have been limited in their 
scope of psychological assessment (e.g., mood, emotion, cognition) are confounded 
by lack of specific controls (e.g., diet) and without a comprehensive analysis of a range 
of biological parameters (e.g., faecal microbiota, metabolomic analysis, inflammatory 
markers) to provide a mechanistic account of the physiological processes mediating a 
gut microbiota influence on brain function. Future intervention studies in healthy 




biological and psychological measures to fully determine the effects of pre or probiotic 
species, on specific aspects of brain function and behaviour. 
In clinical populations, current observational data indicate that the gut 
microbiota composition is altered in individuals with depression, ASD and IBS. Future 
studies are needed to clearly define the nature of gut microbiota changes in these 
disorders, and to understand if these disorders are characterised by a specific microbial 
signature. Such studies will help to narrow the search for bacterial species that can be 
targeted for therapeutic benefit. Determining cause and effect will be problematic in 
defining a microbial signature in any mental health disorder, i.e., is the altered 
microbiota composition a cause or a consequence of mental health problems? As such, 
randomised controlled trials with well phenotyped psychiatric populations are clearly 
warranted. 
Developing our understanding of how the gut microbiota influence brain 
function and behaviour at the extremes of life is key priority of ongoing and future 
research. Preclinical studies with GF rodents have demonstrated that the composition 
of the gut microbiota in early life can significantly influence neurodevelopment and 
subsequent cognitive and behavioural function. In parallel, there is supporting 
evidence from epidemiological studies that environmental factors which disrupt the 
gut microbiota in early life, such as birth by C-section, are associated with altered 
neurodevelopmental functioning. Although there has been relatively less focus on old 
age, preliminary evidence that age-related cognitive decline is influenced by the gut 
microbiota composition indicates that microbiota-targeted therapies may prove to be 
of great importance in promoting healthy brain ageing. 
  Finally, the extent to which functional foods (prebiotics, probiotics, omega-3 




promote normal brain function and mental health or will be effective as adjunct to 
current pharmacological therapies, will be important to determine in future studies 
with clinical populations. As will identifying the potential negative impact of certain 
food additives such as emulsifiers and colorants. 
As a rapidly developing field, new findings are continually emerging which 
bolster our knowledge of how the gut microbiota influence brain function and 
behaviour. Despite significant gains over the past decade in understanding the brain 
mechanisms underlying the development and manifestation of most major psychiatric 
disorders, few advances have been made in the discovery of novel CNS acting agents. 
Future use of paraprobiotics (Enck et al., 2020) or psychobiotics, which target 
pathways of microbiota-gut-brain axis, represent a new era in psychotropic therapies 
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• planned sample processing methods and specific sample use within study design, 
• collected stool samples, 
• carried out DNA extraction, 
• planned and prepared 16 S compositional sequencing library, 
• planned and carried out culture-based work and isolated specific microbes, 
• planned and carried out anaerobic culture isolation, 
• planned and carried out statistical analyses, 
• significantly contributed to manuscript preparation. 





Several factors can disrupt the normal colonisation of the infant gut including 
mode of delivery and antibiotic treatment in early life. Caesarean-section (CS) birth 
can significantly alter the infant gut microbiota composition compared with vaginal 
delivery in the early weeks of life, due to the lack of contact during birth between the 
new-born and maternal vaginal and intestinal microbes. This disruption is associated 
with lower numbers of beneficial bacteria such as Bifidobacterium and Bacteroides 
when compared with standard vaginally delivered infants and has been associated with 
an increased risk of developing several disorders later in life such as inflammatory 
bowel disease, asthma and type I diabetes. The use of antibiotics in early life can also 
have a considerable negative impact on the infant gut microbiota with compositional 
changes persisting for at least 1 year after treatment. Evidence suggests that these 
initial perturbations of the infant gut microbiota can have long-lasting effects on health 
such as increased rates of obesity, metabolic and neurodevelopmental disorders. 
This study aimed to examine the influence of such perinatal factors on the 
development of the infant microbiota composition, particularly, the impact of CS birth 
mode coupled with antibiotic exposure following birth on the developing gut 
microbiota of infants over 24 weeks was assessed. After examining the gut microbiota 
composition of three groups of infants (infants born vaginally, infants born by CS who 
had received antibiotics and infants born by CS who had not received antibiotic 
treatment), it was found that antibiotic exposure and CS delivery had a significant 
impact on the infant gut, with differences noted in the relative abundances of many 
taxa along with changes in alpha diversity and beta diversity when compared to infants 






The infant gut microbiota is dynamic and can be influenced by a variety of 
different factors (Marques et al., 2010). As previously mentioned, the infant gut is 
highly susceptible to compositional changes as a consequence of events which can 
occur before birth and in early life (Mueller et al., 2015). These include birth mode, 
antibiotic treatment, maternal stress or infection, gestational age and diet (Milani et 
al., 2017). It is of great importance to understand the initial gut microbiota colonisation 
pattern of healthy infants and the composition alterations which can occur due to these 
perinatal factors. 
 It is recognised that infant gut microbiota development coincides with 
neurodevelopmental windows (Borre et al., 2014). Development during these periods 
is critical as dysregulation can result in long-lasting consequences. It has also been 
suggested that initial early life microbiota colonisation of the infant gut can have 
profound influences on stress and psychological development later in life (Heijtz et 
al., 2011). Development of the brain in utero and into infancy is a methodical and 
highly regulated process involving growth of axons and dendrites, formation and 
remodelling of synapses and myelination. While the brain is undergoing these rapid 
changes in infancy, similarly the infant gut microbiota is maturing and being colonised 
by various microbes in a regulated sequence. As these two developmental periods are 
highly dynamic and fluid, there is a window where disruption can occur before the 
brain and gut reach a more stable, fixed state (O’Mahony et al., 2017). 
It has been established that birth by CS can significantly alter the infant gut 
microbiota and result in long-term health consequences. Vaginally delivered infants 
acquire maternal vaginal microbes as they pass through the birth canal, including 




contact with the mother’s vaginal microbiome, instead they are colonised by maternal 
skin microbes or bacteria present in the hospital environment (Penders et al., 2006). 
Infants delivered by CS are frequently given antibiotics prophylactically, as mothers 
who deliver via CS are at a higher risk for infection (Opøien et al., 2007). 
 Early antibiotic treatment can have a profound and long-lasting effect on the 
infant gut and subsequently, the development of the immune and metabolic systems 
(Ajslev et al., 2011). Many studies have reported that the infant gut microbiota does 
not recover and return to a pre-antibiotic state for months after the antibiotic treatment 
has concluded (Fouhy et al., 2012). Antibiotic treatment in infancy has been associated 
with the development of several conditions later in childhood, including asthma, 
allergic disease and obesity (Mueller et al., 2015). 
Early microbiota perturbations due to CS delivery and antibiotic treatment 
interrupt the co-maturation and crosstalk between the brain and gut, which can lead to 
significant long-term psychological consequences (Yang et al., 2016). While it has 
been shown that CS delivery and repeated early antibiotic exposure result in 
significant infant gut microbiota perturbations, with such substantial gut microbiota 
alterations, it is often difficult to isolate the effects of CS and antibiotics alone. To 
address this, samples collected from infants delivered by CS who received antibiotic 
treatment (CS+ABX) were compared with infants born by CS who had not received 
antibiotic treatment (CS), as well as infants born vaginally (SVD). This allowed for 
examination of the effects of CS alone when compared with infants delivered by CS 
and treated with antibiotics. It was found that both of these factors had a significant 
effect on infant gut microbiota maturation, when compared with vaginally delivered 




antibiotic-treated and non-treated CS groups, which suggests that many of these 
changes were driven by antibiotic exposure. 
 
Materials and Methods 
Participants and sample collection 
Ethical approval for this study was granted by the Clinical Research Ethics 
Committee of the Cork Teaching Hospitals. Infants born by C-section and treated with 
antibiotics for the first four days of life were recruited between January 2015 and 
January 2018 from Cork University Maternity Hospital (CUMH). Additional 
information was collected including feeding type, antibiotic treatment, weight, head 
circumference and incidence of illness. Faecal samples were collected from infants at 
1, 4, 8 and 24 weeks of life. Fresh faecal samples were collected and stored at 4°C and 
transported in temperature-controlled collection bags to the lab for processing. 
The gut microbiota of these infants was compared with a subset of infants who were 
born vaginally, and a subset of infants born by CS who had not received antibiotic 
treatment in the first four days of life from the INFANTMET study (Hill et al., 2017). 
DNA samples collected from these infants at Week 1, 4, 8 and 24 were prepared for 
16 S MiSeq sequencing with the CS+ABX cohort. The faecal samples from the CS 
and SVD cohort have previously been sequenced, however, as this analysis was 
performed in a different laboratory and using different library preparation steps and 
primers, these infant samples were re-sequenced with the CS+ABX cohort to maintain 
consistency. Culture-based analysis was also carried out following the protocols used 





Fresh faecal samples were weighed and serially diluted in maximum recovery 
diluent (Fluka, Sigma Aldrich, Ireland) from 10-1 to 10-8. Bifidobacteria were 
enumerated by spread-plating serial dilutions onto de Man, Rogosa, Sharpe (MRS) 
agar (Difco, Becton-Dickenson Ltd., Ireland), which had been modified by adding 
0.05% L-cysteine hydrochloride (Sigma Aldrich, Ireland), 100 ug/ml mupirocin 
(Sigma Aldrich, Ireland) and 50 units of nystatin (Sigma Aldrich, Ireland). Agar plates 
were incubated anaerobically for three days at 37°C. Lactobacillus selective (LBS) 
agar (Difco, Becton-Dickenson Ltd., Ireland), supplemented with 50 units of nystatin 
was used to enumerate lactobacilli. Agar plates were incubated anaerobically for five 
days at 37°C. Total anaerobic bacteria were enumerated by spread-plating onto 
Wilkins Chalgren agar (WCA) (Sigma Aldrich, Ireland) supplemented with 50 units 
of nystatin and 7% defibrinated horse blood (Cruinn Diagnostics Ltd., Ireland). Agar 
plates were then incubated anaerobically for five days at 37°C. Brain Heart Infusion 
(BHI) agar supplemented with 50 units of nystatin was used to enumerate total aerobic 
bacteria. These were also incubated anaerobically for five days at 37°C. 
 
DNA Extraction 
DNA was extracted from adult faecal samples using the RBB method (Yu & 
Morrison, 2004). A 0.2 g faecal sample was weighed and added to 2 ml screw-cap 
tubes (Sarstedt, Wexford, Ireland) containing 0.25 g of a 1:1 mix of 0.1 mm and 
1.5 mm diameter sterile zirconia beads plus a single 2.5 mm diameter bead (BioSpec 
Products, Bartlesville, USA). To this, 1 ml of lysis buffer was added (500 mM NaCl, 
50 mM tris-HCL, pH 8.0, 50 mM EDTA and 4% sodium dodecyl sulphate (SDS)). 
Each sample was then homogenised using a Mini-Beadbeater™, BioSpec Products, 




mins to lyse the cells. Samples were then centrifuged for 5 min at 16,000 x g and the 
supernatant was transferred to a fresh Eppendorf tube. The bead beating, heating and 
centrifugation steps were repeated using 300 µl of lysis buffer and the supernatant was 
pooled. Following this, 260 µl of 7.5 M ammonium acetate was added and the samples 
were vortexed and incubated on ice for 5 min. Isopropanol was added to precipitate 
the DNA and samples were centrifuged to pellet the nucleic acid. The pellets were 
then washed with 70% ethanol and allowed to dry before being dissolved in 100 µl TE 
buffer. The DNA was treated with RNAse and Proteinase K and washed with Qiagen 
buffers AW1 and AW2 using columns provided in the QIAmp Fast DNA Stool Mini 
Kit (Qiagen, UK). 
The DNA was then eluted in 200 µl Buffer ATE. DNA was quantified using 
the Qubit™ 3.0 Fluorometer (Bio-Sciences, Dublin, Ireland) along with the high 
sensitivity DNA quantification assay kit (Bio-Sciences, Dublin, Ireland). 
 
16S Compositional Sequencing 
The V3-V4 regions of the 16S rRNA gene were amplified and prepared for 




The protocol involved two PCR reactions on the extracted DNA. The DNA 










Each reaction contained 2.5 µl genomic DNA, 5 μl forward primer (1 μM), 5 μl reverse 
primer (1 μM) and 12.5 μl 2X Kapa HiFi Hotstart ReadyMix (Kapa Biosystems Ltd., 
UK). PCR amplification was carried out using the following programme: 95°C x 3 
min, 25 cycles of 95°C x 30s, 55°C x 30s, 72°C x 30s, 72°C x 5 min and held at 4°C. 
PCR products were visualised using gel electrophoresis and then purified using 
AMPure XP beads (Labplan, Kildare, Ireland). Following this, a second PCR reaction 
was performed on the purified DNA using two indexing primers per sample (Illumina 
Nextera XT indexing primers, Illumina, Netherlands). Each reaction contained 5 μl 
purified DNA, 5μl index 1 primer (N7xx), 5μl index 2 primer (S5xx), 25μl 2x Kapa 
HiFi Hot Start Ready mix and 10μl PCR grade water. PCR amplification was 
completed using the previous programme but with only 8 amplification cycles instead 
of 25. PCR products were visualised and purified as described above. Samples were 
quantified using the Qubit™ 3.0 Fluorometer (Bio-Sciences, Dublin, Ireland) along 
with the high sensitivity DNA quantification assay kit and then pooled in an equimolar 
fashion (20 nM). The sample pool was prepared following Illumina guidelines and 




Microbiome Statistical Analysis 
All data were analysed and graphed using either R-3.3.1, Microsoft Excel or 




(SEM). Statistical analysis was carried out using the Kruskal-Wallis test or the 
Wilcoxon signed-rank test for paired data to identify significant differences between 
the groups. Differences were considered significant at p < 0.05. Correction of p-values 
was performed using the Benjamini-Hochberg method (FDR <0.05). The vegan 
package was used for Bray-Curtis based MDS analysis, and the Adonis function in 
vegan was used for PERMANOVA in beta diversity. 
Bioinformatic Analysis 
In brief, the 16S rRNA gene amplicon sequences were processed through a 
bioinformatics pipeline. Resulting 300 bp paired-end reads were assembled using 
FLASH (FLASH: fast length adjustment of short reads to improve genome 
assemblies; (Magoč & Salzberg, 2011)). Further sequence read processing was 
performed using QIIME (Version 1.8.0.) including quality filtering based on a quality 
score of >25 and removal of mismatched barcodes and sequences below length 
thresholds (QIIME allows analysis of high-throughput community sequencing data). 
Denoising, chimera detection and clustering into operational taxonomic units (OTUs) 
(97% identity) were performed using USEARCH (Version 7, 64-bit, search and 
clustering orders of magnitude faster than BLAST; (Edgar, 2010). OTU sequences 
were aligned using PyNAST (PyNAST: python nearest alignment space termination; 
(Caporaso et al., 2009), a flexible tool for aligning sequences to a template alignment) 
and taxonomy was determined using the SILVA SSURef database release 111 (Quast 
et al., 2012), at 97% similarity. Alpha diversity estimates were calculated using 
QIIME. Beta diversity was calculated using Bray-Curtis based multidimensional 






Culture Dependent Analysis 
Stool samples from infants at each time-point were diluted in MRD and plated 
onto four different types of media. Following incubation, plates were removed, and 
colonies were counted. Statistical analyses were not performed on these samples as 








































Enumeration of Bifidobacterium, Lactobacillus, total aerobes and total anaerobes at Week 1, 
4, 8 and 24. Results are presented as Log CFU/g. 
 
16S Compositional Sequencing 
Following 16 S sequencing, there were differences seen between the groups at 
each taxonomic level, throughout the time-points (see Table 3.1 for overview of 
significant differences). It was seen when comparing the gut microbiota of the three 
groups (SVD: Standard Vaginally Delivered, CS: C-section and CS+ABX: C-section 
plus antibiotic treatment) during Week 1 at the phylum level, Bacteroidetes differed 


































SVD (p=0.005), and, to a lesser extent, between the infants delivered by CS and those 
also delivered by CS but who received antibiotics in the first four days of life (p=0.02). 
Relative abundance of Bacteroidetes was seen to be 11% in SVD infants, but less than 
1% in both CS groups (Figure 3.2 A). Additionally, at Week 1, there was a higher 
relative abundance of Verrucomicrobia present in the CS+ABX group when compared 
to the CS group (p=0.04) (Figure 3.2 B). By Week 4, these differences were no longer 
apparent. However, there was a difference in relative abundance of Firmicutes at Week 
4 between the SVD group and both CS groups (Figure 3.2 C). At Week 8, there were 
no differences at phylum level. One significantly different phylum was noted at Week 
24 between the SVD infants and the CS+ABX with higher levels of Actinobacteria in 
the CS+ABX infants (p=0.009) (Figure 3.2 D). 
 At family level, during Week 1, significant differences in Corynebacteriales 
were seen between SVD infants and CS+ABX (Figure 3.3 A). This difference was 
also noted at Week 4, with an additional significant difference in relative abundance 
between SVD and CS infants (Figure 3.4 A). Bacteroidales levels differed at Week 1 
between SVD infants and both CS groups (Figure 3.3 B). This difference was seen 
again at Week 4, however, only between the SVD and CS+ABX group (Figure 3.4 B). 
These differences in Corynebacteriales and Bacteroidales did not occur beyond the 
Week 4 time-point. Flavobacteriales differed significantly between CS and CS+ABX 
at Week 1 and persisted to the Week 24 time-point (Figures 3.3 C, 3.4 C, 3.5 B and 
3.6 B). Additional differences were noted at Week 1 for Bacillales, Erysipelotrichales, 
Selenomonadales, Rhizobiales and Verrucomicrobiales, all of which were resolved by 
Week 4 (Figure 3.3 D, E, F, H and K). Caulobacterales differed at Week 1 and Week 
4 between SVD and CS+ABX (Figures 3.3 G and 3.4 D). This difference was absent 




differences were noted for Burkholderiales and Pseudomonadales at Week 1 between 
SVD and both CS groups (Figure 3.3 I and J). Pseudomonadales was no longer 
significant after Week 8, however the differences in the relative abundance of 
Burkholderiales was still seen at Week 24. Other family level differences included 
Propionibacteriales which only differed at Week 4 between CS and CS+ABX. 
Additional family differences emerged later including Lactobacillales which began to 
differ at Week 8 and continued to Week 24. Bifidobacteriales and Pasteurellales only 
showed significant differences at the Week 24 time-point (Figure 3.6 A and J). 
 At the genus level, many differences in genera were seen between groups 
throughout the first 24 weeks of life. At Week 1, differences were noted which did not 
persist to Week 4 in the following genera: Leucobacter, Staphyloccus, Enterococcus, 
Eubacterium, Dorea, Lachnospira, Eubacterium.coprostanoligenes.group, Proteus, 
Pseudomonas and Akkermansia (Figure 3.7). There were changes in relative 
abundance of additional genera between the groups which were also seen to continue 
to the Week 4 time-point, including Rhodococcus, Flavobacterium, Dolosigranulum, 
Pseudomonas and a genus of the Phyllobacteriaceae family (Figure 3.8). Only three 
genera were significantly different at three of the four time-points sampled: 
Bacteroides, Burkholderia.Paraburkholderia and Veillonella with just 
Chryseobacterium noted to be consistently significantly higher in the CS+ABX group 
at all four time-points. 
 When examining the overall average phylum level relative abundance between 
the groups from Week 1 to Week 24 (Figure 3.11), three main phyla dominate 
throughout the time-points (Proteobacteria, Firmicutes and Actinobacteria). 
Bacteroides is present at between 10-20% relative abundance in the SVD infants, 




abundance of Bacteroides higher than 7% at any time-point. At family level (Figure 
3.12), the dominant taxa are Bifidobacteriales, Lactobacillales, Clostridiales, 
Enterobacteriales, and to a lesser extent Bacteroidales, Bacillales, Erysipelotrichales, 
and Selenomonadales. The differences in abundances of many of these taxa are 
resolved by Week 24 where the two CS groups resemble that of the infants born 
vaginally. This is also seen at genus level. At Week 1, 19 taxa are significantly 
different between the groups, while at Week 24, many of these initial differences have 
resolved, however changes do persist 9 genera (Figure 3.13). 
 Alpha diversity, including species richness, evenness, diversity and observed 
species, was examined between groups at each time-point (Figure 3.14). At Week 1, 
it was noted that there was a difference in the Chao 1 index between infants born by 
C-section (CS) and those born by C-section and treated with antibiotics (CS+ABX) 
(p=0.01). This difference in Chao 1 was also statistically significant at Week 1 
between the CS group and the SVD group (p=0.01). Similarly, changes between these 
groups were also seen with respect to observed species at Week 1, with CS infants 
showing lower observed species than both the CS+ABX and SVD groups. A 
significant difference in phylogenetic diversity between the infants delivered by CS 
and those delivered by SVD was also seen at Week 1, again with the CS infants 
showing reduced diversity. This reduction in phylogenetic diversity also continued to 
Week 4 between the CS and SVD groups. No other statistically significant differences 
were noted between the groups at Week 1, 4, 8 or 24 for any additional alpha diversity 
measures. 
 When examining beta diversity, which was calculated using Bray-Curtis based 
multidimensional scaling (MDS), it was noted that at each time-point, the samples 





Table 3.1: Significantly different taxa at each time-point between 
CS, CS+ABX and SVD infants 
Phylum Week 1 Week 4 Week 8 Week 24 
Bacteroidetes 
 
   
Verrucomicrobia 
 






   
 
 








    
Bacillales 
 
   
Erysipelotrichales 
 
   
Selenomonadales 
 







   
Burkholderiales 
    
Pseudomonadales 

















   
 
Pasteurellales 
   
 
 
Genus   Week 1 Week 4  Week 8  Week 24 
Rhodococcus     
























   
Dorea 
 
   
Lachnospira 
 


















   
Acinetobacter 
 







































Roseburia   
 
 
Escherichia.Shigella   
 
 
Klebsiella   
 
 
Porphyromonas   
 
 
Acinetobacter   
 
 
Bifidobacterium    
 
Bacteroides    
 
Alistipes    
 
Dialister    
 




Significantly different taxa noted at each time-point at phylum, family and genus levels. Green ticks 








































































































































































Significantly different phyla at Week 1 (A and B), Week 4 (C) and Week 24 (D). No 







































































































































































































































































































































































































































































































































































































































































































































































Figure 3.4. Significantly different taxa at family level at Week 4 
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Figure 3.5. Significantly different taxa at family level at Week 8 
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Average Phylum Level Relative Abundance
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Average Family Level Relative Abundance
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Week 1 Week 4 Week 8        Week 24
Average Genus Level Relative Abundance
Bifidobacterium Bacteroides Parabacteroides Staphylococcus Enterococcus
Lactobacillus Streptococcus Clostridium sensu stricto 1 Lachnoclostridium Lachnospiraceae uncultured
Lachnospiraceae Other Erysipelatoclostridium Veillonella Escherichia-Shigella Klebsiella





     
 
 





         












It has been established that perinatal factors can significantly affect the gut 
microbiota progression in infancy (Penders et al., 2006). C-section delivery has 
previously been shown to result in significant disruption in the typical infant gut early 
colonisation pattern. Infants delivered by C-section are initially colonised by microbes 
that are commonly found on skin or in the hospital environment such as 
Staphylococcus and Corynebacterium (Ximenez & Torres, 2017). This bypassing of 
contact with the maternal birth canal results in a significant lack of colonisation by 
maternal vaginal microbes (Wang et al., 2019). Antibiotic exposure during infancy has 
previously been associated with the reduction of beneficial microbes (Hussey et al., 
2011) and the development of allergic diseases and asthma in childhood (Risnes et al., 
2010). 
In this study, we investigated the impact of CS birth mode coupled with 
antibiotic exposure following birth, on the developing gut microbiota of infants over 
24 weeks. As both CS birth mode and antibiotic exposure following birth have 
previously been shown to contribute to a significantly altered microbiota profile in 
infancy, it is not surprising that the CS+ABX infants have a distinctly altered 
microbiota composition at birth. Additionally, it is noted that many of these 
disturbances persist until at least the first 24 weeks of life. 
 Following compositional sequencing at weeks 1, 4, 8 and 24 of life, when 
comparing the gut microbiota of the three groups (SVD: Standard Vaginally 
Delivered, CS: C-section and CS+ABX: C-section plus antibiotic treatment), it was 
found that the most extensive changes were seen at Week 1 with a statistically 




to the SVD group (Figure 3.2 A). Bacteroidetes was reduced from 11.3% in the SVD 
infants to lower than 1% in both other groups. This reduction in Bacteroidetes has 
previously been noted in infants born by C-section, with delayed colonisation found 
to occur in the first two years of life (Jakobsson et al., 2014). This was reflected at 
family level with a reduction in the relative abundance of Bacteroidales in both the CS 
and CS+ABX groups at weeks 1 and 4 (Figure 3.3 B and 3.4 B), and again for the 
genus Bacteroides at weeks 1 and 4 (Figure 3.7 C and 3.8 C). As Bacteroides has been 
reported to be transmitted from mother to infant during vaginally delivery, it is not 
surprising that this genus is reduced in both CS groups. Bacteroides has also been 
noted to play a role in the early immune system (Gregory et al., 2015). Therefore, this 
delayed colonisation may potentially be associated with the development of conditions 
in childhood that have an immune system component. Additionally, while there is a 
reduction in the relative abundance of Bacteroides in the CS group compared to the 
SVD group throughout the taxonomic levels, at Week 4 the CS group appears to be 
recovering slightly and colonisation increases (Figure 3.8 C). This is not seen in the 
CS+ABX group, as the relative abundance remains under 1%. This may be explained 
by the additional antibiotic usage in this group, with effects persisting and continuing 
to delay Bacteroides colonisation. 
 At phylum level, during Week 1, there was an increase in the relative 
abundance of Verrucomicrobia (Figure 3.2 B). This phylum makes up a small 
percentage of the overall relative abundance of the infant gut. However, increases in 
Verrucomicrobia have been seen previously following the administration of broad-




level during Week 1 for Verrucomicrobiales between the CS and CS+ABX groups 
(Figure 3.3 K). 
 Reflecting the differences in the Bacteroidetes phylum during Week 1, there 
was an increase in the family Flavobacteriales between the groups (Figure 3.3 C). This 
increase continued to remain significant between the CS+ABX group and both other 
groups until Week 24. This family has previously been seen to be increased in infants 
treated with antibiotics (Zou et al., 2018) and given the significance at all time-points 
in just the CS+ABX group, it is not unreasonable to suggest that the higher relative 
abundance of Flavobacteriales may be associated with antibiotic exposure at birth. 
This also appears to be the case for the colonisation of Chryseobacterium (Figures 3.7 
D, 3.8 D, 3.9 B and 3.10 C). 
 Many of the significant differences seen in this study reinforce previous work 
that investigated the gut microbiota composition of infants delivered by C-section. C-
section has previously been associated with a lower relative abundance of 
Bacteroidetes and a higher relative abundance of Firmicutes (Rutayisire et al., 2016). 
This is similar to what we see in this study, as Bacteroidetes is significantly reduced 
in both CS groups at Week 1, while Firmicutes is increased in both CS groups when 
compared with SVD infants at Week 4. This was also true for the increase in 
Veillonella seen at Week 24 (Figure 3.10 F) and Klebsiella at Week 8 (Figure 3.9 F). 
Similar increases have been noted previously (Dogra et al., 2015; Hesla et al., 2014). 
Enterococcus has also previously been shown to be significantly increased in infants 
delivered by C-section (Jakobsson et al., 2014). This is also seen in this study, 




additional substantial colonisation increase in this genus, which was significantly 
different than the infants delivered vaginally at Week 1 (Figure 3.7 H). 
 Given that this study compares infants delivered by C-section with infants who 
also undergo this mode of delivery but are treated with antibiotics, it allows 
examination of those taxa that are significantly different in the CS+ABX group, but 
not the CS group, when compared with SVD infants. This can be seen in the relative 
abundance of Chryseobacterium at weeks 1, 4, 8 and 24. The lack of colonisation by 
this microbe in the SVD and CS infants may suggest that the presence of this genus is 
driven by antibiotic exposure. This can also be seen in the relative abundance of Dorea, 
Lachnosapira and [Eubacterium] coprostanoligenes group (Figure 3.7 J, K and L). 
Additionally, we can see from the data that some genera are present in SVD and CS 
groups but specifically reduced in the CS+ABX group, suggesting that CS alone does 
not result in a loss of abundance. This can be seen in the abundance of Dolosigranulum 
at Week 1 (Figure 3.7 G) and Gemella at Week 4 (Figure 3.8 F). 
 When examining the alpha diversity (richness and evenness among individual 
samples) between infants delivered by SVD, CS and CS+ABX at Week 1, a difference 
was seen between the SVD group and the CS+ABX group and also between the CS 
and CS+ABX group for the chao1 diversity measure, with the CS+ABX significantly 
reduced compared to the other two groups (Figure 3.14). Similarly, at Week 1 for the 
number of observed species, there was also a significant reduction in the CS+ABX 
group when compared to the two others. The CS+ABX group was also shown to be 
reduced for the phylogenetic diversity (PD whole tree) at Week 1 when compared with 
the SVD infants. No other differences were noted at Week 1. The differences seen at 




were noted between the groups for the Shannon or Simpson diversity measures at any 
time-point. 
Overall, there was a reduction in alpha diversity between the infants delivered 
vaginally and the two other CS groups, however, this was mostly resolved by week 
four of life. Low alpha diversity has previously been reported as a hallmark of infants 
born by C-section (Wang et al., 2020). In this study, we see a further reduction of alpha 
diversity in the infants who were treated with antibiotics. This has been widely 
reported for both infants and adults and can occur regardless of the specific antibiotic 
type (Di Gioia et al., 2014; Dubourg et al., 2013; Fouhy et al., 2012). However, due to 
the unstable nature of the infant gut microbiome, antibiotic-associated changes can 
take considerably longer to resolve (Yassour et al., 2016). 
In this study, the specific effect of antibiotic treatment on the early gut 
microbiota composition was apparent, with delays in colonisation and increases in 
microbial groups that are not present in the gut of vaginally delivered infants. 
Interestingly, while the significant differences in alpha diversity appear to resolve after 
the first four weeks of life, we can see that longer lasting effects can occur for specific 
microbes. The influence of antibiotics on certain groups of microbes can have 
significant consequences, for example, a reduction in short chain fatty acid producing-
microbes can potentially affect the maturation of the infant immune system (Bokulich 
et al., 2016). 
When examining beta diversity, at each time-point, the groups cluster based 
on their relatedness to each other. The samples cluster or separate based on their 
delivery mode and previously assigned groups (SVD, CS, CS+ABX) at each time-




particularly the SVD group (Figure 3.15 A). At Week 4, the two CS groups overlap 
but are still separating from each other, while the SVD group remains significantly 
separated from the other groups (Figure 3.15 B). During weeks 8 and 24, the groups 
are still clustering based on mode of delivery. However, at Week 24, while they are 
still diverging from each other, there is some increasing overlap when the groups begin 
to show more similarity to the infants born by vaginally delivered. The PCA plots 
show that while the alpha diversity of the samples may not be significant at Week 24, 
and many of the taxa may not show significantly different levels of relative abundance, 
the groups are still more similar to each other based on their mode of delivery than the 
infants in the other groups until at least Week 24. 
Following the analysis of the three groups of infants, when examining the 
impact of mode of delivery and antibiotic exposure, it is evident that these factors 
contribute significantly to disturbances in the infant gut microbiota profile. 
Throughout the compositional data, the significant impact of both C-section delivery 
and antibiotic treatment was apparent, whether it results in a complete lack of 
colonisation by certain microbes that are present in infants delivered vaginally, a 
reduction based on antibiotics specifically, or an increase in microbes that are not 
typically present in the infant gut after vaginal delivery. Additionally, changes are seen 
in both alpha and beta diversity which can persist until at least the first 24 weeks of 
life. These initial gut microbiota disturbances can significantly alter the colonisation 
pattern of the infant gut and have been associated with several negative consequences 
during childhood. Long-lasting C-section- and antibiotic- driven gut microbiota 
disturbances have been shown to increase the risk of developing allergies and asthma 




al., 2017) in childhood, potentially due to the lack of protective effect that early 
colonising microbes can provide. 
Here we have detailed some of the specific microbes which may contribute to 
these long-lasting detrimental effects. Many of the altered taxa reported here due to 
mode of delivery or antibiotic exposure are consistent with previous findings, 
however, we have examined those microbes that are colonising the gut at very low 
relative abundances and potentially are driven by early antibiotic exposure. These low 
relative abundance colonisers should be examined further, to examine the effect these 
may have on the overall microbial profile and whether they are exclusively driven by 
antibiotic exposure in infants. 
Further analysis is warranted in this area to disentangle the specific effects of 
each insult on the developing infant gut. Additional data should be taken into 
consideration including antibiotic type and treatment duration, elective versus 
emergency C-section, inflammatory profile, psychological and cognitive assessments 
and feeding regime. In addition, comprehensive data should be collected on maternal 
health and any other potential factors that may contribute to the immediate 
disturbances of the early infant gut microbiota and the associated negative 
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Colonisation of the infant gut early in life has an important role in directing 
development of the immune system, nervous system and brain. It is well established 
that birth by Caesarean (C)-section disrupts the normal colonisation of the infant gut 
due to the lack of contact between the new-born and maternal vaginal and intestinal 
microbes. Indeed, there is accumulating evidence that C-section delivery bypasses 
stress and immune priming and can have many long-lasting health effects. 
The long-term effects of C-section birth were investigated by examining the 
gut microbiota of a cohort of matched healthy young male university students aged 
between 18 and 24, either born vaginally (N=39) or by C-section (N=37) during a 
Non-Stress period and during university exam stress. The Trier Social Stress Test 
(TSST) was also used to investigate the hypothalamic, pituitary, adrenal (HPA) axis, 
inflammatory and psychological responses to acute psychosocial stress. Participants 
completed a battery of cognitive tests and self-reported measures assessing mood, 
anxiety and perceived stress. Saliva, blood and stool samples were collected for 
analysis of cortisol, peripheral immune profile and microbiota analyses. 
The gut microbiota of C-section and vaginally-born subjects showed similar 
pair-wise relative abundances at phylum, family and genus levels. Additionally, 
diversity levels were not influenced by mode of delivery. However, participants born 
by C-section showed increased psychological vulnerability to acute psychosocial 
stress and exam stress. In conclusion, this study reveals that differences in gut 
microbial profiles that are found between infants born by C-section versus those 
vaginally delivered do not persist into young adulthood. However, the long-term 








Birth by Caesarean-section (C-section) disrupts the normal microbial 
colonisation of the gut, in addition to preventing early stress- and immune-priming, 
increasing the risk of metabolic and immune disorders. The microbiota-brain-gut axis 
plays an important role in psychological processes, but the impact of birth by C-section 
on psychological processes is largely unknown (Dominguez-Bello et al., 2010). 
The timing of developmental processes in the brain is highly precise and occurs 
in distinct phases (Ben‐Ari, 2013). Early colonisation and maturation of the gut 
microbiome occurs in a similarly defined manner. Alterations during these key 
developmental periods of the microbiota-gut-brain axis have been associated with 
long-term consequences in brain signalling and can influence mental health later in 
life (Borre et al., 2014). As the natural progression and maturation of the gut 
microbiota occurs in tandem with immune and brain development, the absence of key 
microbes during this developmental period could potentially have long-term effects. 
C-section delivery can affect the normal colonisation pattern due to lack of 
vaginal microbiota transfer between the mother and the infant. However, these 
microbial alterations appear to be largely resolved by early childhood, with the gut 
microbiota of children who were born by C-section resembling that of children who 
were born vaginally (Fouhy et al., 2019). While initial gut microbiota changes may 
appear to be fully resolved early in life, it is important to note that during this key 




Birth by C-section can have a variety of implications during the first years of 
life. Here, we aimed to examine the long-term consequences of birth by C-section on 
the gut microbiota. We profiled the gut microbiota of 18- to 24-year-old, healthy male 
participants to assess whether those C-section-driven microbiota alterations which 
occur at birth and continue during the first weeks of life progress to adulthood. 
Although microbiome changes have been well documented in C-section born 
individuals (Dominguez-Bello et al., 2010; Hill et al., 2017; Penders et al., 2006), there 
has been limited investigation on the long-term effects of altered gut microbial profile 
on psychological and physiological responses to stress. To fill this knowledge gap, 
adult human volunteers of known birth mode underwent a Trier Social Stress Test 
(TSST) to investigate the HPA axis, inflammatory and psychological response to acute 
psychosocial stress (Allen et al., 2014). While no differences were seen in the gut 
microbiota profile of these participants, long-term psychological vulnerabilities were 




Materials and Methods 
Participants and Sample Collection 
Ethical approval for this study was granted by the Clinical Research Ethics 
Committee of the Cork Teaching Hospitals. Healthy participants aged 18-24 years 
were recruited between December 2014 and December 2015 at the Clinical Research 
Facility, Mercy University Hospital, Cork. An initial screening visit was undertaken 
involving a MINI neuropsychiatric interview and collection of medical history and 
demographics. Study participants were matched on the basis of age, years of 
education, body mass index (BMI) and units of alcohol consumed per week. 
Various clinical, physiological, psychological, psychiatric and cognitive data 
were also collected (see Table 4.1). Half of the participants were initially born by CS 
and half were delivered vaginally. Faecal samples were collected from participants at 
two time-points: during a Non-Stress period and during University exam stress. These 
fresh faecal samples were collected and stored at 4°C and transported in temperature-
controlled collection bags to the lab for processing. In order to assess the impact of 
altered gut microbiota during early life on cognition, endocrine and immune 
responses, a laboratory based public speaking stress (Trier Social Stress Test), eliciting 






Type Measure Baseline Non-Stress Exam Stress TSST (Acute 
stress) 
Clinical C-section/Non-section X    
Medical history X    
Family history X    
Medication record X    
BMI X    
Alcohol intake X    
Smoking habits X    
Birth Info X    
Nutrition: Food frequency questionnaire  X X  
Exercise levels: MET-min  X X  
Sleep quality  X X  
Gut health baseline X    
GI symptoms during stress v Non-Stress  X X  
Physiological Stress, saliva - cortisol levels during acute stress  X  X 
Stress, saliva - cortisol awakening response  X X  
Inflammatory profile, bloods -IL-10   X X X 
Inflammatory profile, bloods -IL-1b   X X X 
Inflammatory profile, bloods -IL-6   X X X 
Inflammatory profile, bloods -IL-8   X X X 
Inflammatory profile, bloods -TNF-a   X X X 






Clinical and psychological data collected from the participants at baseline, during a Non-Stress period, during exam stress and during 
acute stress. 
Urinary metabolomics   X X  
Psychiatric & 
Psychological 
Traumatic life events - childhood X    
Social-cognitive - autism measures X    
Social-cognitive - emotional measures X    
Empathy measures X    
Personality measure X    
Depression & Anxiety - self-report 1  X X  
Depression & Anxiety - self-report 2  X X  
Perceived Stress - self-report  X X  
Stress & Mood - self-report 1  X  X 
Stress & Mood - self-report 2  X  X 
Stress & Mood - self-report 3  X  X 
Cognitive Visuospatial memory (Computer based)  X X  
Impulse control (Computer based)  X X  
Rule acquisition and reversal (Computer based)  X X  
Emotion identification (Computer based)  X X  





Fresh faecal samples were weighed and serially diluted in maximum recovery 
diluent (Fluka, Sigma Aldrich, Ireland) from 10-1 to 10-8. Bifidobacteria were 
enumerated by spread-plating serial dilutions onto de Man, Rogosa, Sharpe (MRS) 
agar (Difco, Becton-Dickenson Ltd., Ireland), which had been modified by adding 
0.05% L-cysteine hydrochloride (Sigma Aldrich, Ireland), 100 ug/ml mupirocin 
(Sigma Aldrich, Ireland) and 50 units of nystatin (Sigma Aldrich, Ireland). Agar plates 
were incubated anaerobically for three days at 37°C. Lactobacillus selective (LBS) 
agar (Difco, Becton-Dickenson Ltd., Ireland), supplemented with 50 units of nystatin 
was used to enumerate lactobacilli. Agar plates were incubated anaerobically for five 
days at 37°C. Total anaerobic bacteria were enumerated by spread-plating onto 
Wilkins Chalgren agar (WCA) (Sigma Aldrich, Ireland) supplemented with 50 units 
of nystatin and 7% defibrinated horse blood (Cruinn Diagnostics Ltd., Ireland). Agar 
plates were then incubated anaerobically for five days at 37°C. Brain Heart Infusion 
(BHI) agar supplemented with 50 units of nystatin was used to enumerate total aerobic 
bacteria. These were also incubated anaerobically for five days at 37°C. 
 
Faecal Water Preparation 
Faecal samples were weighed into a sterile 2 ml Eppendorf tube (0.4 g sample 
in 0.8 ml sterile H20 (2x wt/vol)). Samples were vortexed continuously for 5-10 mins 
to produce a slurry and then centrifuged at 16000 x g for 30 mins. The supernatant 
was removed and transferred to a fresh Eppendorf and centrifuged again for 30 mins 
at 16000 x g. This was repeated once more (three 30 min centrifugations). Following 




(0.2 µm) for 10 mins or as long as needed to fully filter the sample. The faecal water 
was stored at -20 °C until processing. 
 
DNA Extraction 
DNA was extracted from adult faecal samples using the RBB method (Yu & 
Morrison, 2004). A 0.2 g faecal sample was weighed and added to 2 ml screw-cap 
tubes (Sarstedt, Wexford, Ireland) containing 0.25 g of a 1:1 mix of 0.1 mm and 
1.5 mm diameter sterile zirconia beads plus a single 2.5 mm diameter bead (BioSpec 
Products, Bartlesville, USA). To this, 1 ml of lysis buffer was added (500 mM NaCl, 
50 mM tris-HCL, pH 8.0, 50 mM EDTA and 4% sodium dodecyl sulphate (SDS)). 
Each sample was then homogenised using a Mini-Beadbeater™, BioSpec Products, 
Bartlesville, OK, USA) at maximum speed for 3 min and incubated at 70° C for 15 
mins to lyse the cells. Samples were then centrifuged for 5 min at 16,000 x g and the 
supernatant was transferred to a fresh Eppendorf tube. The bead beating, heating and 
centrifugation steps were repeated using 300 µl of lysis buffer and the supernatant was 
pooled. Following this, 260 µl of 7.5 M ammonium acetate was added, and the 
samples were vortexed and incubated on ice for 5 min. 
 Isopropanol was added to precipitate the DNA and samples were centrifuged 
to pellet the nucleic acid. The pellets were then washed with 70% ethanol and allowed 
to dry before being dissolved in 100 µl TE buffer. The DNA was treated with RNAse 
and Proteinase K and washed with Qiagen buffers AW1 and AW2 using columns 
provided in the QIAmp Fast DNA Stool Mini Kit (Qiagen, UK). 
The DNA was then eluted in 200 µl Buffer ATE. DNA was quantified using 
the Qubit™ 3.0 Fluorometer (Bio-Sciences, Dublin, Ireland) along with the high 




16S Compositional Sequencing 
The V3-V4 regions of the 16S rRNA gene were amplified and prepared for 




The protocol involved two PCR reactions on the extracted DNA. The DNA 







Each reaction contained 2.5 µl genomic DNA, 5 μl forward primer (1 μM), 5 
μl reverse primer (1 μM) and 12.5 μl 2X Kapa HiFi Hotstart ReadyMix (Kapa 
Biosystems Ltd., UK). PCR amplification was carried out using the following 
program: 95°C x 3mins, 25 cycles of 95°C x 30s, 55°C x 30s, 72°C x 30s, 72°C x 
5mins and held at 4°C. PCR products were visualised using gel electrophoresis and 
then purified using AMPure XP beads (Labplan, Kildare, Ireland). 
Following this, a second PCR reaction was carried out on the purified DNA 
using two indexing primers per sample (Illumina Nextera XT indexing primers, 
Illumina, Netherlands). Each reaction contained 5 μl purified DNA, 5μl index 1 primer 
(N7xx), 5μl index 2 primer (S5xx), 25μl 2x Kapa HiFi Hot Start Ready mix and 10μl 




with only 8 amplification cycles instead of 25. PCR products were visualised and 
purified as described above. 
Samples were quantified using the Qubit™ 3.0 Fluorometer (Bio-Sciences, 
Dublin, Ireland) along with the high sensitivity DNA quantification assay kit and then 
pooled in an equimolar fashion (20 nM). The sample pool was prepared following 
Illumina guidelines and sequenced on the MiSeq sequencing platform in Clinical 
Microbiomics, Denmark using standard Illumina sequencing protocols. 
 
Metabolomics 
Faecal water and urine collected from the participants were shipped to the 
University of Reading, UK for analysis. A total of 111 urine (61 natural-born - VD, 
and 50 Caesarean-section born - CS) and 140 faecal water samples (76 VD and 64 CS) 
were acquired on a Bruker AV700 NMR Spectrometer equipped with a 5mm 1H 
(13C/15 N) inverse Cryoprobe. All samples were analysed at 300K with a standard 
1H-1 D NOESY (noesypr) with water signal suppression. For each spectrum, 8 
dummy transients were followed by a total of 64 scans, with a relaxation delay (RD) 
of 5 s and acquisition time of 1 s. 
Scans were accumulated in 64k data points with a spectral width of 9803.9 Hz. 
The FIDs were multiplied by an exponential function corresponding to 0.3 Hz line 
broadening. All spectra were referenced to the singlet peak of 3-(trimethylsilyl)-
2,2′,3,3′- tetradeuteropropionic acid (TSP) at 0.0 ppm, manually phased and 
automatically baseline corrected applying a Whittaker smoother algorithm in MNova 
NMR Version 10.0.2 (Mestrelab Research, Spain). Spectra were digitalised and 
imported in Matlab, where the residual water signal, and urea in the urine samples, 




variance (UV) scaled. Principal Component Analysis (PCA) was performed to detect 
metabolic group variations and detect possible outliers. 
Data were further analysed using orthogonal projection to latent structure-
discriminant analysis (OPLS-DA) with 0 or 1 orthogonal components where 1H-NMR 
spectroscopic profiles were used as a matrix of independent variables (X) and birth 
delivery modality as response vector (Y). Data were also analysed using PLS 
regression where independent variables of individual’s bacterial taxa counts (X) were 
used to predict the intensity of the trimethylamine / dimethylamine ratio as response 
vector (Y). The two values R2Y (goodness of fit: percentage of Y explained by the 
model) and Q2Y (the goodness of prediction: percentage of Y predicted after 7-fold 
cross validation) were considered for the OPLS models. Significance of selected 
models was validated by random permutation tests (500 permutations). 
Correlation coefficients plots were constructed from the model outputs by 
back-scaling transformation of the loading to display the contributions of each 
metabolite to sample classification. Metabolites were assigned using Chenomx 
Software (Chenomx Inc.), public metabolic databases (HMDB, http://www.hmdb.ca, 














The TSST procedure began between 13.00-14.30h for each participant, to 
control for diurnal fluctuations in cortisol levels. Participants were instructed to 
abstain from alcohol and strenuous physical exercise for 24 hours prior to visits. In 
addition, they were asked not to consume any caffeine containing products on the day 
of their Non-Stress study visit, and to consume only water for 2 hours prior to the 
TSST procedure. 
After collection of the first saliva sample for measuring salivary cortisol, 
participants rested for a 45-minute baseline period. Participants were then given 
standardised written instructions, introducing the TSST (Figure 4.1) which was carried 
out as previously described by Allen and colleagues (Allen et al., 2014). Participants 
were then led to a separate room, equipped with a video camera and microphone and 
two desks. After reiterating the task instructions, participants were then given a 3-
minute speech preparation period after which, participants were required to perform a 
5 minute speech outlining their suitability for an ideal job of their choice, followed by 
a 5 minute mental arithmetic task in which they serially subtract 17 from 2023. 
Tasks were performed in front of two committee members (one male and one 
female), wearing white laboratory coats and introduced as being experts in identifying 
non-verbal aspects of behaviour. Participants were also informed that their speech 
would be both audio and video recorded for later behavioural analysis. Saliva samples 
and self-reported measures of mood and stress were collected at a number of time-
points pre- and post- the TSST procedure (see below). Participants were fully 






Key stages of the Trier Social Stress Test 
 
Self-Report Measures TSST Mood & Stress Measures 
Mood was assessed using the Positive and Negative Affect Schedule (PANAS; 
(Watson et al., 1988), and psychological stress was measured using a visual analogue 
scale (VAS), ranging from 0 (“not stressed at all”) to 100 (“as stressed as I could 
possibly imagine”). 
 
State Trait Anxiety Inventory 
The STAI is a self-report measure consisting of two subscales each with 20 
items, one measuring trait anxiety and the other measuring state anxiety (Spielberger 
& Gorsuch, 1983). Participants rate how they feel either right now (state) or generally 
(trait), in response to each item on a 4-point scale from ‘not at all’ to ‘very much.’ The 







Perceived Stress Scale (PSS) 
The PSS is a self-report measure in which participants rate, on a 5-point scale 
ranging from 0 (never) to 4 (very often), how often they have particular thoughts or 
feelings described by each of the 10 items (Cohen et al., 1983). Scores range from 0-
40 with higher scores indicating greater stress over the previous month. 
 
Beck Depression Inventory (BDI)-II 
The BDI-II is a self-report measure consisting of 21 items rated on a 4-point 
scale from 0 (absence of symptom) to 3 (severe manifestation of symptom) (Beck et 
al., 1996). Scores range from 0-63. Cut-off scores indicating clinically relevant levels 
of depression have been determined as 0-13 (minimal); 14-19 (mild); 20-28 
(moderate); 29-63 (severe). 
 
Cognitive assessment: Tests from the CANTAB battery 
(http://www.cambridgecognition.com/) 
CANTAB tests were presented on a high-resolution touch-screen monitor under 
computer control. Participants interact with the system by touching the touch-screen 
while a test administrator provides verbal instructions from a standardised script, and 
specific verbal prompts and encouragement when needed. The test administrator has 
full control of a keyboard used to start, pause or abort each test. Participants were 
assessed on the following tests from the battery: 
a) IED: Attentional flexibility and reversal learning 
The IED is a test of executive function and assesses rule acquisition and reversal, 
attentional set formation, maintenance and shifting. The outcome measures assessed 




9, and to determine attentional flexibility performance the errors made on stage 6 and 
8. 
b) Stop Signal Task (SST): Response inhibition 
The SST assesses participant’s ability to inhibit a prepotent response. The outcome 
measure assessed was the stop signal reaction time (SSRT; calculated for last 20 sub-
blocks) 
c) Paired Associates Learning (PAL): Visuospatial memory 
The PAL assess conditional learning of pattern-location associations and gives an 
index of visuospatial memory. The outcome measure assessed to determine 
visuospatial memory was the PAL total errors adjusted. 
 
Statistical analyses for human data 
Independent sample t-tests were used to explore differences in group 
characteristics (age, BMI, years of education and units of alcohol per week). To allow 
for repeated measures analysis and to avoid bias that may be introduced by using list-
wise deletion of incomplete cases (Graham, 2009), missing data analysis was 
performed on physiological, psychological and cognitive variables subject to repeated 
measures analysis. 
In total, 5.95% of data were missing and determined to be missing completely 
at random (MCAR) using Little’s MCAR test (Little, 1988); χ2 (688) = 703.356, 
p=0.334)). Missing values were imputed by assigning the group mean for that variable 
except for cytokine and cortisol awakening response data. All analyses were carried 
out with missing data excluded (data not shown) and missing data imputed, which 
showed that imputing values using this method did not significantly change the nature 




during the TSST were excluded from this analysis. If a participant had missing data at 
all time-points for a given variable (during the TSST or Exam Stress/Non Stress visit) 
missing values were not imputed and the participant was excluded from this analysis. 
Following data imputation, normality checks were performed using the 
Shapiro-Wilk test and visual inspection of histograms. Outliers were checked using 
box and whisker plots and only extreme outliers were considered for exclusion from 
analysis. Salivary cortisol (TSST), IL-10 (TSST), IL 1β (TSST), IL-6 (TSST), IL-8 
(TSST), TNF-α (TSST), IL-8 (Non-Stress/Exam Stress), TNF-α (Non-Stress/Exam 
Stress), PANAS, STAI, BDI and CANTAB PAL (Visuospatial Memory) data were 
not normally distributed and transformed using a natural log transformation (ln); VAS 
psychological stress data were transformed using a square-root transformation; IL-10 
(Non-Stress/Exam Stress), IL-1β (Non-Stress/Exam Stress), IL-6 (Non-Stress/Exam 
Stress), CANTAB IED (Attentional Flexibility / Reversal Learning) data were not 
normally distributed, but no transformations improved normality, so we proceeded 
with parametric analysis but with caution in interpreting the data. 
Salivary cortisol awakening response values at each time-point were converted 
to area under the curve with respect to ground (AUCg) values (Pruessner et al., 2003). 
AUCg cortisol data were not normally distributed, and no transformations improved 
normality, so again we proceeded with parametric analysis but with caution in 
interpreting the data. PSS and CANTAB SST data (stop signal response time last 20) 
were normally distributed and no transformations were performed. Following data 
imputation and transformation (if needed) to improve normality, repeated measures 
analysis of variance (ANOVA) with group as between-subjects factor and change 
across time-points due to stress in each variable (salivary cortisol (TSST), IL-10 




response AUCg ((Non-Stress/Exam Stress), IL-10 (Non-Stress/Exam Stress), IL-1β 
(Non-Stress/Exam Stress), IL-6 (Non-Stress/Exam Stress), IL-8 (Non-Stress/Exam 
Stress), TNF-α (Non Stress/Exam Stress), PANAS Positive/Negative, VAS 
psychological stress, STAI State, BDI, PSS, PAL Total Errors Adj., SSRT last 20, 
IED Attentional Flexibility, IED Reversal Learning) as the within-subjects factor. 
Significant main effects were followed by post-hoc comparisons using a 
Bonferroni correction for multiple comparisons as appropriate. Where Mauchly’s test 
of sphericity was significant, the Greenhouse-Geisser or Huynh-Feldt correction was 
applied. Our primary outcome variable was salivary cortisol output in response to the 
TSST. Based on previous findings from our laboratory, we powered our study to detect 
between-group differences in the salivary cortisol response with a medium effect size 
(f= 0.25). At an alpha of 0.05 and obtaining a power of 0.08, a total sample size of 74 
was required. This calculation is based on a repeated measures ANOVA, between 
factors, using G*Power software. 
Non transformed data are presented as mean ± standard error of the mean 
(SEM). Effect sizes are reported as partial Eta squared (ηp2). All statistical analyses 
were performed using IBM SPSS Statistics 22.0 for Windows software package. 
 
Microbiome Statistical Analysis 
All data were analysed and graphed using either R-3.3.1, Microsoft Excel or 
GraphPad Prism (Version 5). Data are expressed as SEM. Statistical analysis was 
carried out using the Kruskal-Wallis test or the Wilcoxon signed-rank test for paired 
data to identify significant differences between the groups. Differences were 
considered significant at p < 0.05. Correction of p-values was performed using the 




Curtis based MDS analysis, and the Adonis function in vegan was used for 
PERMANOVA in beta diversity. 
Bioinformatic Analysis 
In brief, the 16S rRNA gene amplicon sequences were processed through a 
bioinformatics pipeline. Resulting 300 bp paired-end reads were assembled using 
FLASH (FLASH: fast length adjustment of short reads to improve genome 
assemblies; (Magoč & Salzberg, 2011)). Further sequence read processing was 
performed using QIIME (Version 1.8.0.) including quality filtering based on a quality 
score of >25 and removal of mismatched barcodes and sequences below length 
thresholds (QIIME allows analysis of high-throughput community sequencing data). 
Denoising, chimera detection and clustering into operational taxonomic units (OTUs) 
(97% identity) were performed using USEARCH (Version 7, 64-bit, search and 
clustering orders of magnitude faster than BLAST; (Edgar, 2010). OTU sequences 
were aligned using PyNAST (PyNAST: python nearest alignment space termination; 
(Caporaso et al., 2009), a flexible tool for aligning sequences to a template alignment) 
and taxonomy was determined using the SILVA SSURef database release 111 (Quast 
et al., 2012), at 97% similarity. Alpha diversity estimates were calculated using 
QIIME. Beta diversity was calculated using Bray-Curtis based multidimensional 







Culture Dependent Analysis 
Fresh faecal samples were plated on agar plates to enumerate bifidobacteria, 
lactobacilli, total aerobes and total anaerobes. It was found that there were no 
differences between either VD or CS participants between Non-Stress and Exam 
Stress time-points (Figure 4.2). Additionally, there were no differences seen due to 
mode of delivery at either time-point (Figure 4.3). Samples were compared separately 
using paired and non-paired statistical analyses to examine both the influence of mode 
of delivery and stressed state (VD n=30, CS n=30). There were no effects seen on plate 
counts based on either mode of delivery or time-point. 
  
Figure 4.2 
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Culture dependent analysis examining plate counts to assess if birth mode influences bacterial counts 
 
16S Compositional Sequencing 
Following 16 S compositional sequencing, it was found that the gut microbiota 
composition did not differ between participants born vaginally and those born by C-
section. Average relative abundances were similar between the vaginally delivered 
and the C-section groups (Figure 4.4). Additionally, relative abundances at phylum, 
family and genus levels did not differ between participants based on stress. No 
significant differences were seen at any taxonomic levels between the period of Non-
Stress and the University exam stress (See Figure 4.4). Examination of alpha diversity 
between the groups using the following metrics: Chao 1, Observed Species, 
Phylogenetic Diversity Whole Tree, Simpson index and Shannon index did not show 
any changes between the groups at either time-point (Figure 4.5). Similarly, when 
investigating beta diversity using Bray-Curtis based multidimensional scaling (MDS), 
the samples did not cluster or separate based on mode of delivery or stress time-point 
(Figure 4.6). 
The effect of inflammatory biomarkers Il-10, IL-1B, IL-6, IL-8 and TNF-α on 
the gut microbiota was analysed. A permutational analysis of variance test was 
performed using the function Adonis from the vegan package in R. Adonis models the 
effect of variables on the beta diversity of microbiome samples. At the 5% level of 
significance, the inflammatory biomarkers were found to have no effect on the 
microbiota. 
Furthermore, the effect of stress hormones on the gut microbiota was tested. 




Area Under the Curve metric. This was also tested using the Adonis function. At the 
5% level of significance, the cortisol awakening response was found to have no effect 



















Alpha diversity, calculated using Chao 1, Observed Species, 
Phylogenetic Diversity Whole Tree, Simpson index and Shannon 
index. 
Figure 4.6 
Beta diversity, represented by Bray-Curtis 
based multidimensional scaling (MDS) analysis of faecal microbiota composition in 





Multivariate statistical analysis was applied to the urine samples collected from 
male participants, born by either natural vaginal delivery (VD) or C-section (CS). 
PCAs were applied to identify clustering and outliers. PLS-DA models were built 
using delivery mode as a response vector to identify a linear correlation between the 
two groups and their metabolic patterns. PLS-DA models were built using either 
samples from the Non-Stress (NS) time-point (basal state), samples from the exam 
stress (ES) time-point or a delta matrix (Z). This delta matrix was obtained by 
subtracting Non-Stress samples from exam stress samples, in order to identify 
differences in the metabolic response to stress relative to each individual’s basal Non-
Stress state. 
Analyses undertaken on the Non-Stress samples did not reveal any association 
between birth mode and metabolic fingerprint, therefore these results are not 
discussed. 
PCA analysis on the exam stress samples showed a tendency for the CS group 
to cluster and separate from the VD group along the first component, which describes 
12% of the metabolic variation (Figure 4.7A). The O-PLS-DA model (Figure 4.7B) 
computed using the metabolic stressed state profiles and the mode of delivery as a 
response vector showed a positive Q2Y value (0.1721) associated with a relatively 
good goodness of fit (R2Y=0.61). The OPLS-DA model was validated by 500 random 
permutations, resulting in a p-value of 0.0160, which indicates the robustness of the 
model. 
Analysis of the loadings plot derived from the validated OPLS-DA model 
indicated that most metabolites were moderately contributing to the separation 




trimethylamine (TMA), which was associated with the VD group and dimethylamine, 
which was associated with the CS group (Figure 4.8). 
Trimethylamine (TMA) takes its source directly from the diet and is produced 
as a result of microbial metabolism from amines such as choline, betaine or carnitine. 
In the gut, TMA can then be converted to either dimethylamine (DMA) or 
trimethylamine N-oxide (TMAO) by distinct microbes. Similarly, once TMA is 
absorbed through the intestinal barrier and reaches the liver, its main fate is to be 
oxidised by FMO3, although a small minority can be demethylated into DMA but the 
latter has been shown to be negligible in humans. As a consequence, it can be 
concluded that DMA is mostly from microbial metabolism origin. 
A comparison between the two groups of TMA/DMA ratios can therefore give 
an indication of the ability of gut microbes to demethylate TMA, which was associated 
with vaginal delivery. Hence, the association of DMA with CS volunteers indicates 
that demethylation was increased compared to the VD group. We therefore calculated 
the relative amounts of TMA/DMA in each group (Figure 4.9A). This indicated that 
there was a tendency for the VD samples to be associated with higher TMA/DMA, 
although this difference was not statistically significant with a risk alpha of 5% (t test 
p-value=0.0627). 
We then questioned whether these ratios could be associated with a specific 
gut microbial profile and performed an OPLS (Figure 4.9B) model computed using 
taxa counts as X matrix and TMA/DMA ratio values as Y response vector. However, 
this model had poor predictability and was classed as non significant. 
The statistical analysis summarised here allowed to evaluate whether birth 
delivery modality was associated with different metabolic profiles in stressed state (ES 




from the VD groups, which was also supported by a robust OPLS-DA model (p-value= 
0.0160; Q2Y = 0.1721; R2Y = 0.61). The analysis of the corresponding loadings plot 
to identify the metabolic variations driving the model revealed a complex mixture of 
metabolites. Trimethylamine (TMA) and dimethylamine (DMA) were identified as 
key metabolites involved in this model, as they were associated with the vaginal-born 
group and the Caesarean-born group, respectively. TMA conversion to trimethylamine 
N-oxide (TMAO) or DMA is driven by different microbial metabolic pathways. 
Differences in the TMA/DMA ratio between the two groups (p = 0.06) is therefore 
indicative of distinct microbiota metabolic activity but a regression using individual’s 
microbial composition and TMA/DMA values as response vector failed to link any 
specific microbial profile to this ratio. 
A similar statistical approach was applied to a Z matrix obtained by subtracting 
the NS baseline from ES samples. The PCA analysis showed a tendency to separate 
between the VD and CS groups (Figure 4.10A) along the first components and the O-
PLS-DA model (Figure 4.10B) built on the same matrix using the delivery mode as 
response vector gave a positive Q2Y value (0.2250) associated with a relatively good 
value of goodness of fit (R2Y = 0.59). The strength of the model was validated by 500 
random permutations test (p-value=0.012). The correlation coefficients plot of the 
validated OPLS-DA model was computed to identify the metabolic contribution 
driving the separation. The loading plot resulted in a complex mixture of metabolites 
of low to medium correlation. An identifiable metabolite was DMA, correlated with 
the CS group (Figure 4.11). Compared to the ES dataset, the difference of TMA/DMA 
ratios between the two groups was less pronounced, which was mostly due to a higher 




any linear relationship between TMA/DMA variations and their gut microbial 
composition (Figure 4.12 B). 
The statistical analysis summarised here allowed to evaluate whether the 
delivery modality was associated with a different metabolic response between the two 
investigated groups (VD and CS) in stressful situations. The analysis showed a 
tendency to cluster VD and CS groups and the O-PLS-DA model (p-value=0.012) 
built on the same matrix using the delivery mode as response vector gave a positive 
Q2Y value (0.2250) associated with a relatively good goodness of fit (R2Y = 0.59), 
which indicates that post stress urinary metabolic profiles were affected by the method 
of delivery in some individuals. This is consistent with the results obtained for the 
analysis of ES samples only. An identifiable metabolite was DMA, correlated with the 
CS group, which was also consistent with the ES dataset. The OPLS-DA model failed 
to reveal any linear relation between TMA/DMA ratios in these two groups and their 
gut microbial composition. 
A similar approach to urine samples was applied for the analysis of faecal 
water samples. PCA and O-PLSDA models were built using either only the samples 
collected in the Non-stress (NS) condition (basal state), in the Exam stress (ES) 
condition or a Z matrix obtained by subtracting NS samples from ES samples. PCA 
analyses did not show any clustering of the two groups and all OPLS-DA models 
returned negative Q2Y values, indicating poor model predictability. Overall, 
multivariate statistical analysis of faecal water samples of male adults did not reveal 
any linear variation between birth delivery modality and faecal metabolic profiles in 






Figure 4.7 Supervised and unsupervised multivariate statistical analysis of urine metabolic profile in 
stressed state (ES). 
A - Principal component analysis (PCA) scores plot; B - Scores plot derived from the O-PLS-DA model 
using delivery modality as response vector. The calculated scores (x axis) are plotted against the cross-
validated scores (y axis); R2Y = 0.61; Q2Y = 0.1721; Blue: Vaginal-delivered individuals; Red: 








Figure 4.8 Loadings plot derived from OPLS-DA model using samples in stressed state (ES) and 









Figure 4.9 TMA/DMA values distribution and association with bacterial taxa counts in a stressed 
situation. A – Boxplot describing the distribution of TMA/DMA values of VD and CS groups in stressed 
metabolic state; B - OPLS model using taxa counts as matrix of independent variables and TMA/DMA 
ratios as response vector. The calculated scores (x axis) are plotted against the cross-validated scores (y 









Figure 4.10 Multivariate statistical analysis of urine metabolic profile variation in response to 
stress. A - Principal component analysis (PCA) scores plot; B - Scores plot derived from the O-PLS-
DA model using delivery modality as response vector. The calculated scores (x axis) are plotted 
against the cross-validated scores (y axis); R2Y = 0.59; Q2Y = 0.2250; Blue/VD: Vaginal-delivered 






Figure 4.11 Loadings plot derived from OPLS-DA model using a matrix obtained by 
subtraction of NS basal metabolic profile from the ES stressed profile and delivery modality 
as response vector. Dimethylamine (DMA) was the metabolite with the strongest association 
with CS group. 
 
 
Figure 4.12 TMA/DMA values distribution and association with bacterial taxa counts in response to 
stress. A - Boxplot describing the distribution of TMA/DMA values in VD and CS groups; B - OPLS-DA 
model using taxa counts as matrix of independent variables and TMA/DMA ratios as response vector. 
The calculated scores (x axis) are plotted against the cross-validated scores (y axis); R2Y (variation of 
X explained by the model)= 0.7885; Q2Y (cross-validated predicted percentage of the response Y)= -










In order to assess the impact of altered gut microbiota during early life (due to 
mode of delivery at birth) on cognition, endocrine and immune response to laboratory 
based public speaking stress (Trier Social Stress Test), and a 3-week period of 
naturalistic (university examination) stress, during young adulthood, saliva, blood, 
urine and stool samples were collected from all participants during the acute stress 
exposure (Laboratory based) while a subset of participants (38 natural-born and 32 C-
section) further completed a visit during a period of naturalistic stress (university exam 
period). 
To determine the HPA axis response to acute psychosocial stress, saliva 
samples were collected at seven time-points throughout the TSST; t -45, t0, t+20, t+35, 
t+50, t+65, t+80. C-section participants did not exhibit a differential salivary cortisol 
response to the TSST (Figure 4.14 A). Plasma levels of IL-7, IL-10, IL-1β, IL-6, IL-
8, and TNF-α were assayed in duplicate from blood collected throughout the acute 
stress protocol (TSST). Concentrations of IL-1β (Figure 4.14 B) and IL-10, but not 
IL-6, IL-8 or TNF-α (Figure 4.15; A-D), were significantly higher in C-section 
subjects compared with vaginally-born participants throughout the testing period, 
although this was due to elevated baseline levels and not acute stress. However, the 
anti-inflammatory cytokine IL-10 was significantly elevated during the Exam Stress 
period in C-section participants (Figure 4.16 A). There was no group difference in IL-
1β, IL-6 or IL-8 (Figure 4.16; B-D). Marginally elevated levels of TNF- α were 
observed in the C-section participants during the Non-Stress and Exam Stress periods 
compared with vaginally-born participants (Figure 4.16 E). 
Measures of positive affect were significantly lower throughout the procedure 




participants born by C-section reported greater psychological stress in response to the 
TSST when compared to vaginally-born participants (Figure 4.17 C). To further 
examine the effect of exam stress on HPA axis function, the salivary cortisol 
awakening response (CAR) was measured at each time-point (Non-Stress and Exam 
Stress), but this was not significantly different between C-section and vaginally-born 
participants (Figure 4.17 D). 
When comparing psychological distress levels during the Non-Stress and 
Exam Stress periods, participants born by C-section reported significantly greater 
levels of trait anxiety, perceived stress, but not depression when compared to 
vaginally-born participants, during the Exam Stress period but not during the Non-
Stress period (Figure 4.19). To determine the effect of stress on cognitive function, 
tasks from the CANTAB battery of cognitive tests were used at each time-point (Non-
Stress and Exam Stress). Interestingly, we identified no difference in cognitive 
performance on tests of visuospatial memory, response inhibition attentional 
flexibility or reversal learning between C-section and vaginally-born participants 
during the Non-Stress or Exam Stress period (Figure 4.19). 
 
Figure 4.14 No stress differences were seen between participants during the TSST as measured by 






Figure 4.15 The TSST had no differential effect on immune activity in C-section 
participants in response to the TSST procedure. 
A) Levels of the anti-inflammatory cytokine IL-10 are elevated in C-section participants from baseline 




(Post hoc comparisons using Bonferroni correction: *p> 0.05; **p< 0.01. Data are presented as mean 




















Figure 4.16 Exam stress causes elevated levels of the anti-inflammatory cytokine IL-10 in C-




D) IL- 8 
E) TNF-α 





























Figure 4.17 Positive affect is lower in C-section participants throughout the TSST procedure. C-
section participants also reported increased psychological stress 
A) Positive Affect response as measured using the Positive and Negative Affect Schedule 
B) Negative Affect response to the TSST procedure as measured using the Positive and Negative Affect 
Schedule 
C) Psychological Stress 


























Figure 4.19 Stress response and mood during Non-Stress and Exam Stress periods 
A) Psychological stress as measured using the Perceived Stress Scale showing a significant increase 
in perceived stress levels in the CS delivered participants during exam stress 
B) Depression levels as measured using the Beck Depression Inventory-II. No differences were 
noted between groups at either time-point 
C) Trait anxiety levels as measured using the State Trait Anxiety Inventory showing increased trait 
anxiety level in CS delivered participants during the exam stress period 
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Figure 4.20 Cognitive function did not differ in response to exam stress in C-section 
participants. 
A) Visuospatial memory as measured by the Paired Associates Learning (PAL) test 
B) Response inhibition as measured by the Stop Signal Task (SST), stop signal reaction time (SSRT; 
calculated for last 20 sub-blocks) 
C) Attentional Flexibility as measured by the Intra-Extra Dimensional Set Shift (IED) 
D) Reversal Learning as measured by the IED 






Mode of delivery is a significant factor affecting the microbiota composition 
of infants (Brestoff & Artis, 2013; Makino et al., 2013). Disturbances in the 
appropriate establishment of the microbiota composition at the beginning of life have 
been implicated in long-term programming of health and in increasing susceptibility 
of immune and metabolic disorders (Brestoff & Artis, 2013). Here, we report that the 
known negative outcomes of C-section can include lasting changes in behaviour and 
stress sensitivity, demonstrated by increased psychological distress and anxiety in 
healthy young adults born by C-section. 
We demonstrate that, by adulthood, all differences in gut microbiota which 
would have occurred due to differing birth modes (Dominguez-Bello et al., 2010; Hill 
et al., 2017) are resolved in this adult human population. It was found that the gut 
microbiota of participants delivered by C-section did not differ from those born 
vaginally. In terms of bacterial culture counts, there were no differences noted between 
microbial abundances based on stress or birth mode. This was also true for 
compositional sequencing and diversity analyses. It is interesting to note that while 
the faecal metabolic profiles of the participants did not vary based on delivery mode, 
the urinary metabolic profile indicated that the diversity of metabolic responses to 
stress was partially influenced by birth mode. As there was no correlation between the 
metabolic profile and birth mode during the Non-Stress period, this supports the 
hypothesis that delivery mode has an influence on the individual response to stress. 
The poor correlation between gut microbial profiles and urinary metabotypes indicates 
that this distinction may be due to the collegial action of multiple microbes composing 




models failed to represent the colonic ecosystem associated with this specific 
metabolism. 
 The lack of changes detected in the gut microbiota profiles of these individuals 
supports previous work describing progression towards normalisation of gut 
microbiota profile in C-section babies by 24 weeks post-birth and four years (Fouhy 
et al., 2019; Hill et al., 2017). However, altered microbiome composition at critical 
periods during early life, at a time during which the central nervous system is in a state 
of rapid development, has been negatively implicated in a number of behavioural 
changes in both animals (O’Mahony et al., 2017) and humans (Carlson et al., 2018; 
Christian et al., 2015). 
It is therefore interesting to note, that while the alterations in microbial 
composition have recovered in the young adult cohort, negative psychological effects 
of C-section endure. These preliminary data from healthy human volunteers, implies 
that mode of delivery at birth has a long-lasting effect on immune and stress responses. 
As previously mentioned, the gut microbiota composition of the participants in both 
groups is indistinguishable (Figures 4.4-4.6). However, high levels of IL-1β and IL-
10 noted in C-section participants support a dysregulation of immune-brain signalling 
in regulating behaviour, possibly as a consequence of altered immune priming at birth, 
as certain early microbiome colonisers can influence the maturation of the immune 
system, including promoting production of certain cytokines (Dominguez-Bello et al., 
2010). 
Measures of positive affect in the human cohort were significantly lower 
throughout the acute stress procedure and these individuals reported greater 
psychological stress in response to the TSST. Perhaps surprisingly, there is a 




However, there are a large number of studies which have not reported any relationship 
between self-reported stress and cortisol output (Campbell & Ehlert, 2012). 
To probe this dysregulation in stress sensitivity we took advantage of a 
naturalistic stressor, University examination stress, and found that the anti-
inflammatory cytokine IL-10 was significantly elevated during the Exam Stress period 
in C-section participants and levels of TNF-α were increased. Individuals born by C-
section also reported significantly greater levels of trait anxiety and perceived stress 
during the Exam Stress period but not during the Non-Stress period. 
 Given the importance of mode of delivery in microbiota composition and 
subsequent immune and HPA axis priming, it is tempting to speculate that it may be 
causally related to the changes observed. However, the nature of the current study 
design does not allow us to investigate factors that are responsible for such changes in 
this cohort as they occurred >20 years prior to testing. 
Future studies investigating the role of mode of delivery on the gut microbiome 
and subsequent long-term psychological effects should also include additional details 
on participants, for example, rationale behind CS delivery, details of complicated 
pregnancy, comprehensive maternal information i.e., stress, anxiety, obesity, to allow 
for various microbiome influences to be considered. Additionally, examining the role 
of sex and birth order may be interesting to explore in future similar studies. 
Together, these findings raise significant concerns regarding the increased use 
of C-section deliveries due to the long-term implications for psychological 
vulnerability, immune parameters, and cognition. However, as C-section deliveries are 
frequently unavoidable lifesaving interventions, the possibility of developing 
microbiota-targeted therapies to alleviate any long-term negative consequence on 
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Communication pathways between the brain and the gut have received 
significant attention in recent years. Additionally, it has been shown that the microbes 
residing in the gut can affect the brain and have an impact on several neurological 
processes. This has led to the emergence of the microbiota-gut-brain axis, and further 
examination of the mechanisms involved in communication between the gut 
microbiota and the CNS and implications for brain health. 
Indeed, microbiota-gut-brain axis disruption has been implicated in a variety 
of psychological disorders. Prebiotics and probiotics have gained significant interest 
in recent years as possible therapeutic strategies to alleviate the effects of microbiota 
disturbances on neurological processes. The aim of the current study was to examine 
the impact of treatment with a probiotic, Bifidobacterium longum 1714™, on stress, 
cognition and mood, in a healthy population. A randomised, placebo-controlled, 
repeated measures, cross-over intervention was used. Measures focusing on stress, 
mood and cognition were conducted. In addition, stool samples were also collected to 
examine the gut microbiota composition in response to probiotic treatment. 
Mood was found to deteriorate during the naturalistic stressor for both 
probiotic and placebo groups. However, significant changes in the participants’ sleep 
were noted between the groups. It was found that, during exam stress, while sleep 
quality deteriorated in those individuals consuming the placebo, it remained stable in 










It has become apparent that the gut microbiota, and consequently, the 
microbiota-gut-brain axis, plays a significant role in maintaining and influencing brain 
health (Sampson & Mazmanian, 2015). Several studies have shown the importance of 
a normal microbiota composition with respect to neurodevelopment and behaviour 
(Dinan & Cryan, 2016). Indeed, alterations in microbiota composition can have 
significant effects on physiology and host health (Cryan & Dinan, 2012). As this has 
become more apparent, the use of probiotics to potentially target the microbiota-gut-
brain axis and influence brain function and behaviour has emerged as an interesting 
therapeutic avenue to explore. 
The use of probiotics to alleviate the effects of gut microbiota disruption on 
psychological processes has increased recently, with most clinical interventions 
focused on mood, stress and cognition. However, most probiotic studies to date have 
been conducted animal models, rather than in human subjects. While treatment with 
probiotic strains in animal models is important to examine the potential effects on gut 
microbiota composition and on psychological processes, it is important to recognise 
that many preclinical findings are not translated in human subjects. Promising 
probiotic interventions in animal models cannot always be corroborated in clinical 
studies, the use of a psychobiotic, Lactobacillus rhamnosus JB-1 which had previously 
been shown to affect behaviour in a preclinical study, did not modify any related 
behaviours in a healthy male cohort (Kelly et al., 2017). 
This study investigated the use of a probiotic on chronic stress. Exam stress 
was used as a naturalistic stressor. Utilising the period of exam stress as a 




representation of chronic stress responses on psychological and immunological 
parameters (Zunhammer et al., 2013). 
This intervention was carried out for between seven and nine weeks leading 
up to the participants’ university exams. Several self-report measures and biological 
analyses were used to examine stress, mood and cognition during the exam stress 
periods. Stool samples were also collected to examine the gut microbiota composition. 
While mood and cognition were not statistically significantly different between 
probiotic and placebo groups, a difference was noted in the subjects’ sleep quality. 
Additionally, no differences were seen in the gut microbiome composition in response 

















Materials and Methods 
Participants and Sample Collection 
This study was approved by the Clinical Research Ethics Committee of the 
Cork Teaching Hospitals and conducted in accordance with the ICH Guidelines 
on Good Clinical Practice and the Declaration of Helsinki. Written informed 
consent was obtained from all participants at the screening visit, before any study 
procedures were conducted. Participants were free to withdraw from the study at 
any time. The main inclusion criteria were; that the participant be between 18 and 
30 years of age; be male; be in generally good health as determined by the 
investigator. Exclusion criteria included being less than 18 and greater than 40 
years of age; having a significant acute or chronic illness; having a condition or 
taking a medication that would interfere with the objectives of the study, pose a 
safety risk or confound the interpretation of the study results. From the 30 
participants who were included, 20 completed the study. 
This study was a double-blind, randomised, placebo-controlled, repeated 
measures, cross-over design. Participants were screened before the beginning of 
the intervention and asked a variety of standard demographic and health 
questions. Participants were also screened using the common self-report 
measures (see Table 5.1 for an overview). Following screening, participants were 
assigned to two groups. One group of participants were randomly assigned to 
either the placebo group (maltodextrin) or the probiotic group, while the second 
group received the opposite during the first interveention period. This was 
reversed for the second invertention period in a cross-over, double-blind study 




and intervention) were both taken in once a day in capsule form, with the 
probiotic containing 1 x 109 CFU. 
The study visits involved collection of various samples and measurements, 
including saliva, blood, sand samples and several self-report measures examining 

















Fresh faecal samples were weighed and serially diluted in maximum recovery 
diluent (Fluka, Sigma Aldrich, Ireland) from 10-1 to 10-8. Bifidobacteria were 
enumerated by spread-plating serial dilutions onto de Man, Rogosa, Sharpe (MRS) 
agar (Difco, Becton-Dickenson Ltd., Ireland), which had been modified by adding 
0.05% L-cysteine hydrochloride (Sigma Aldrich, Ireland), 100 ug/ml mupirocin 
(Sigma Aldrich, Ireland) and 50 units of nystatin (Sigma Aldrich, Ireland). Agar plates 
were incubated anaerobically for three days at 37°C. Lactobacillus selective (LBS) 
agar (Difco, Becton-Dickenson Ltd., Ireland), supplemented with 50 units of nystatin 
was used to enumerate lactobacilli. Agar plates were incubated anaerobically for five 
days at 37°C. Total anaerobic bacteria were enumerated by spread-plating onto 
Wilkins Chalgren agar (WCA) (Sigma Aldrich, Ireland) supplemented with 50 units 
of nystatin and 7% defibrinated horse blood (Cruinn Diagnostics Ltd., Ireland). Agar 
plates were then incubated anaerobically for five days at 37°C. Brain Heart Infusion 
(BHI) agar supplemented with 50 units of nystatin was used to enumerate total aerobic 
bacteria. These were also incubated anaerobically for five days at 37°C. 
 
DNA Extraction 
DNA was extracted from adult faecal samples using the RBB method (Yu & 
Morrison, 2004). A 0.2 g faecal sample was weighed and added to 2 ml screw-cap 
tubes (Sarstedt, Wexford, Ireland) containing 0.25 g of a 1:1 mix of 0.1 mm and 
1.5 mm diameter sterile zirconia beads plus a single 2.5 mm diameter bead (BioSpec 
Products, Bartlesville, USA). To this, 1 ml of lysis buffer was added (500 mM NaCl, 
50 mM tris-HCL, pH 8.0, 50 mM EDTA and 4% sodium dodecyl sulphate (SDS)). 




Bartlesville, OK, USA) at maximum speed for 3 min and incubated at 70° C for 15 
mins to lyse the cells. Samples were then centrifuged for 5 min at 16,000 x g and the 
supernatant was transferred to a fresh Eppendorf tube. The bead beating, heating and 
centrifugation steps were repeated using 300 µl of lysis buffer and the supernatant was 
pooled. Following this, 260 µl of 7.5 M ammonium acetate was added and the samples 
were vortexed and incubated on ice for 5 min. 
Isopropanol was added to precipitate the DNA and samples were centrifuged 
to pellet the nucleic acid. The pellets were then washed with 70% ethanol and allowed 
to dry before being dissolved in 100 µl TE buffer. The DNA was treated with RNAse 
and Proteinase K and washed with Qiagen buffers AW1 and AW2 using columns 
provided in the QIAmp Fast DNA Stool Mini Kit (Qiagen, UK). 
The DNA was then eluted in 200 µl Buffer ATE. DNA was quantified using 
the Qubit™ 3.0 Fluorometer (Bio-Sciences, Dublin, Ireland) along with the high 
sensitivity DNA quantification assay kit (Bio-Sciences, Dublin, Ireland). 
 
16S Compositional Sequencing 
The V3-V4 regions of the 16S rRNA gene were amplified and prepared for 




The protocol involved two PCR reactions on the extracted DNA. The DNA 










Each reaction contained 2.5 µl genomic DNA, 5 μl forward primer (1 μM), 5 
μl reverse primer (1 μM) and 12.5 μl 2X Kapa HiFi Hotstart ReadyMix (Kapa 
Biosystems Ltd., UK). PCR amplification was carried out using the following 
program: 95°C x 3mins, 25 cycles of 95°C x 30s, 55°C x 30s, 72°C x 30s, 72°C x 
5mins and held at 4°C. PCR products were visualised using gel electrophoresis and 
then purified using AMPure XP beads (Labplan, Kildare, Ireland). 
Following this, a second PCR reaction was carried out on the purified DNA 
using two indexing primers per sample (Illumina Nextera XT indexing primers, 
Illumina, Netherlands). Each reaction contained 5 μl purified DNA, 5μl index 1 primer 
(N7xx), 5μl index 2 primer (S5xx), 25μl 2x Kapa HiFi Hot Start Ready mix and 10μl 
PCR grade water. PCR amplification was completed using the previous program but 
with only 8 amplification cycles instead of 25. PCR products were visualised and 
purified as described above. Samples were quantified using the Qubit™ 3.0 
Fluorometer (Bio-Sciences, Dublin, Ireland) along with the high sensitivity DNA 
quantification assay kit and then pooled in an equimolar fashion (20 nM). The sample 
pool was prepared following Illumina guidelines and sequenced on the MiSeq 
sequencing platform in Teagasc Food Research Centre, Moorepark, Fermoy, using 






Microbiome Statistical Analysis 
All data were analysed and graphed using either R-3.3.1, Microsoft Excel or 
GraphPad Prism (Version 5). Data are expressed as means ± the standard error of the 
mean (SEM). Statistical analysis was carried out using the Kruskal-Wallis test or the 
Wilcoxon signed-rank test for paired data to identify significant differences between 
the groups. Differences were considered significant at p < 0.05. Correction of p-values 
was performed using the Benjamini-Hochberg method (FDR <0.05). The vegan 
package was used for Bray-Curtis based MDS analysis, and the Adonis function in 
vegan was used for PERMANOVA in beta diversity. 
Bioinformatic Analysis 
In brief, the 16S rRNA gene amplicon sequences were processed through a 
bioinformatics pipeline. Resulting 300 bp paired-end reads were assembled using 
FLASH (FLASH: fast length adjustment of short reads to improve genome 
assemblies; (Magoč & Salzberg, 2011)). Further sequence read processing was 
performed using QIIME (Version 1.8.0.) including quality filtering based on a quality 
score of >25 and removal of mismatched barcodes and sequences below length 
thresholds (QIIME allows analysis of high-throughput community sequencing data). 
Denoising, chimera detection and clustering into operational taxonomic units (OTUs) 
(97% identity) were performed using USEARCH (Version 7, 64-bit, search and 
clustering orders of magnitude faster than BLAST; (Edgar, 2010). OTU sequences 
were aligned using PyNAST (PyNAST: python nearest alignment space termination; 
(Caporaso et al., 2009), a flexible tool for aligning sequences to a template alignment) 
and taxonomy was determined using the SILVA SSURef database release 111 (Quast 




QIIME. Beta diversity was calculated using Bray-Curtis based multidimensional 
scaling (MDS) analysis of faecal microbiota. 
 
Psychological Measures 
As mentioned, a wide variety of psychological measures were examined 
throughout this intervention. However, for the purpose of this manuscript, only certain 
stress response measures have been selected for discussion. 
 
Pittsburgh Sleep Quality Index 
The PSQI measures the sleep quality of the participants using questions 
concerning sleep quality and sleep-related issues. It consists of 19 items referring to 
the last month (Buysse et al., 1989). 
 
Cortisol Awakening Response 
Saliva samples were stored at -80°C before being analysed using a 
commercially available ELISA kit (Enzo Life Sciences). The saliva samples were 
diluted 1:3 with assay buffer and pipetted into a 96-well goat anti-mouse IgG 
microtiter plate. After the addition of cortisol conjugate and mouse monoclonal 
antibody to cortisol, the plate was incubated on a plate shaker at room temperature for 
two hours. Following washing with buffer and removal of air bubbles, the plate was 
incubated at RT for one hour without shaking. Finally, a stop solution was added, and 






Statistics on psychological data 
Following data imputation and transformation (if needed) to improve 
normality, repeated measures analysis of variance (ANOVA) with Time and 
Treatment as the within-subject factors for each variable was performed. Significant 
interaction effects were followed by post-hoc comparisons with paired sample t-tests 
using a Benjamini-Hochberg (BH) correction with a false discovery rate (FDR) of 0.10 
for multiple comparisons as appropriate. Non-parametric equivalents, Friedman and 
Wilcoxon respectively, were used if parametric assumptions were violated. An α of 






















As shown in Table 5.2, there was no significant difference between groups 
on compliance and days on treatment. No effects of time or treatment were found 
for BMI, GI symptom satisfaction, GI symptom life interference, and the Bristol 
Stool Chart. There was a significant effect on physical activity (χ2(3)=10.32, 
p=0.016), expressed in metabolic equivalent (MET)-minutes per week. The higher 
the MET-minutes per week, the more physical activity was carried out. The 
Wilcoxon test showed that there was a significant decrease in total physical 















Compliance - 102.50 - - 94.75 ns 
Days on 
treatment 
- 52.55 - - 53.20 ns 
BMI 24.14 (0.65) 24.26 
(0.72) 
ns 24.23 (0.77) 24.1 (0.71) ns 
MET-
min/week 
5805 (3689) 3408 
(2895) 
0.002 4529 (2973) 4111 (2903) ns 
GI-VAS 
      
-Abdominal 
pain (%) 






0 1 (5) 
 




25.14 (4.83) 17.04 
(4.67) 
ns 20.35 (5.09) 22.76 (5.52) ns 
-Life 
interference 
11.54 (2.93) 8.56 
(2.91) 
ns 9.35 (2.88) 9.75 (2.94) ns 
Bristol Stool 
Chart 
3.33 (1.34) 3.88 
(1.51) 
ns 3.32 (1.56) 3.50 (1.24) ns 
 




Values are the mean score (SEM) or frequency (%). Physical activity, expressed in MET-minutes per 
week, decreased significantly for placebo (p=0.002). BMI: Body Mass Index; MET: metabolic 
equivalent; GI-VAS: Gastrointestinal Visual Analogue Scale. 
 
Pittsburgh Sleep Quality Index (PSQI) 
Significant differences were seen between the baseline and exam stress 
period in the placebo group for subjective sleep quality and sleep latency (see 
Figure 5.2 A & B). Additionally, a trend was noticed for global PSQI score between 
baseline and exam stress in the placebo group (see Figure 5.2 F). During the exam 
period, sleep duration decreased for the placebo group. However, participants 
taking the probiotic had improved sleep duration (Figure 5.3 B). There were no 
effects for the subscales habitual sleep efficiency, sleep disturbances or daytime 
dysfunction (see Figure 5.2 A-C). 
 
Perceived Stress Scale 
There was no effect on the PSS, see Figure 5.4. Total scores (range: 0-40) that 
are ≤13 are considered as a low stress level, 14-26 is moderate, and ≥27 is high. 
 
Beck’s Depression Inventory (BDI-II) 
There was a significant increase for both groups on the BDI-II (χ2(3)=16.120, 
p=0.001). A Wilcoxon test subsequently showed that the depression score increased 
significantly for both probiotic (Z=- 2.769, p=0.006) and placebo (Z=-3.220, 
p=0.001), see Figure 5.5. 
 




There was no effect on cortisol concentrations (χ2(3)=2.116, p=0.549; 
N=19 due to missing samples), see Figure 5.5. 
 
 
Figure 5.2 Pittsburgh sleep quality index (PSQI). 
There was a difference over time for placebo on subjective sleep quality (A; p=0.021), sleep 
latency (B; 0.036), and the global score (F;0.023) of the PSQI. Data is presented as mean ± 






Figure 5.3. Pittsburgh sleep quality index (PSQI) – sleep duration. 
Change from baseline in sleep duration (B) differed significantly between groups (p=0.039). 
Data is presented as mean ± SEM. * p<0.05. 
 
 
Figure 5.4 Perceived Stress Scale (PSS). 




Figure 5.5 Beck’s Depression Inventory (BDI-II). 
Depression score increased over time for both probiotic (p=0.006) and placebo (p=0.001). 






Figure 5.6 Cortisol awakening response (CAR). 
There was no effect on cortisol concentrations. Data is presented as mean ± SEM. 
 
Microbiome Results 
Culture Dependent Analysis 
Stool samples from participants at all time-points were diluted in MRD and 
plated onto four different types of media. Following incubation, plates were removed, 
and colonies were counted. Media used were selective for bifidobacteria, Lactobacilli, 
total number of aerobes and total number of anaerobes. Following enumeration and 
analysis, it was found that there were no differences in bacterial culture numbers 






Figure 5.7 Culture dependent analysis examining bacterial counts for both placebo and probiotic 
groups, before and after interventions. No differences were seen. 
 
16S Compositional Sequencing 
Following compositional sequencing, no differences were noted in relative 
abundance levels between the probiotic and placebo groups for any taxonomic levels 
(Figures 5.8-5.10). Additionally, when examining the alpha diversity, there were no 
probiotic-driven differences noted within samples in terms of species richness, 
evenness, diversity or observed species (Figure 5.11). When investigating the 
relatedness of samples, it was found that the samples did not cluster based on probiotic 





































































































































































































            





The use of probiotics has gained significant attention in recent years, however, 
many of the studies that have been completed to date have been in preclinical animal 
models. Many examples of interventions in rodent models have shown promise, 
including the use of Bifidobacterium longum NCC3001 over a 2 to 3-week period, 
which showed a reduction in anxiety-like behaviour in a mouse model of colitis 
(Bercik et al., 2011). Additionally, intervention with Lactobacillus rhamnosus JB-1 
has been shown to reduce stress-induced anxiety (Bharwani et al., 2017). Previously, 
two Bifidobacterium strains have shown to reduce stress, anxiety and depression- 
related behaviours in BALB/C mice, suggesting that some Bifidobacterium strains 
may have significant psychobiotic potential (Savignac et al., 2014; Savignac et al., 
2015). 
Of the limited number of human probiotic interventions conducted to date, 
several strains have shown promise, including L. casei strain Shirota, which has been 
shown to reduce symptoms of anxiety and stress in cohorts experiencing exam stress 
and chronic fatigue (Rao et al., 2009; Takada et al., 2016). Bifidobacterium longum 
NCC3001 has been shown to reduce anxiety and depression in IBS suffers (Pinto-
Sanchez et al., 2017), while depression scores have also been reduced after 
intervention with a cocktail of L. acidophilus, L. casei, and B. bifidum in a cohort of 
individuals suffering from MDD (Akkasheh et al., 2016). For a comprehensive list of 
probiotic interventions in preclinical models and clinical cohorts, see an extensive 
current review by Cryan and colleagues (Cryan et al., 2019). 
This study aimed to examine the effect of Bifidobacterium longum 1714 
supplementation on stress, mood and cognitive performance in healthy participants 




identified as a modifier of stress and cognition in preclinical studies (Savignac et al., 
2014; Savignac et al., 2015). Following this, it was investigated whether these 
promising findings could be translated to a human cohort. In a repeated measures, 
placebo-controlled design, 22 healthy male participants were given placebo for four 
weeks followed by 1 x 109 CFU/day for four weeks (Allen et al., 2016). The socially 
evaluated cold pressor test (SECPT) was used to elicit an acute stress response in the 
volunteers. Intervention with the probiotic was found to result in a reduction in daily 
stress and state anxiety, accompanied by a reduction in cortisol output in response to 
the cold pressor test. 
Our current study examined the use of this promising psychobiotic in a double-
blind, randomised, placebo-controlled, repeated measures, crossover study design. 
Each intervention period lasted for 8 weeks, twice as long as the previous clinical 
study. Stool samples were collected from participants before and after each 
intervention period. It was found that the probiotic was well tolerated by the 
participants, with no GI issues reported. When examining the gut microbiota profile 
of the participants, it was seen that no differences were present between the placebo 
and treatment groups for culture-based analysis. Additionally, following 16 S 
compositional sequencing, the probiotic was not seen to affect the gut microbiota 
profile. There were no differences seen in relative abundances at any taxonomic levels. 
Additionally, no changes were observed within samples with respect to sample 
diversity or evenness. Furthermore, samples did not cluster based on probiotic or 
placebo treatment. This is unsurprising, given the length of the intervention. However, 
with longer intervention periods, reduced compliance is more common. Additionally, 
a lack of major changes in the gut microbiota composition after administration with a 




microbiota composition after the probiotic intervention at relative abundances higher 
than 1%, it may be interesting to examine any subtle microbial changes or trends 
toward reduced or increased abundance in genera present at lower abundance levels. 
Indeed, many subtle probiotic-driven changes that have been reported in clinical 
studies have been minimal and required further investigation than what has been 
completed here to notice associations between specific OTUs and probiotic 
administration (Bagga et al., 2018). Furthermore, studies that have reported such 
minimal changes have used a cocktail of 8 or 9 different bacterial strains. 
Additionally, the lack of gut microbiota changes is consistent with the lack of 
probiotic effects seen on stress and depression in this study. This absence of influence 
can possibly be explained by the cohort examined. These healthy male individuals are 
not stressed at baseline and have low baseline BDI scores. Additionally, the 
participants’ responses to the Primary Appraisal Secondary Appraisal (PASA), 
suggest that this cohort are particularly capable of dealing with stress. They perceive 
their exams as somewhat more of a challenge, rather than a stressor that they have no 
control over. Furthermore, while the naturalistic exam stressor did increase depression 
scores in both groups, it did not have an effect on salivary cortisol in these participants. 
In contrast, the acute stressor used in the previous clincial study conducted by Allen 
and colleagues did increase salivary cortisol and allowed for the influence of the 
probiotic to be measured (Allen et al., 2016). It is not unreasonable to hypothesise that 
this cohort, who are quite capable of coping with exam stress, may be affected by 
hypothalamic-pituitary-adrenal axis habituation across repeated exposure, with a 
reduction in stress responses over successive exam periods, and thus, this stressor may 
not be the most suitable for this particular cohort. Perhaps if, in addition to naturalistic 




efficacy of this probiotic could be examined more comprehensively. Additionally, it 
is important to note the sample size used in this study may not be sufficient. 
While there were no influences of the probiotic on stress or depression noted 
in this cohort, an effect on sleep quality was found. Differences were seen between the 
baseline and exam stress period in the group consuming placebo for subjective sleep 
quality and sleep latency. Sleep duration was also seen to decrease during exam stress 
in the placebo group, while those participants taking the probiotic had improved sleep 
duration. This suggests that the probiotic may be beneficial during stress to maintain 
sleep quality. 
A study investigated the ability of this Bifidobacterium longum 1714 strain to 
modulate brain function in a human cohort (Wang et al., 2019). The study was 
conducted with 40 volunteers using a randomised, double-blinded, placebo-controlled 
design. Participants received either placebo or 1 x 109 CFU/day of the probiotic for 
four weeks. Brain activity was measured using magnetoencephalography. The effects 
on neural responses to social stress were examined. This was conducted using the 
“Cyberball Game” (CBG), a social stressor. The CBG is a ball tossing game in which 
the participant has to toss the ball to two other virtual players who are programmed by 
the tester. The participant believes that these two players are real and are playing the 
game, just the same as they are. This induces social stress through periods of inclusion 
and exclusion, where the two other players just throw the ball to each other and leave 
the participant out. All participants experienced social stress, however, neuroimaging 
showed that the neural activities of the participants consuming the probiotic were 
significantly altered after the four-week intervention, both at rest and during social 
stress. Neural activity was measured, examining frequency band power in various 




associated with mental fatigue, while a reduction in beta band power is linked to 
alertness and reduced anxiety. They concluded that consumption of the probiotic led 
to neural alterations in a manner associated with increased vitality and reduced mental 
fatigue. While both groups responded to social stress, only the participants consuming 
the probiotic showed changes in neural processing, which suggests that 
Bifidobacterium longum 1714 may play a role in how stress is processed in the brain 
and could possibly manage stress by modulating certain neural processes. 
While the potential for interventions using Bifidobacterium longum 1714 and 
other psychobiotics targeting stress and anxiety is an attractive one, further 
investigations are necessary to examine the mechanisms by which stress can be 
modulated. While Bifidobacterium longum 1714 in the above study did not reduce 
levels of social stress when compared with placebo, the authors noticed that the neural 
changes in the probiotic group were also present at baseline and not in the placebo 
group, suggesting that this probiotic might be involved in priming of the individuals 
in anticipation of the stressor and subsequently modifying neural processes to 
modulate stress responses. This may be interesting to note in further study designs 
investigating the effect of Bifidobacterium longum 1714 during acute stress. Perhaps 
for an effect to be noted, the stressor should be conducted at the end of the intervention 
period. Furthermore, in light of this study examining B. longum induced neural 
changes, it is not unreasonable to assume that perhaps in our current study, this 
probiotic did have an effect on brain function which led to the improvements noted in 
the sleep quality. 
The use of Bifidobacterium longum 1714 in this current study had an effect on 
sleep quality and duration during exam stress when compared with placebo, which 




as this cohort was uniquely adapted to stress, there were no influences noted on mood 
or stress responses. Additionally, it has been previously reported that probiotics 
exhibit the maximum influence if they are given to a population that requires an 
intervention, i.e., Benton and colleagues showed that after probiotic consumption, 
effects were noted in participants who were experiencing more depressive symptoms 
than those whose mood was generally higher (Benton et al., 2007). 
It is tempting to speculate that this probiotic may be more beneficial and show 
greater effects during acute stress periods. Further investigations should be carried out 
in different populations, instead of healthy volunteers, for example, in those who are 
experiencing clinical anxiety or depression. This would allow for examination of the 
impact of Bifidobacterium longum 1714 in a cohort whose baseline levels are lower 
than the normal population, to assess the ability of the probiotic as a possible 
restorative treatment back to baseline levels seen in a healthy population. 
While many positive effects on stress, cognition and behaviour have been 
noted after probiotic administration, additional robust clinical trials are necessary, 
accompanied by the analysis of wider biological parameters, particularly focusing on 
the mechanisms involved in probiotic modifications. The continued research into the 
use of probiotics targeting mood, stress responses and cognition promises to be an 
important avenue of investigation however, much additional work is needed before 
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REVISITING METCHNIKOFF: AGE-RELATED 
ALTERATIONS IN MICROBIOTA-GUT-BRAIN AXIS 
















• planned sample quantity and processing methods, 
• carried out DNA extraction, 
• conducted short chain fatty acid analysis, 
• planned and prepared 16 S compositional sequencing library, 
• planned and carried out statistical analyses, 
• significantly contributed to manuscript preparation. 
 






Over the last decade, there has been increased interest in the role of the gut 
microbiome in health including brain health. This is by no means a new theory; Elie 
Metchnikoff proposed over a century ago that targeting the gut by consuming lactic 
acid bacteria such as those in yogurt, could improve or delay the onset of cognitive 
decline associated with ageing. However, there is limited information characterising 
the relationship between the behavioural and physiological sequelae of ageing and 
alterations in the gut microbiome. 
To this end, we assessed the behavioural, physiological and caecal microbiota 
profile of aged male mice. Older mice (20-21 months old) exhibited deficits in spatial 
memory and increases in anxiety-like behaviours compared to younger mice (2-3 
months old). They also exhibited increased gut permeability, which was directly 
correlated with elevations in peripheral pro-inflammatory cytokines. Furthermore, 
stress exacerbated the gut permeability of aged mice. Examination of the caecal 
microbiota revealed significant increases in phylum TM7, family 
Porphyromonadaceae and genus Odoribacter of aged mice. This represents a shift of 
aged microbiota towards a profile previously associated with inflammatory disease, 
particularly gastrointestinal and liver disorders. Furthermore, Porphyromonadaceae, 
which has also been associated with cognitive decline and affective disorders, was 
directly correlated with anxiety-like behaviour in aged mice. 
These changes suggest that changes in the gut microbiota and associated 
increases in gut permeability and peripheral inflammation may be important mediators 





Over 100 years ago, Nobel Prize winner Elie Metchnikoff hypothesised that 
beneficial bacteria contained in fermented foods could influence health and delay 
cognitive decline by manipulating the intestinal environment (Cryan & Dinan, 2015; 
Mackowiak, 2013). Although popular at the time, the theory was largely ignored by 
the medical community until a recent resurgence in interest over the past 20 years 
(Mackowiak, 2013). The gut microbiome is now recognised to play a critical role in 
health and disease, and this is especially true at the extremes of life (Borre et al., 2014; 
Brüssow, 2013; Candela et al., 2014; Heijtz, 2016; Dinan & Cryan, 2016). Indeed, 
changes in microbial composition have been shown to have a distinct impact on health 
outcomes in infants and in the elderly and also is thought to play a key role in 
modulating gut-brain axis function, influencing brain and behaviour (Borre et al., 
2014; Jeffery & O'Toole, 2013). However, there is limited information on how ageing 
regulates this axis. With advances in healthcare, longevity has markedly increased; 
currently it is estimated that within 50 years, approximately 20% of the world 
population will be classified as elderly (Ellison et al., 2015). Ageing is associated with 
a number of behavioural and physiological changes, including physical decline, 
altered mood and cognitive impairments (Ellison et al., 2015; Eshkoor et al., 2015; 
Joyce & Reich, 2015). Although we cannot stop the march of time, the manner in 
which one ages can vary greatly; thus there is significant research interest in 
understanding the biological basis of healthy ageing (Li & Schmiedek, 2002). 
 
Gastrointestinal (GI) disorders are frequently reported in elderly individuals, 




Meerveld, 2013). These include malnutrition as a result of poor nutrient absorption, 
reduced gut motility, associated with constipation, diverticulosis from structural 
weakening of the GI tract, and increased susceptibility to colon cancer (Langille et al., 
2014). Ageing in humans and laboratory animals is also related to increased intestinal 
permeability and increased colonic cytokine expression resulting in chronic systemic 
inflammation which has been termed “inflamm-ageing,” (Deleidi et al., 2015; 
Peterson et al., 2015; Tran & Greenwood-Van Meerveld, 2013). 
The mechanisms underlying the increased intestinal permeability and 
peripheral inflammation are still unclear, but the gut microbiota is thought to play a 
critical role. It is now widely recognised that the gut microbiota is a key modulator of 
homeostasis, and perturbation of its composition can result in gut dysfunction. 
Furthermore, the composition of the gut microbiota in both humans and laboratory 
animals varies across the lifespan (Biagi et al., 2013; Jeffery & O'Toole, 2013; 
Langille et al., 2014; Lynch et al., 2015; Rehman, 2012). In general, as an individual 
ages, the microbiota shifts in numerous ways that may predispose one to inflammation. 
In addition to the physical deterioration of the body, such as increased risk of 
disease and frailty, there is great interest in the effects of ageing on the central nervous 
system (Prenderville et al., 2015). Psychiatric conditions, most notably anxiety, 
depression, and social withdrawal are frequently reported in the elderly 
(Kastenschmidt & Kennedy, 2011; Prenderville et al., 2015). It is also well established 
that peripheral inflammation can directly affect neuroimmune processes in the central 
nervous system (CNS) resulting in impaired cognitive function (Block et al., 2007; 
Perry, 2010; Zheng et al., 2015). Moreover, circulating inflammatory markers are 
often elevated in individuals with mood disorders (Block et al., 2007; Kelly et al., 




age-related alterations in intestinal microbiota and function contribute to chronic 
systemic inflammation. This may, in turn, lead to central inflammation, manifesting 
in cognitive impairment. 
Taken together, it is clear that the microbiota-gut-brain axis plays a critical role 
in health, and perturbations in this axis have been implicated in numerous pathological 
conditions. However, there are a limited number of studies focused on its impact on 
ageing-induced behavioural and neurobiological outcomes, notwithstanding 
Metchnikoff’s theory that microbes may be the underpinnings of longevity (Cryan & 
Dinan, 2015). To this end, we hypothesised that alterations in the gut microbiota of 
young and aged mice will correlate with changes in intestinal permeability, 




Materials and Methods 
Animals 
All animal protocols were approved by the Animal Experimentation Ethics 
Committee at University College Cork (UCC) and by the Health Products Regulatory 
Authority (HPRA) of Ireland, in accordance with EU Directive 2010/63/EU. Twelve 
young (2 month old) and 10 aged (18 month old) male C57BL/6 J mice were obtained 
from Charles River (France) and housed 2-4 per cage. All mice were housed in the 
same temperature and humidity-controlled animal room with a 12 h light:dark cycle 
and were maintained on ad libitum standard chow and water unless otherwise noted. 




All mice were exposed to a battery of well-validated behavioural tests designed 
to assess cognitive function as well as depressive- and anxiety-like behaviours over a 
period of 5 weeks. Young mice were approximately 2-3 months old and aged mice 
were approximately 20-21 months old at the time of behavioural testing. Behavioural 
tests were performed in what we considered to be increasing severity to lessen the 
likelihood of the prior testing influencing future tests. Tests were performed in the 
following order: 1) Object location, 2) Y-maze, 3) 3 chamber, 4) elevated plus maze, 
5) open field, 6) forced swim test and 7) gut permeability tests. A washout period of 2 
days was observed between behavioural tests 1-6. A washout period of 2 weeks 





Forced swim test 
The forced swim test (FST) was used to assess anti-depressant-sensitive 
behaviours and is based on the premise that immobility, performing the minimum 
amount of movement to keep one’s head above water, is a marker of depressive-like 
or despair-like behaviour (Cryan & Mombereau, 2004; Porsolt, 1979; Porsolt et al., 
1978). FST was performed under full light conditions (1000 lux). The tank was a glass 
cylinder measuring 21 cm in diameter and filled to a depth of 15 cm with 24°C tap 
water. The test was videorecorded from above for 6 min, and afterwards the mouse 
was removed from the tank, dried with a towel and placed into an individual cage for 
recovery. Ninety minutes post-test, mice were returned to their home cages. Water was 
changed between each test. Immobility was assessed for the last 4 min of the FST and 
was defined as the animal not actively swimming or moving and performing the 
minimal amount of activity necessary to keep the head above water. 
Spontaneous alteration in the Y-maze 
The Y-maze was performed as a test of spontaneous alternation, used to assess 
exploration, cognition and hippocampal-dependent memory (Hughes, 2004; Senechal 
et al., 2007). It is based on the premise that mice will alternate between arms visited 
when exploring a new environment. The test was performed as previously described 
with minor adaptation (Senechal et al., 2007). Mice were brought into the testing room 
and allowed to habituate for at least half an hour before testing. The Y-maze was 
constructed from black plastic and each arm measured 16 x 6.5. Lighting within the 
Y-maze was 25 lux. The mouse was placed at the end of the first arm facing the wall. 
Behaviour was videorecorded from above for 5 min after placement within the maze. 
The Y-maze was wiped down with 70% ethanol between tests. An entry into an arm 




of consecutive entries into the three maze arms. This was calculated as the number of 
alternations divided by the total number of arm entries during the 5 min test period. 
Novel Object/Object Displacement test 
The combined Novel Object/Object Displacement test (NOR) was used to 
assess cognitive function, including and spatial working memory and is based on the 
premise that mice will spend more time interacting with a novel or displaced object in 
comparison with a familiar object in a familiar location (Antunes & Biala, 2012). Mice 
were brought into the testing room and allowed to habituate for at least half an hour 
before testing. The test arena was a grey plastic box, measuring 32 x 40 cm. Lighting 
within the test arena was approximately 60 lux. The arena was wiped with ethanol 
after each test. Day one consisted of habituation to the empty test arena; the mouse 
was placed in the centre and allowed to explore for 10 min, while behaviour was 
videorecorded from above. After this period, the mouse was returned to its home cage. 
The acquisition phase of the study was performed on day 2. Again, mice were given 
at least 30 min to habituate to the testing room. During the acquisition phase, the 
mouse was placed in the centre of the test arena where 2 identical objects were placed. 
The mouse was allowed to explore for 10 min, after which it was returned to its home 
cage. After a 3 h period, the mouse was returned to the test arena with the same objects, 
however one of the objects was now in a different location. The mouse was allowed 5 
min to explore and time spent interacting with the 2 objects was videorecorded, after 
which it was returned to its home cage. This comprised the Object Displacement phase 
of the study. Following a 5 min break, the mouse was returned to the test arena where 
the displaced “familiar” object was replaced with a novel one. Exploration of an object 




Open field test 
The open field (OF) test was used to assess locomotor activity and anxiety-like 
behaviour and is based on the premise that mice will avoid open areas (the centre of 
the test arena), which are anxiety-provoking and will spend more time near the walls 
(thigmotaxis) (Gould, 2009; Hall & Ballachey, 1932). Mice were brought into the 
testing room and allowed to habituate for at least half an hour before testing. The OF 
arena was a white plastic box measuring 32 x 40 cm and the test was performed under 
full light conditions (1000 lux). Mice were placed in the centre of the arena and 
behaviour was recorded from above for 10 min. Mice were returned to their home cage 
following the test and the arena was wiped down with ethanol. Distance travelled and 
entries into centre of the arena was analysed using Ethovision (Noldus, Waeginingen, 
Netherlands). 
Elevated Plus Maze 
The elevated plus maze (EPM) was used to assess anxiety-like behaviour and 
is based on the premise that mice prefer enclosed areas when exposed to a novel 
environment and will spend less time in open areas, which are anxiety-inducing 
(Pellow et al., 1985). Mice were brought into the testing room and allowed to habituate 
for at least half an hour before testing. The room was lit by one red light and the 
lighting in the centre of the EPM measured 9 lux. The elevated plus maze was 
constructed of black plastic and had 4 arms measuring 50 x 5 cm. Walls on the 2 closed 
arms were 15 cm high whereas the 2 open arms had no walls. The plus maze rested on 
a platform 1 m high. For testing, the mouse was placed in the centre of the EPM facing 
an open arm. Behaviour was videorecorded from above for 5 min, after which the 
mouse was returned to its home cage. The EPM was wiped down with ethanol solution 




arm. The number of entries and percentage of time spent in open and closed arms were 
calculated. 
3-chamber test of social behaviour 
Sociability was assessed using the 3-chamber social interaction test, in which 
time spent interacting with a novel conspecific is compared to time spent with a novel 
object or familiar conspecific. It is based on the premise that mice will spend more 
time interacting with a novel conspecific than novel object, and that they will prefer a 
novel conspecific to a familiar one. Mice were brought into the testing room and 
allowed to habituate for at least half an hour before testing. The 3-chamber social 
interaction test was performed as previously described (Desbonnet et al., 2014; 
O'Tuathaigh et al., 2007). The test arena consisted of 3 chambers; the left and right 
chambers measured 13.5 x 20 x 20 cm and the centre chamber was 9 x 20 x 20 cm. A 
solid partition separated the chambers, which could be replaced with partitions with a 
small hole enabling access to the other chambers. There were 3 phases of the test: 
habituation, sociability, and social novelty preference. All phases of the test were 10 
min in duration, performed sequentially and videorecorded from above for later 
analysis. During Phase 1, the habituation phase, the mouse was placed into the centre 
chamber and then allowed access to the empty left and right chambers for 10 min. The 
mouse was then returned to the centre chamber and a novel mouse was placed in a 
mesh cage in one of the side chambers, whereas a novel object (a small rubber duck) 
was placed in a mesh cage in the other side chamber for Phase 2. Location of the novel 
mouse and novel objects were randomised between animals to eliminate side 
preferences. The mouse was then allowed to explore these chambers for 10 min, after 
which it was returned to the centre chamber. For the 3rd phase, a new, novel mouse 




was then allowed to explore the chambers, which held the familiar mouse (from Phase 
2) and the novel mouse, for 10 min. The 3-chamber apparatus was cleaned with 
ethanol between animals. The number of entries and time spent in each chamber were 
then measured. 
Intestinal permeability (FITC-D) 
Intestinal barrier function was assessed using fluorescein isothiocyanate-
labelled dextran (FITC-D) (FD4, Sigma Aldrich, Ireland). FITC-D (MW= 4 kDa) was 
dissolved in phosphate buffered saline (pH 7.4) to make a solution of 80 mg/ml. Mice 
were fasted overnight, prior to the study, and in the morning (9.00), they were gavaged 
with FITC-D (600 mg/kg). Two hours following gavage, mice were placed in 
ventilated plastic restrainers and a basal blood sample was taken. Briefly, a scalpel 
blade was used to remove the very tip (<1 mm) of the tail. Blood was then collected 
using a heparinised capillary tube and transferred to a microcentrifuge tube. To assess 
the impact of acute stress on gut permeability, a small piece of gauze was used to 
gently remove the clot at the tip of the tail and another blood sample was collected 1 
h post-restraint. Mice were then returned to their home cages. Blood samples were 
kept on ice and then centrifuged at 2500 x g. Plasma was collected and stored at -20°C 
for later analysis. To assess FITC-D, samples were analysed using a spectrometer 
(Victor Spectrometer, excitation max= 490 nm, emission max= 520 nm). Serial 
dilutions of FITC-D in PBS were used to generate a standard curve. A separate aliquot 
of plasma was collected at each time-point to assess basal and stressed corticosterone 
levels. 




Plasma corticosterone (CORT) levels prior to, and following exposure to 
forced swim and restraint stress were used to assess hypothalamic-pituitary-adrenal 
(HPA) axis activity. On the day of the forced swim test, each mouse was removed 
from its home cage and moved to a testing room where a basal blood sample was 
taken. Blood samples were also taken 15, 45, and 90 min following the onset of the 
FST to assess peak and recovery CORT levels. Blood was processed as previously 
described, and stored at -20°C for later analysis. Blood samples were also collected to 
assess HPA axis response to restraint stress (in conjunction with the FITC-D test of 
intestinal permeability). Plasma CORT was assessed by ELISA, following vendor 
instructions (Enzo Corticosterone ELISA, ADI-900-097, Enzo Life Sciences, Exeter, 
UK). 
Plasma cytokines 
At the end of the study, trunk blood was collected and processed as described 
above for collection of plasma. Samples were analysed using the MSD V-Plex Custom 
Mouse Cytokine kit (MesoScaleDiscovery, Brinny, Ireland) as per vendor 
instructions. The lower limits of detection for the kit ranged from 0.11 pg/ml (IL-1β) 
to 0.95 pg/ml (IL-10). 
 
Caecal microbiota analysis 
DNA extraction 
Caecal contents were snap frozen at the end of the study and stored at -80°C 
until the samples could be processed. DNA was extracted from caecum using the 
QIAmp Fast DNA Stool Mini Kit (Qiagen, UK) according to manufacturer’s 




(Sarstedt, Wexford, Ireland) containing 0.25 g of a 1:1 mix of 0.1 mm and 1.5 mm 
diameter sterile zirconia beads plus a single 2.5 mm diameter bead (BioSpec Products, 
Bartlesville, USA). Briefly, 200 mg of each caecal sample was added to a screw-cap 
tube containing beads with 1 ml of Qiagen InhibitEX® Buffer and vortexed for 3 min. 
Samples were then incubated at 70°C for 5 min to lyse cells. Samples were centrifuged 
and the DNA was pelleted and treated with proteinase K. The DNA was then washed 
with buffers AW1 and AW2 and eluted in 200 µl Buffer ATE. DNA was quantified 
using the Qubit™ 3.0 Fluorometer (Bio-Sciences, Dublin, Ireland) along with the high 
sensitivity DNA quantification assay kit (Bio-Sciences, Dublin, Ireland). 
PCR and 16S compositional sequencing 
The V3-V4 regions of the 16S rRNA gene were amplified and prepared for 




The protocol involved two PCR reactions on the extracted DNA. The DNA 




reverse primer  
5'GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGG




primer (1 μM), 5 μl reverse primer (1 μM) and 12.5 μl 2X Kapa HiFi Hotstart 
ReadyMix (Kapa Biosystems Ltd., UK). PCR amplification was carried out using the 
following program: 95°C x 3 min, 25 cycles of 95°C x 30s, 55°C x 30s, 72°C x 30s, 
72°C x 5 min and held at 4°C. PCR products were visualised using gel electrophoresis 
and then purified using AMPure XP beads (Labplan, Kildare, Ireland). Following this, 
a second PCR reaction was carried out on the purified DNA using two indexing 
primers per sample (Illumina Nextera XT indexing primers, Illumina, Netherlands). 
Each reaction contained 5 μl purified DNA, 5 μl index 1 primer (N7xx), 5 μl index 2 
primer (S5xx), 25 μl 2x Kapa HiFi Hot Start Ready mix and 10 μl PCR grade water. 
PCR amplification was completed using the previous program but with only 8 
amplification cycles instead of 25. PCR products were visualised and purified as 
described above. Samples were quantified using the Qubit™ 3.0 Fluorometer (Bio-
Sciences, Dublin, Ireland) along with the high sensitivity DNA quantification assay 
kit and then pooled in an equimolar fashion (20 nM). The sample pool was prepared 
following Illumina guidelines and sequenced on the MiSeq sequencing platform in 
Clinical Microbiomics, Denmark using standard Illumina sequencing protocols. 
Bioinformatic analysis 
Paired-end reads were assembled using FLASH. Raw sequence reads were 
quality trimmed using the QIIME suite of tools (Version 1.8.0). This included the 
filtering of reads which failed to reach a quality score of > 25 and the removal of 
mismatched barcodes and sequences below length thresholds. Denoising, chimera 
detection and operational taxonomic unit (OTU) grouping at 97% similarity were 
performed in QIIME using USEARCH v7. OTU sequences were aligned using 
PyNAST and the SILVA SSURef database release 111 was used to determine 




alpha and beta diversity. Alpha diversity was calculated using the Shannon index, 
Mann Whitney U test was performed to assess significance between groups. Principal 
coordinate analysis (PCoA) plots were used to visualise beta diversity between groups 
based on Bray-Curtis distance matrices; significance of beta diversity between groups 
was computed by performing an ADONIS PERMANOVA test. 
Statistical analyses 
All data, with the exception of microbiota data, are presented as mean +/- SEM. 
Data were excluded from analyses if greater than 2 standard deviations from the mean. 
Two-way ANOVAs were used to assess percentage of time interacting for object 
location, social interaction, plasma FITC-D and CORT. When a main effect was 
detected, a Bonferroni post-hoc test of multiple comparisons was used. Unpaired t-
tests were used to analyse behaviour in the OF, EPM, FST and plasma cytokines. 
Correlations were performed using Spearman correlation coefficient (r). Mann 
Whitney U analysis was used to assess statistical differences in microbiota 
compositions and p-values were corrected for multiple comparisons using the 
Benjamini-Hochberg (BH) correction (FDR<0.05). Microbiota were analysed by 






Aged mice do not differ in spontaneous alternation behaviour, but exhibit 
impaired displaced object recognition. 
Ageing is associated with cognitive decline, including impaired memory. 
Therefore, we performed the Y-maze test of spontaneous alternation and a novel 
object/object location test to assess memory in aged and young mice. Aged mice 
performed similarly to young mice in the spontaneous alternation test (Figure 6.1A). 
Whereas young mice spent a significantly greater percentage of time interacting with 
a displaced familiar object (p<0.01), aged males did not (Figure 6.1B). 
 
Aged mice exhibit behaviours associated with anxiety but not depression. 
Because ageing is often associated with changes in mood, we also investigated 
anxiety- and depressive- like behaviours using the open field, elevated plus maze, and 
forced swim tests. Aged mice spent less time in the centre arena and made fewer 
entries into this area during the open field test (p<0.01) (Figure 6.1C and 6.1 D). Aged 
animals also spent a significantly lower percentage of time in the open arms of the 
plus maze (p<0.05) (Figure 6.1E), and together, these findings suggest increased 
anxiety. Immobility, used as a marker of depressive- or despair- like behaviour did not 





Figure 6.1. Behavioural tests of cognitive function, anxiety-, and depressive-like behaviours in young 
(n=9-12) and aged (n=8-10) mice. (A) No differences in spontaneous alternation were observed. (B) 
Young mice spent a significantly greater percentage of time interacting with a displaced, familiar 
object compared to a stationary, familiar object. (C) Aged mice spent significantly lower percentage 
of time in the centre of the open field. (D) Aged mice made fewer entries into the centre of the open 
field. E. Aged mice spent a significantly lesser percentage of time in the open arms of the EPM. F No 






Aged mice exhibit behaviours associated with reduced social recognition and/or 
preference for social novelty. 
As ageing is also associated with social withdrawal, social preference and 
social recognition were assessed using the 3-chamber social interaction test. Both aged 
and young mice spent more time investigating a novel mouse as opposed to a novel 
object, suggesting that there were no differences in preference for a conspecific 
(p<0.0001)(Figure 6.2A). However, whereas younger mice spent significantly more 
time interacting with a novel mouse than a familiar mouse (p<0.0001), aged mice spent 
similar amount of time investigating the novel and familiar mice, suggesting an 
impairment in social recognition or a reduced preference for social novelty (Figure 
6.2B). 
 
Figure 6.2. Behaviours of young (n=9) and aged (n=9) mice in the 3-chamber test. (A) Aged and 
young mice spent significantly more time investigating a novel mouse than a novel object. (B) Young 
mice spent significantly more time investigating a novel mouse than a familiar mouse. Aged mice 
exhibited no preference for the novel mouse. 
****p<0.0001 
 
Aged mice exhibit increased basal gut permeability, which is further exacerbated 




Gut permeability was assessed in young and aged mice prior to and following 
1 h of restraint stress. Aged mice had significantly greater basal intestinal permeability 
than young mice (p<0.05). Whereas gut permeability of young mice was unaffected 
by restraint stress, permeability was further enhanced in aged mice (Aged basal v. 
aged-stressed, p<0.01, Young-stressed v. aged-stressed, p<0.001) (Figure 6.3). 
 
 
Figure 6.3. Basal and stress-induced gut permeability in young (n=12) and aged (n=10) mice. Basal 
gut permeability of aged mice was significantly greater than that of young mice and was significantly 
increased in response to acute restraint. Gut permeability of young mice was not increased in response 
to acute restraint stress. 
*p<0.05 **p<0.01 ***p<0.001 
 
Aged mice exhibit alterations in corticosterone response to acute stress exposure. 
Despite seeing no behavioural effect, aged mice exhibited altered plasma 
CORT responses to the FST. Although basal CORT levels did not differ between 




onset of the test (p<0.001) (Figure 6.4A). Plasma CORT did not differ 45 and 90 min 
post FST; however, the trajectory of the CORT response differed. Although levels 
were dropping at these time-points in young mice, suggesting recovery, they were 
rising in aged mice, suggesting prolonged CORT release. CORT was also measured 
pre- and post- acute restraint, which was employed during the FITC-D test of intestinal 
permeability. Similar to our findings in the FST, basal CORT levels did not differ 
between young and aged mice. However, while plasma CORT was significantly 
increased in young mice following 1 h of restraint (p<0.001), CORT was unchanged 
in aged mice (young-stressed v. aged-stressed, p<0.001) (Figure 6.4B). 
 
Figure 6.4. Corticosterone response to acute stress exposure in young (n= 12) and aged (n=10) mice. 
(A) Young mice had a significantly greater peak CORT response 15 min after the onset of FST (B) 
Young mice had significantly higher plasma CORT following 1 h of restraint in comparison with 
basal levels and significantly higher plasma CORT than aged mice exposed to restraint. 
***p<0.001 
 
Circulating plasma cytokines are elevated in aged mice and correlate with gut 
FITC-D permeability 
Plasma cytokines were assessed as markers of peripheral inflammation at the 
end of the study. A number of pro-inflammatory cytokines were elevated in aged mice, 




(Figure 6.5C, p<0.01). There was a trend towards increased IL-6 expression in aged 
mice (Figure 6.5E, p=0.07). Anti-inflammatory cytokine IL-10 was unchanged in aged 
mice (Figure 6.5F). Plasma cytokines assessed at the end of the experiment were also 
plotted against plasma FITC-D levels assessed prior to and following restraint stress. 
In the basal state, IL-6 and TNF-α were significantly and positively correlated with 
plasma FITC-D levels (p<0.05), while there was a trend towards positive correlation 
between IL-1β (p=0.07), (Figure 6.6A). In the stressed state, all 3 of these cytokines 






Figure 6.5. Plasma cytokines in young (n= 11-12) and aged (n=7-8) mice. (A) Plasma IL-1β was 
significantly elevated in aged mice. (B) Plasma TNF-α was significantly elevated in aged mice. (C) 
Plasma IL-2 was significantly elevated in aged mice. (D) There was no difference in plasma IL-4. (E) 
There was a trend towards increased plasma IL-6 levels in aged mice (p=0.07). (F) Plasma IL-10 did 








Figure 6.6. Correlation between plasma cytokines and gut permeability in young (n= 11-12) and aged 
(n= 8) mice. A positive correlation was found between plasma cytokines and basal (unstressed) gut 
permeability and in response to acute restraint stress (D-F). Open circles represent young and shaded 
circles represent aged mice. 
*p< 0.05 
 
The caecal microbiota of mice is significantly altered with ageing 
MiSeq sequencing yielded a total of 8,339,660 raw reads, ranging from 
108,541 to 339,456 reads per sample. Following quality filtering, reads were clustered 
into 1033 OTUs, which were assigned to taxa from phylum to genus level. Due to the 
variation in read number, the OTU table was rarefied to 108,000 reads, to allow for 
comparison between samples. The microbiota of aged mice differed significantly from 
that of young mice. Interestingly, only significant increases in bacterial taxa were seen 
in aged mice compared to young (Table 6.1). 
At phylum level the most prevalent microbial taxa in both sample groups were 
Bacteroidetes and Firmicutes accounting for a combined relative abundance of >95% 




abundances of <2% in both groups. The large abundance of S24-7 and Rikenellaceae 
at family level was reflected at genus level as S24-7 uncultured, Alistipes, and RC9 
gut group. Together, these highly abundant genera account for approximately 50% 





Figure 6.7. Visual representation of relative abundance of caecal bacterial changes on the order of 
(A) Phylum, (B) Family and (C) Genus of young (n=10) and aged (n=7) mice. Significant changes are 
denoted by bold type. 
 
Several statistically significant changes in bacterial groups were observed in 
aged mice (Table 6.1). At the phylum level, TM7 was significantly higher in aged 
mice (p<0.01). At family level abundance less than 1%, significant increases in 
Porphyromondaceae (p<0.01), TM7 uncultured (p<0.01) Clostridiaceae (p<0.05), 
Thermoanaerobacteraceae (p<0.05), Desulfovibrionaceae (p<0.05) and 
Oxalobacteraceae (p<0.05) were seen in aged mice compared to young. Genera 
Odoribacter was much higher in the aged group (5.14%) than in the young mice 
(0.16%) (p<0.01). In addition, aged mice had significant increases in other bacterial 
genera, including Butyricimonas (p<0.01), TM7 uncultured (p<0.01), Gelria (p<0.05), 
Anaerosporobacter (p<0.05), Clostridium (p<0.05), Oxalobacter (p<0.05). 
 
Table 6.1. Differences in caecal microbiota between young (n=10) and aged (n=7) mice. Arrows in 
bold type denote significant changes within aged mice. 
 
The Chao 1 index (which estimates species richness) was significantly higher 
in the aged group (p=0.01). In addition, the number of observed species and the 
phylogenetic diversity were also higher in the aged mice (p=0.01, p=0.03). The 
Shannon index (alpha diversity) was significantly higher in aged mice (p<0.0001, 




Figure 6.8A). Beta diversity was significantly different between aged and young 
groups (p=0.001, Figure 6.8B). 
 
Figure 6.8. Alpha diversity, quantified by the Shannon index (A) and beta diversity, represented by 
principal coordinate analysis (B) of caecal bacteria of young (n=10) and aged (n=7) mice. 
 
The relative abundance of Porphyromonadaceae correlates with anxiety-like 
behaviour in aged mice 
Because some of the microbiota changes observed have been associated with 
cognitive dysfunction, we compared relative abundance of 3 taxa that were 
significantly altered in aged mice, Porphyromonadaceae, Odoribacter and TM7, with 
behavioural data. Interestingly, in aged mice, the relative abundance of members of 
the family Porphyromonadaceae was significantly and negatively correlated with the 
number of entries and time spent in the open arms of the elevated plus maze (Figure 
6.9A and 6.9B, p<0.05). That is, as Porphyromonadaceae increased in caecal contents, 
so did anxiety-like behaviour in aged mice. No correlations with anxiety-like 




Porphyromonadaceae family was so low. We found no other correlations between 
behaviours and the relative abundance of Porphyromonadaceae, Odoribacter or TM7 
bacterial groups. 
 
Figure 6.9. Correlation between behaviours and relative abundance of Porphyromonadaceae. 
Porphyromonadaceae and (A) time spent in the EPM and (B) entries into open arms of the EPM were 







Although the microbiome has been implicated in the ageing process, there have 
been few studies investigating the age-related changes in microbiota concomitant with 
gut permeability, stress response, peripheral inflammation and behaviour. Here we 
show that ageing is associated with marked changes in microbiota composition 
coupled with behavioural and physiological alterations. 
Some of the most troubling features associated with ageing are negative affect 
and cognitive decline (Eshkoor et al., 2015; Prenderville et al., 2015). In these studies, 
we found that aged mice exhibited several behavioural changes that are thought to 
reflect these symptoms. The most robust of these were increases in anxiety-like 
behaviours, as assessed by thigmotaxis during the open field test and less time spent 
in the open arms of the elevated plus maze. It should be noted that aged mice exhibit 
reductions in overall locomotor activity; therefore, all data were expressed as 
percentages to avoid this as a confounding variable. However, we cannot rule out the 
possibility that reduced activity influenced the results. Anxiety is often reported in the 
elderly, as are anxiety-like behaviours in aged laboratory animals (Andreescu & 
Varon, 2015; Brouwer-Brolsma et al., 2014; Creighton et al., 2016; Ellison et al., 
2015; Kastenschmidt & Kennedy, 2011). Importantly, epidemiological studies suggest 
that anxiety disorders in the elderly predispose or exacerbate the onset of cognitive 
impairments and other conditions, including cardiovascular disease (Andreescu & 
Varon, 2015). 
Impaired performance of aged mice in the object displacement task is in line 
with other studies suggesting age-associated deficits in hippocampal-dependent spatial 




Whereas both young and aged mice demonstrated a preference for a novel conspecific 
over a novel object, aged mice did not exhibit a preference for novel mice when 
presented with the choice between novel and familiar mice. However, it is unclear 
whether these findings reflect a true impairment in social recognition or a lack of 
preference for a novel conspecific. 
In addition to alterations in behaviour, aged mice exhibited several 
physiological changes. It is well established that many aspects of gut function, 
including intestinal barrier function, are impaired with age, and we observed a similar 
impairment in aged mice (Man et al., 2014; Saffrey, 2014; Tran & Greenwood-Van 
Meerveld, 2013). Interestingly, acute restraint stress exacerbated gut permeability in 
aged animals, despite a lack of rise in plasma glucocorticoid levels; in our studies, 
aged mice actually had a blunted and slower HPA axis response to acute stress, 
although it appears that they may also experience prolonged corticosterone release. 
The reason for this disconnect between plasma glucocorticoids and increased gut 
permeability is unclear, as the general consensus is that elevations in glucocorticoids 
contribute to increased gut permeability (Bhatia & Tandon, 2005; Meddings & Swain, 
2000). However, other studies suggest that glucocorticoids may actually serve to 
protect the gastrointestinal tract (Filaretova, 2007). Furthermore, Crohn’s disease, 
marked by increased inflammation and gut permeability has been associated with 
hypoactivity of the HPA axis; this may arise because glucocorticoids have anti-
inflammatory effects, and insufficient corticosteroid levels may result in excessive 
inflammation (Stasi & Orlandelli, 2008). Although ageing is often associated with 
basal hyperactivity of the hypothalamic-pituitary-adrenal axis, blunted and delayed 
activation and recovery of the HPA axis has also been previously reported (Buechel 




that the intestinal microbiota is sensitive to stress exposure, and this may in turn, 
modulate immune responses (Bailey, 2014; Mackos et al., 2016). In the current study 
we employed acute stressors, but future studies will incorporate chronic stress, which 
is particularly relevant to unhealthy ageing. 
Numerous factors are thought to contribute to age-associated impairments in 
gut function. These include histological changes within the structure of the gut, 
including decreased expression of tight junction proteins and altered morphology of 
intestinal villi (Ren et al., 2014; Tran & Greenwood-Van Meerveld, 2013). Mucous 
and bicarbonate secretion by the gut and short chain fatty acid (SCFA) production by 
the gut microbiota, which serve to protect the intestinal epithelia, also decrease with 
ageing (Rehman, 2012; Saffrey, 2014; Woodmansey, 2007). Moreover, gut motility is 
also often reported to decrease in the elderly and in aged laboratory animals, likely 
due to changes in the smooth muscle structure, gut innervation and disrupted 
signalling. 
Previous studies have demonstrated that the gut microbiota also influences gut 
permeability and behaviour (Saffrey, 2014; Yarandi et al., 2016). The age-related 
changes in microbiota that we observed have been previously implicated in 
inflammation and cognitive decline. The most significant increases that we observed 
are seen in phylum TM7, family Porphyromonadaceae and genus Odoribacter. These 
bacteria have been previously associated with inflammatory diseases such as cirrhosis 
and inflammatory bowel disease (IBD) (Collins et al., 2012; Giannelli et al., 2014). 
Interestingly, our studies also revealed changes in bacteria previously associated with 
cognitive decline. In a study of encephalopathic patients with cirrhosis, increases in 
Porphyromonadaceae positively correlated with increased cognitive dysfunction 




cognitive performance in the elderly was associated with increases in 
Porphyromonadaceae irrespective of cirrhosis (Bajaj et al., 2016). Caecal microbiota 
analysis in our studies revealed bacterial changes that have been previously observed 
in studies of depression and exposure to psychological stressors (Bangsgaard Bendtsen 
et al., 2012; Desbonnet et al., 2015; Watanabe et al., 2016). We found that relative 
abundance of Porphyromonadaceae was directly correlated with anxiety-like 
behaviours in aged mice. Increases in bacterial taxa from this family have also been 
observed in faecal samples from individuals with major depressive disorder (Jiang et 
al., 2015). 
While we did not observe behavioural changes in the forced swim test, a 
common assay of anti-depressant-sensitive behaviours, this may reflect the overall 
sensitivity of the test. In future studies we may incorporate other methods of assessing 
depressive-like behaviour across different endophenotypes of the disorder (Kelly et 
al., 2016; Slattery & Cryan, 2012; Slattery & Cryan, 2014). The increased anxiety that 
we observed in aged mice may reflect microbiota changes in stress sensitivity, as noted 
above (Bangsgaard Bendtsen et al., 2012; Desbonnet et al., 2014; Watanabe et al., 
2016). Interestingly, the caecal microbiota of aged mice was significantly more rich 
and diverse than that of young mice. Reductions in microbial diversity are often 
reported with ageing, but some studies have challenged these findings (Biagi et al., 
2012). The reasons for increased diversity in aged mice is unclear; however, decreases 
in diversity are often reflective of unhealthy ageing and frailty, which we did not 
subjectively observe in this study (Claesson et al., 2012; Jackson et al., 2016). Another 
possibility is that with ageing, the stability of the microbiota is reduced, leading to 




Perturbations in gut structure, function, and microbiota are believed to 
contribute to an increased risk of infection and inflammation, and markers of 
inflammation and immune responses have been reported in aged humans and in 
laboratory animals (Chung et al., 2009; Krabbe et al., 2004; Mabbott, 2015; Man et 
al., 2014; Tran & Greenwood-Van Meerveld, 2013). Similarly, we observed that 
plasma levels of several pro-inflammatory cytokines were elevated in aged mice, and 
IL-6, IL-1β and TNF-α correlated positively with gut permeability. Indeed, chronic 
systemic inflammation is linked to numerous neurodegenerative disorders and 
cognitive deficits associated with ageing, including Alzheimer’s disease (Chung et al., 
2009; Deleidi et al., 2015; Perry, 2010). Moreover, there is a growing literature linking 
microbiome-based changes with susceptibility to Alzheimer’s disease and 
neurodegenerative disorders (Cattaneo et al., 2016; Fröhlich et al., 2016; Xu & Wang, 
2016). 
In conclusion, we show, for the first time to our knowledge, that perturbations 
of the microbiome-gut-brain axis, resultant of normal ageing, may contribute to 
peripheral inflammation and the development of altered anxiety behaviours and 
cognitive impairments. Aged male mice exhibited significant shifts in gut microbiota 
and marked differences in stress responsivity, gut permeability and peripheral 
inflammation in comparison with young adult mice. In addition, they exhibited 
behavioural changes associated with cognitive deficits and increased anxiety. These 
increases in anxiety-like behaviour were directly correlated with abundance of bacteria 
from the Porphyromonadaceae family; this is in agreement with previous studies 
finding an association between this family and cognitive dysfunction and mood 




Future studies should focus on the mechanisms that are at play in driving these 
changes. There is increasing emphasis on understanding pathways of microbiome to 
brain signalling (including vagus nerve, neuroendocrine pathways, enteric nervous 
system short chain fatty acids, tryptophan metabolism and the immune system) but 
there is still a lack of knowledge in this field (Cryan & Dinan, 2012; Galland, 2014; 
O'Mahony et al., 2015; Rogers et al., 2016). Moreover, the microbiome has been 
shown to regulate adult hippocampal neurogenesis (Möhle et al., 2016; Ogbonnaya et 
al., 2015), microglia activation (Erny et al., 2015), blood brain barrier function 
(Braniste et al., 2014) and neuroinflammation (D'Mello et al., 2015), all of which are 
altered in ageing. Future studies should also address the relative contribution of these 
to the alterations in behaviour seen in ageing. These studies suggest that the gut 
microbiota may prove a worthy target for the development of novel therapies to 
ameliorate or prevent some of the adverse neurobehavioural consequences of 
unhealthy ageing. 
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General Discussion and Conclusions 
The overall aim of this thesis was to examine the current understanding of the 
microbial colonisation of the gut from birth and throughout life, as well as the 
implications of an altered microbiome profile on brain development, stress reponses, 
immunity and behaviour. In Chapter 1, the progression of a typical healthy 
microbiome composition was examined from birth to adulthood. Following this, we 
focused on the factors known to significantly impact this progression (Marques et al., 
2010). Beginning during the perinatal period and continuing into adulthood, many 
influences on the gut microbiota composition throughout life are discussed including 
diet, stress, infection and age (Milani et al., 2017). We then examined the use of 
probiotics and prebiotics as a promising avenue for gut microbiota modulation, 
including viable methods of delivery and key research investigating the effects of 
probiotics and prebiotics on the gut microbiota composition in both infants and adults. 
The role of potential probiotics which target the gut-brain axis to confer a mental 
health benefit (psychobiotics) was then explored (Dinan et al., 2013). 
In Chapter 2, we discussed the microbiota-gut-brain axis in more detail, 
examining signalling pathways and potential future psychobiotic targets. The 
communication network between the gut microbiota and the brain is explored as well 
as the role of the gut-brain axis in mood, cognition and mental health (Sampson & 
Mazmanian, 2015). Potential microbiota-targeted functional foods for brain health are 
discussed including polyphenols and omega-3 PUFAs. This field has grown 
significantly in recent years with new strains of bacteria emerging as potential 





Chapter 3 focused on the impact of an altered gut microbiota composition from 
birth. Faecal samples were collected from infants who were born by C-section and 
also received antibiotic treatment in the first four days of life. It is widely known that 
C-section delivery can cause significant disturbances in the infant gut (Bäckhed et al., 
2015). The gut microbiota composition of these infants was analysed from birth until 
24 weeks. The impact of both antibiotic treament and mode of delivery was seen when 
the gut microbiota composition was compared to infants who were born vaginally (Hill 
et al., 2017). Several key microbial communities were absent in the first weeks of life 
and many alterations at phylum, family and genus levels were still present 24 weeks 
later. The examination of the impact of both insults (antibiotic exposure and C-section 
delivery) on the maturing infant gut highlights not only the magnitude of the gut 
microbiota disturbances, but also the fact that these alterations persist for at least 24 
weeks after birth with respect to composition and diversity. 
In Chapter 4 we investigated the long-term effects of an altered microbiota 
composition at birth. We examined the gut microbiota composition and stress 
responses of a cohort of young adults who had been born by C-section. It was found 
that the gut microbiota composition did not differ between individuals born by C-
section or those born naturally. However, when examining stress responses, it was 
seen that the participants who were born by C-section reported higher levels of anxiety 
during an exam stress period and higher psychological stress during an acute stressor. 
This highlights the negative impact of gut microbiota alterations during infancy on 
psychological processes into adulthood. 
Chapter 5 explored the effects of a potential probiotic, Bifidobacterium longum 
1714™, on mood, stress, and cognition. A cohort of healthy male participants were 




placebo-controlled, repeated measures, cross-over design. It was noted that the 
probiotic did not affect the gut microbiota in terms of composition or diversity. 
Additionally, the probiotic did not show a significant effect on measures of mood or 
stress. However, while the sleep quality of the placebo group decreased during the 
exam stress period, it remained consistent for the individuals consuming the probiotic. 
While this probiotic did not directly influence measures of mood and stress, it is known 
that anxiety and sleep quality are linked and thus, future work on the effects of this 
probiotic is warranted (Ramsawh et al., 2009; Vandekerckhove & Cluydts, 2010). 
While previous chapters have focused on the microbiota-gut-brain axis in 
young adults, Chapter 6 examined associations between the gut microbiota and the 
ageing brain and cognitive decline. The caecal microbiota of aged and young male 
C57BL/6 J mice was analysed along with a variety of behavioural tests designed to 
examine cognition and mood. It was found that ageing is associated with microbiota 
alterations accompanied by behvaioural and physiological changes. Aged mice 
displayed increased anxiety-like behaviour and gut pereability when compared to 
young mice. Additionally, the microbiota of aged mice demonstrated a shift toward a 
compositional profile consistant with increased inflammation. 
In conclusion, the role of the gut microbiota throughout life, from infancy to 
adulthood has been shown to be significant. This thesis has highlighted the 
implications of an altered gut microbiota at birth, resulting in a substantial change in 
the development and progression of the gut microbiota over the first 24 weeks of life. 
The disruption in the normal colonisation pattern of the infant gut as it co-matures 
with the infant brain can be seen in later life psychological vulnerabilities. It is evident 
that the gut microbiota is dynamic and fluid throughout life, from infancy into 




profile shifts. Many of the factors discussed that affect the gut microbiota disturbances 
are unavoidable, however, the continued use of probiotics as intervention therapies to 
restore gut microbiota composition and diversity in infants and adults and the elderly 
is a growing and promising area of investigation. Continued exploration into the 
relationship between the gut-microbiota-brain axis and altered microbiota profiles, as 
well as cognitive, psychological, behavioural and mood disorders is key to providing 
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